CN101184774A

CN101184774A - Human cancer suppressor gene, protein encoded therein

Info

Publication number: CN101184774A
Application number: CNA2006800188974A
Authority: CN
Inventors: 金弦起; 金振宇
Original assignee: Individual
Current assignee: Individual
Priority date: 2005-03-30
Filing date: 2006-03-30
Publication date: 2008-05-21
Also published as: EP1866333A4; JP2008534006A; KR20060104265A; EP1866333A1; WO2006109941A1; KR100689276B1; CA2602976A1

Abstract

Disclosed are a human cancer suppressor gene, a protein encoded therein, an expression vector containing the same and a microorganism transformed with the vector. The cancer suppressor gene of the present invention may be effectively used for diagnosing, preventing and treating human cancers.

Description

Human tumor suppressor gene and encoded protein matter thereof

Technical field

The present invention relates to a kind of human tumor suppressor gene, its encoded protein matter, comprise this expression carrier and with this carrier cell transformed.

Background technology

Cancer suppressor protein plays and suppresses the effect that normal cell changes into certain cancer cells, so the forfeiture of this function of cancer suppressor protein makes normal cell become vicious transformation body (Klein, G, FASEB J., 7,821-825 (1993)).In order to make cancer cells develop into cancer, cell should be lost the function of the normal copy number of control cancer suppressor gene.Find variation in the encoding sequence of p53 cancer suppressor gene be one of genovariation the most general in the human cancer (Bishop, J.M., Cell, 64, 235-248 (1991); And Weinberg, R.A., Science, 254, 1138-1146 (1991)).

Yet, because the p53 that reports in mammary cancer sudden change amounts in 30% scope of total mammary cancer, so infer to have only some breast cancer tissues to show p53 sudden change (Keen, J.C. ﹠amp; Davidson, N.E., Cancer, 97, 825-833 (2003)) and Borresen-Dale, A-L., Human Mutation, 21, 292-300 (2003)).And, because the p53 that reports in leukemia sudden change amounts in total leukemic 20% scope, so infer to have only some leukemia organization table to reveal p53 sudden change (Boyapati, A., wait the people, Acta Haematol., 111 (1-2), 100-106 (2004)).

The p53 sudden change accounts at least 50% of liver cancer, especially suffer aflatoxin B1's or have the zone that high-frequency B virus infects, its principal character is missense mutation (Montesano, the people such as R. of codon 249 in the p53 oncogene, J.Natl.Cancer Inst. 89, 1844-1851 (1997); Szymanska, K.﹠amp; Hainaut, P.Acta Biochimica Polonica, 50, 231-238 (2003)).Yet, it is reported in the U.S. and West Europe p53 sudden change only amounts to 30% scope in liver cancer there be not frequent focus (Szymanska, the K. ﹠amp that takes place of this sudden change here; Hainaut, P.Acta Biochimica Polonica, 50, 231-238 (2003)).

Simultaneously because the p53 that reports in cervical cancer sudden change only amounts in 2～11% scope of total cervical cancer, so infer have only some cervical cancer tissues show the p53 sudden change (Crook, people such as T., Lancet, 339, 1070-1073 (1992); And Busby-Earle, people such as R.M.C., Br.j.Cancer, 69, 732-737 (1994)).

And, it is reported the mutation frequency of p53 cancer suppressor gene in nonsmall-cell lung cancer and the small cell lung cancer amount to account for respectively total lung cancer about 50% and 70% (Takahashi, people such as T., Science, 246, 491-4941989; Bodner, people such as S.M., Oncogene, 7, 743-749 (1992); Mao, L.Lung Cancer, 34, S27-S34 (2001)).Smoking is one of most critical factor of lung cancer morbidity and expansion, except p53, other multiple cancer suppressor gene and oncogene common with lung cancer morbidity and expand relevant (Osada, H. ﹠amp; Takahashi, T.Oncogene, 21, 7421-7434 (2002)).

Therefore, the inventor actively attempts showing that by mRNA difference (DD) method is from the cancer suppressor gene new as separation the healthy tissues of mammary gland, liver, uterine cervix, lung etc., mRNA difference shows that (DD) method is used for more effectively showing as the healthy tissues of mammary gland, liver, uterine cervix and lung with as the gene difference expression (Liang between the cancerous tissue of mammary cancer, liver cancer, cervical cancer and lung cancer, P. and Pardee, A.B., Science 257, 967-971 (1992); And Liang, people such as P., Cancer Res., 52, 6966-6968 (1993)).

Summary of the invention

For this reason, the present invention attempts to solve prior art problems, therefore an object of the present invention is to provide a kind of new human tumor suppressor gene.

Another object of the present invention provides the cancer suppressor protein by described cancer suppressor gene coding.

Another purpose of the present invention provides the expression vector that comprises described cancer suppressor gene.

One of for achieving the above object, the invention provides a kind of have be selected from NO:1 by SEQ ID, SEQID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:57, SEQID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO:105, the human tumor suppressor gene of the dna sequence dna in the group that SEQ ID NO:109 and SEQ ID NO:113 form.

According to another above-mentioned purpose of the present invention, the invention provides a kind of have be selected from NO:2 by SEQ ID, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ IDNO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:58, SEQ ID NO:62, SEQ ID NO:66, SEQ ID NO:70, SEQ ID NO:74, SEQID NO:78, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:98, SEQ ID NO:102, SEQ ID NO:106, people's cancer suppressor protein of the aminoacid sequence in the group that SEQ ID NO:110 and SEQID NO:114 form.

According to another above-mentioned purpose, the invention provides a kind of expression vector that comprises described cancer suppressor gene.

According to another above-mentioned purpose, the invention provides the described expression vector cell transformed of a kind of usefulness.

Description of drawings

These and other feature, technical scheme and the advantage of preferred implementation of the present invention are described in being discussed in more detail below in conjunction with the accompanying drawings, more fully.In the accompanying drawings:

Fig. 1 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:3 '-13-mer random primer H-AP33 and SEQ IDNO:4 is shown;

Fig. 2 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:7 '-13-mer random primer H-AP10 and SEQ IDNO:8 is shown;

Fig. 3 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:11 '-13-mer random primer H-AP5 and SEQ IDNO:12 is shown;

Fig. 4 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:15 '-13-mer random primer H-AP2 and SEQ IDNO:16 is shown;

Fig. 5 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:19 '-13-mer random primer H-AP8 and SEQ IDNO:20 is shown;

Fig. 6 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:23 '-13-mer random primer H-AP7 and SEQ IDNO:24 is shown;

Fig. 7 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:27 '-13-mer random primer H-AP11 and SEQ IDNO:28 is shown;

Fig. 8 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:31 '-13-mer random primer H-AP3 and SEQ IDNO:32 is shown;

Fig. 9 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:35 '-13-mer random primer H-AP4 and SEQ IDNO:36 is shown;

Figure 10 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:39 '-13-mer random primer H-AP8 and SEQ IDNO:40 is shown;

Figure 11 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:43 '-13-mer random primer H-AP33 and SEQ IDNO:44 is shown;

Figure 12 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:47 '-13-mer random primer H-AP35 and SEQ IDNO:48 is shown;

Figure 13 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:51 '-13-mer random primer H-AP3 and SEQ IDNO:52 is shown;

Figure 14 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:55 '-13-mer random primer H-AP12 and SEQ IDNO:56 is shown;

Figure 15 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:59 '-13-mer random primer H-AP12 and SEQ IDNO:60 is shown;

Figure 16 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:63 '-13-mer random primer H-AP7 and SEQ IDNO:64 is shown;

Figure 17 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:67 '-13-mer random primer H-AP8 and SEQ IDNO:68 is shown;

Figure 18 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:71 '-13-mer random primer H-AP10 and SEQ IDNO:72 is shown;

Figure 19 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:75 '-13-mer random primer H-AP16 and SEQ IDNO:76 is shown;

Figure 20 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:79 '-13-mer random primer H-AP2 and SEQ IDNO:80 is shown;

Figure 21 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:83 '-13-mer random primer H-AP9 and SEQ IDNO:84 is shown;

Figure 22 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:87 '-13-mer random primer H-AP9 and SEQ IDNO:88 is shown;

Figure 23 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:91 '-13-mer random primer H-AP32 and SEQ IDNO:92 is shown;

Figure 24 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:95 '-13-mer random primer H-AP10 and SEQ IDNO:96 is shown;

Figure 25 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:99 '-13-mer random primer H-AP22 and SEQ IDNO:100 is shown;

Figure 26 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:103 '-13-mer random primer H-AP12 and SEQID NO:104 is shown;

Figure 27 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:107 '-13-mer random primer H-AP10 and SEQID NO:108 is shown;

Figure 28 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:111 '-13-mer random primer H-AP12 and SEQID NO:112 is shown; And

Figure 29 is the gel figure that the PCR result of the oligo-dT anchor primer that uses 5 of SEQ ID NO:115 '-13-mer random primer H-AP4 and SEQ IDNO:116 is shown;

Figure 30～Figure 58 is respectively GIG8 gene product of the present invention (Figure 30) is shown, GIG10 gene product (Figure 31), GIG13 gene product (Figure 32), GIG15 gene product (Figure 33), GIG16 gene product (Figure 34), GIG24 gene product (Figure 35), GIG26 gene product (Figure 36), GIG29 gene product (Figure 37), GIG30 gene product (Figure 38), GIG32 gene product (Figure 39), GIG33 gene product (Figure 40), GIG34 gene product (Figure 41), GIG35 gene product (Figure 42), GIG38 gene product (Figure 43), GIG39 gene product (Figure 44), GIG40 gene product (Figure 45), GIG42 gene product (Figure 46), GIG43 gene product (Figure 47), GIG46 gene product (Figure 48), PIG33 gene product (Figure 49), PIG35 gene product (Figure 50), PIG36 gene product (Figure 51), MIG20 gene product (Figure 52), PIG49 gene product (Figure 53), PIG51 gene product (Figure 54), MIG12 gene product (Figure 55), PIG37 gene product (Figure 56), the figure of the SDS-PAGE analytical results of GIG44 gene product (Figure 57) and GIG31 gene product (Figure 58);

Figure 59, Figure 60, Figure 61, Figure 67, Figure 68, Figure 69, Figure 70, Figure 71, Figure 72, Figure 73, Figure 76, Figure 82, Figure 83, Figure 86 and Figure 87 are respectively the GIG8 gene are shown, the GIG10 gene, the GIG13 gene, the GIG30 gene, the GIG32 gene, the GIG33 gene, the GIG34 gene, the GIG35 gene, the GIG38 gene, the GIG39 gene, the GIG43 gene, the PIG49 gene, the PIG51 gene, GIG44 gene and GIG31 gene are in normal galactophore tissue, the RNA trace result's of differential expression figure in primary breast cancerous tissue and the breast cancer cell line;

Figure 62 is the figure that GIG15 gene of the present invention RNA trace result of differential expression in normal bone marrow tissue, leukemia myeloid tissue and K562 leukemia cell is shown;

Figure 63, Figure 64, Figure 65, Figure 66, Figure 74, Figure 75, Figure 78, Figure 79, Figure 80 and Figure 85 are respectively the figure that GIG16 gene, GIG24 gene, GIG26 gene, GIG29 gene, GIG40 gene, GIG42 gene, PIG33 gene, PIG35 gene, PIG36 gene and the PIG37 gene RNA trace result of differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line is shown;

Figure 77 and Figure 81 are respectively the figure that GIG46 gene and MIG20 gene RNA trace result of differential expression in normal ectocervix tissue, primary uterus carcinoma tissue and uterus carcinoma clone are shown;

Figure 84 is the figure that MIG12 gene of the present invention RNA trace result of differential expression in normal lung tissue, primary pulmonary cancerous tissue, transitivity cancerous lung tissue and lung cancer cell line is shown, and the bottom of Figure 59～87 is respectively and illustrates by making the RNA trace result's that identical trace and beta-actin probe hybridization obtain figure;

Figure 88～116 are respectively GIG8 gene (Figure 88) are shown, GIG10 gene (Figure 89), GIG13 gene (Figure 90), GIG15 gene (Figure 91), GIG16 gene (Figure 92), GIG24 gene (Figure 93), GIG26 gene (Figure 94), GIG29 gene (Figure 95), GIG30 gene (Figure 96), GIG32 gene (Figure 97), GIG33 gene (Figure 98), GIG34 gene (Figure 99), GIG35 gene (Figure 100), GIG38 gene (Figure 101), GIG39 gene (Figure 102), GIG40 gene (Figure 103), GIG42 gene (Figure 104), GIG43 gene (Figure 105), GIG46 gene (Figure 106), PIG33 gene (Figure 107), PIG35 gene (Figure 108), PIG36 gene (Figure 109), MIG20 gene (Figure 110), PIG49 gene (Figure 111), PIG51 gene (Figure 112), MIG12 gene (Figure 113), PIG37 gene (Figure 114), GIG44 gene (Figure 115) and GIG31 gene (Figure 116) the RNA trace result's of differential expression in multiple healthy tissues figure, and the bottom of Figure 88～116 is respectively and illustrates by making the RNA trace result's that identical trace and beta-actin probe hybridization obtain figure;

Figure 117～145 are respectively GIG8 gene (Figure 117) are shown, GIG10 gene (Figure 118), GIG13 gene (Figure 119), GIG15 gene (Figure 120), GIG16 gene (Figure 121), GIG24 gene (Figure 122), GIG26 gene (Figure 123), GIG29 gene (Figure 124), GIG30 gene (Figure 125), GIG32 gene (Figure 126), GIG33 gene (Figure 127), GIG34 gene (Figure 128), GIG35 gene (Figure 129), GIG38 gene (Figure 130), GIG39 gene (Figure 131), GIG40 gene (Figure 132), GIG42 gene (Figure 133), GIG43 gene (Figure 134), GIG46 gene (Figure 135), PIG33 gene (Figure 136), PIG35 gene (Figure 137), PIG36 gene (Figure 138), MIG20 gene (Figure 139), PIG49 gene (Figure 140), PIG51 gene (Figure 141), MIG12 gene (Figure 142), PIG37 gene (Figure 143), GIG44 gene (Figure 144) and GIG31 gene (Figure 145) the RNA trace result's of differential expression in multiple cancerous cell line figure, and the bottom of Figure 117～145 is respectively and illustrates by making the RNA trace result's that identical trace and beta-actin probe hybridization obtain figure;

Figure 146, Figure 147, Figure 148, Figure 154, Figure 155, Figure 156, Figure 157, Figure 158, Figure 159, Figure 160, Figure 169, Figure 170, Figure 173 and Figure 174 are respectively wild-type MCF-7 cell are shown, and use the GIG8 gene respectively, the GIG10 gene, the GIG13 gene, the GIG30 gene, the GIG32 gene, the GIG33 gene, the GIG34 gene, the GIG35 gene, the GIG38 gene, the GIG39 gene, the PIG49 gene, the PIG33 gene, the MCF-7 breast cancer cell of GIG44 gene and GIG31 gene transfection and with the figure of the growth curve of the MCF-7 cell of expression vector pcDNA3.1 transfection;

Figure 149 be wild-type K562 clone is shown, with the K562 leukemia cell of GIG15 gene transfection with the figure of the growth curve of the K562 cell of expression vector pcDNA3.1 transfection;

Figure 150, Figure 151, Figure 152, Figure 153, Figure 161, Figure 162, Figure 163, Figure 165, Figure 166, Figure 167 and Figure 172 are for illustrating wild-type HepG2 hepatoma cell line, use the HepG2 liver cancer cell of GIG16 gene, GIG24 gene, GIG26 gene, GIG29 gene, GIG40 gene, GIG42 gene, GIG43 gene, PIG33 gene, PIG35 gene, PIG36 gene and PIG37 gene transfection respectively, and with the figure of the growth curve of the HepG2 cell of expression vector pcDNA3.1 transfection;

Figure 164 and Figure 168 be respectively wild-type HeLa cell be shown, respectively with the HeLa uterus carcinoma cell of GIG46 gene and MIG20 gene transfection and with the figure of the growth curve of the HeLa cell of expression vector pcDNA3.1 transfection; And

Figure 171 be wild-type A549 lung cancer cell line is shown, with the A549 lung carcinoma cell of MIG12 gene transfection with and with the figure of the growth curve of the A549 cell of expression vector pcDNA3.1 transfection.

Embodiment

Hereinafter describe preferred implementation of the present invention with reference to the accompanying drawings in detail.

1.GIG8

Gene of the present invention is the human tumor suppressor gene 8 (GIG8) with dna sequence dna of SEQ ID NO:1, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in combines the dna sequence dna of gene of supressor 2 (being dominance negative helix-loop-helix protein (ID2)) with the human DNA that is deposited in database with the number of including of NM_002166 similar with the number of including of AY634687.Yet it is closely related from these results of study discovery GIG8 genes and multiple human carcinogenesis.Seldom or not express during comprising the multiple human tumor of mammary cancer from these results of study discoveries GIG8 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:1 has an open reading frame (ORF) (terminator codon is represented in 522～524 base position) corresponding to 120～524 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 134 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:2 and the molecular weight of about 15kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:1.As another example, can use the random primer H-AP33 (5 '-AAGCTTGCTGCTC-3 ') of SEQ ID NO:3 and the oligo-dT anchor primer of SEQID NO:4 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 163-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.3kb size carry out overexpression.

2.GIG10

Gene of the present invention is the human tumor suppressor gene 10 (GIG10) with dna sequence dna of SEQ ID NO:5, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human c-Cb1-interaction protein (CIN85) the mRNA gene that is deposited in database with the number of including of AF230904 with the number of including of AY542305.

Yet it is closely related from these results of study discovery GIG10 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from these results of study discoveries GIG10 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:5 has an open reading frame (ORF) (terminator codon is represented in 2,047～2,049 base position) corresponding to 52～2,049 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 665 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:6 and the molecular weight of about 73kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:5.As another example, can use the random primer H-AP10 (5 '-AAGCTTCCACGTA-3 ') of SEQ ID NO:7 and the oligo-dT anchor primer of SEQID NO:8 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 321-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 3.5kb size carry out overexpression.

3.GIG13

Gene of the present invention is the human tumor suppressor gene 13 (GIG13) with dna sequence dna of SEQ ID NO:9, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in and the human diel rhythm gene hypotype 3 (period homolog 3) (fruit bat) that is deposited in database with the number of including of NM_016831 be gene similar (PER3) with the number of including of AY493418.

Yet it is closely related from these results of study discovery GIG13 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from these results of study discoveries GIG13 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.The dna sequence dna of SEQ ID NO:9 has an open reading frame (ORF) (terminator codon is represented in 3,675～3,677 base position) corresponding to 72～3,677 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 1,201 amino-acid residue, and it has the aminoacid sequence of SEQID NO:10 and the molecular weight of about 132kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:1.As another example, can use the random primer H-AP5 (5 '-AAGCTTAGTAGGC-3 ') of SEQ ID NO:11 and the oligo-dT anchor primer of SEQID NO:12 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 347-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland and liver overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.3kb size carry out overexpression.Especially, gene of the present invention differential expression in healthy tissues only.For example, gene of the present invention is seldom expressed in as the cancerous tissue of breast cancer tissue and breast cancer cell line MCF-7 and cancer cells or is not expressed, and only in normal galactophore tissue otherness ground improve and express.

4.GIG15

Gene of the present invention is the human tumor suppressor gene 15 (GIG15) with dna sequence dna of SEQ ID NO:13, its deposited in the number of including of AY927233 NIH (NIH) gene database (date of publication of regulation: on October 1st, 2006), the dna sequence dna of the gene that this deposits in and the human chromosomal 11 that is deposited in database with the number of including of AC116533, clone RP11-466H18 gene similar.Yet it is closely related from these results of study discovery GIG15 genes and multiple human carcinogenesis.During comprising leukemic multiple human tumor, seldom express or do not express from these results of study discoveries GIG15 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:13 has an open reading frame (ORF) (terminator codon is represented in 366～338 base position) corresponding to 18～338 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 106 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:14 and the molecular weight of about 12kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:13.As another example, can use the random primer H-AP2 (5 '-AAGCTTCGACTGT-3 ') of SEQ ID NO:15 and the oligo-dT anchor primer of SEQ ID NO:16 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 133-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 0.5kb size carry out overexpression.Especially, gene of the present invention differential expression in healthy tissues only.For example, gene of the present invention is seldom to express in the cancer cells of K562 at cancerous tissue with as leukemia cell and leukemia cell, and only in normal galactophore tissue otherness ground improve and express.

5.GIG16

Gene of the present invention is the human tumor suppressor gene 16 (GIG16) with dna sequence dna of SEQ ID NO:17, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY513277, some dna sequence dnas of the gene that this deposits in and the human hydroxy acid oxidase 2 (long-chain) that is deposited in database with the number of including of NM_016527 be gene different (HAO2), known HAO2 gene is three and has one of the active gene of 2-hydroxy acid oxidase (Jones, J.M., Deng the people, J.Biol.Chem.275 (17), 12590-12597 (2000)).Yet find the expression during comprising the multiple human tumor of liver cancer of GIG16 cancer suppressor gene from these results of study, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:17 has an open reading frame (ORF) (terminator codon is represented in 1,094～1,096 base position) corresponding to 41～1,096 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 351 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:18 and the molecular weight of about 39kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:17.As another example, can use the random primer H-AP8 (5 '-AAGCTTTTACCGC-3 ') of SEQ ID NO:19 and the oligo-dT anchor primer of SEQ ID NO:20 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 213-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG16cDNA, the U.S.), expression vector transformed into escherichia coli (E.coli) the DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG16/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver and kidney overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.0kb size carry out overexpression.Especially, gene of the present invention is only at the healthy tissues differential expression.For example, gene of the present invention is not expressed in as the cancerous tissue of liver cancer tissue and hepatoma cell line HepG2 and cancer cells, and differential expression in normal galactophore tissue only.

6.GIG24

Gene of the present invention is the human tumor suppressor gene 24 (GIG24) with dna sequence dna of SEQ ID NO:21, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY513275, the dna sequence dna of the gene that this deposits in and human cDNA FLJ35730 fis, clone TESTI2003131's is similar, and similar to the height of the α 1-chymotrypsin inhibitor precursor-gene that is deposited in database with the number of including of AK093049.Yet find the expression during comprising the multiple human tumor of liver cancer of GIG24 cancer suppressor gene from these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:21 has an open reading frame (ORF) (terminator codon is represented in 1,303～1,305 base position) corresponding to 34～1,305 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 423 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:22 and the molecular weight of about 47kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:1.As another example, can use the random primer H-AP7 (5 '-AAGCTTAACGAGG-3 ') of SEQ ID NO:23 and the oligo-dT anchor primer of SEQ ID NO:24 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 221-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG24cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG24/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, heart and muscle overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.4kb size carry out overexpression.

7.GIG26

Gene of the present invention is the human tumor suppressor gene 26 (GIG26) with dna sequence dna of SEQ ID NO:25, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY544126, the dna sequence dna of the gene that this deposits in is similar to human benign prostatic specific membrane antigen (PSMAL) gene that is deposited in database respectively with the number of including of NM_153696 and AF261715 and human benign prostatic specific membrane antigen albumen (PSMAL/GCP III) mRNA gene, known prostate specific membrane antigen is the marker protein ((Lee that mainly expresses in prostatic epithelium, S.J., Deng the people, J.Mol.Biol.330 (4), 749-760 (2003)).Yet find the expression during comprising the multiple human tumor of liver cancer of GIG26 cancer suppressor gene from these results of study, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:25 has an open reading frame (ORF) (terminator codon is represented in 1,352～1,354 base position) corresponding to 26～1,354 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 442 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:26 and the molecular weight of about 50kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:25.As another example, can use the random primer H-AP11 (5 '-AAGCTTCGGGTAA-3 ') of SEQ ID NO:27 and the oligo-dT anchor primer of SEQ ID NO:28 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 204-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG26cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG26/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, kidney, brain and heart overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.0kb size carry out overexpression.

8.GIG29

Gene of the present invention is the human tumor suppressor gene 29 (GIG29) with dna sequence dna of SEQ ID NO:29, its deposited in the number of including of AY544127 NIH (NIH) gene database (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in and the human solute transhipment family 10 that is deposited in database with the number of including of NM_003049 (sodium/bile acide cotransport family) gene similar.Yet find the expression during comprising the multiple human tumor of liver cancer of GIG29 cancer suppressor gene from these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:29 has an open reading frame (ORF) (terminator codon is represented in 1,109～1,111 base position) corresponding to 62～1,111 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 349 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:30 and the molecular weight of about 38kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:29.As another example, can use the random primer H-AP3 (5 '-AAGCTTTGGTCAG-3 ') of SEQ ID NO:31 and the oligo-dT anchor primer of SEQ ID NO:32 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 277-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG29cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG29/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.4kb size carry out overexpression.

9.GIG30

Gene of the present invention is the human tumor suppressor gene 30 (GIG30) with dna sequence dna of SEQ ID NO:33, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human cloned DNA43305RIPK2 (UNQ277) gene that is deposited in database with the number of including of AY358814 with the number of including of AY524045.Yet it is closely related from these results of study discovery GIG30 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG30 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:33 has an open reading frame (ORF) (terminator codon is represented in 1,708～1,710 base position) corresponding to 88～1,710 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 540 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:34 and the molecular weight of about 61kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:35.As another example, can use the random primer H-AP4 (5 '-AAGCTTCTCAACG-3 ') of SEQ ID NO:35 and the oligo-dT anchor primer of SEQ ID NO:36 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 278-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, muscle and liver overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.9kb size carry out overexpression.

10.GIG32

Gene of the present invention is the human tumor suppressor gene 32 (GIG32) with dna sequence dna of SEQ ID NO:37, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY762103, (caveolin, 22kDa) (CAV1) gene is similar with the human caveolin 1 that is deposited in database with the number of including of NM_001753 for the dna sequence dna of the gene that this deposits in.Yet it is closely related from these results of study discovery GIG32 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG32 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:37 has an open reading frame (ORF) (terminator codon is represented in 577～579 base position) corresponding to 43～579 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 178 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:38 and the molecular weight of about 20kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:37.As another example, can use the random primer H-AP8 (5 '-AAGCTTTTACCGC-3 ') of SEQ ID NO:39 and the oligo-dT anchor primer of SEQ ID NO:40 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 172-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 4.0kb size carry out overexpression.

11.GIG33

Gene of the present invention is the human tumor suppressor gene 33 (GIG33) with dna sequence dna of SEQ ID NO:41, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on October 1st, 2006), the dna sequence dna of the gene that this deposits in is similar to human ribosomal protein L35a (RPL35A) gene that is deposited in database with the number of including of NM_000996 with the number of including of AY871273.Ribosomal gene is a catalytic proteins cell within a cell device synthetic and that be made up of 40S small subunit and the big subunit of 60S.Yet the function of this gene awaits detailed description, and (Herzog, H. wait the people, Nucleic Acids Res., 18 (15), 4600 (1990); Kenmochi, N. waits the people, GenomeRes., 8 (5), 509-523 (1998); Lopez, C.D. waits the people, Cancer Lett.180 (2), 195-202 (2002)).Yet it is closely related from these results of study discovery GIG33 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG33 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:41 has an open reading frame (ORF) (terminator codon is represented in 404～406 base position) corresponding to 74～406 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 110 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:42 and the molecular weight of about 12kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:41.As another example, can use the random primer H-AP33 (5 '-AAGCTTGCTGCTC-3 ') of SEQ ID NO:43 and the oligo-dT anchor primer of SEQ ID NO:44 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 182-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line system, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 0.6kb size carry out overexpression.

12.GIG34

Gene of the present invention is the human tumor suppressor gene 34 (GIG34) with dna sequence dna of SEQ ID NO:45, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on October 1st, 2006), the dna sequence dna of the gene that this deposits in is similar to the human ribosomal protein L11 gene that is deposited in database with the number of including of BC018970 with the number of including of AY871274.Yet it is closely related from these results of study discovery GIG34 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG34 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:45 has an open reading frame (ORF) (terminator codon is represented in 536～538 base position) corresponding to 5～538 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 177 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:46 and the molecular weight of about 20kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:45.As another example, can use the random primer H-AP35 (5 '-AAGCTTCAGGGCA-3 ') of SEQ ID NO:47 and the oligo-dT anchor primer of SEQ ID NO:48 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 205-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

13.GIG35

Gene of the present invention is the human tumor suppressor gene 35 (GIG35) with dna sequence dna of SEQ ID NO:49, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human eukaryotic translation EF-1 γ (EEF1G) gene that is deposited in database with the number of including of NM_001404 with the number of including of AY542307.This gene is subunit's ((Kumabe, T. wait the people, Nucleic Acids Res., 20 (10), 2598 (1992)) of the EF-1 that plays an important role in being transported to aminoacyl-tRNA on the rrna.Yet it is closely related from these results of study discovery GIG35 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG35 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:49 has an open reading frame (ORF) (terminator codon is represented in 1,330～1,332 base position) corresponding to 19～1,332 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 437 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:50 and the molecular weight of about 50kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:49.As another example, can use the random primer H-AP3 (5 '-AAGCTTTGGTCAG-3 ') of SEQ ID NO:51 and the oligo-dT anchor primer of SEQ ID NO:52 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 212-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

14.GIG38

Gene of the present invention is the human tumor suppressor gene 38 (GIG38) with dna sequence dna of SEQ ID NO:53, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in and the human sin3 related polypeptide (18kDa) that is deposited in database with the number of including of NM_005870 be gene similar (SAP18) with the number of including of AY550970.Yet it is closely related from these results of study discovery GIG38 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG38 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:53 has an open reading frame (ORF) (terminator codon is represented in 476～478 base position) corresponding to 17～478 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 153 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:54 and the molecular weight of about 17kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:53.As another example, can use the random primer H-AP12 (5 '-AAGCTTGAGTGCT-3 ') of SEQ ID NO:55 and the oligo-dT anchor primer of SEQ ID NO:56 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 172-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, muscle, kidney, liver and placenta overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 0.7kb size carry out overexpression.

15.GIG39

Gene of the present invention is the human tumor suppressor gene 39 (GIG39) with dna sequence dna of SEQ ID NO:57, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human chromosomal 1 open reading frame 24 genes that deposited in database with the number of including of BC030531 with the number of including of AY550972.Yet it is closely related from these results of study discovery GIG39 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG39 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:57 has an open reading frame (ORF) (terminator codon is represented in 2,854～2,856 base position) corresponding to 70～2,856 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 928 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:58 and the molecular weight of about 103kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:57.As another example, can use the random primer H-AP12 (5 '-AAGCTTGAGTGCT-3 ') of SEQ ID NO:59 and the oligo-dT anchor primer of SEQ ID NO:60 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 327-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland and liver overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.4kb size carry out overexpression.

16.GIG40

Gene of the present invention is the human tumor suppressor gene 40 (GIG40) with dna sequence dna of SEQ ID NO:61, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), (EGFR) gene is similar to the human epidermal growth factor acceptor that is deposited in database with the number of including of NM_005228 (birds EBL virus (v-erb-b) oncogene autoploid) for the dna sequence dna of the gene that this deposits in the number of including of AY550966.Yet find the seldom expression during comprising the multiple human tumor of liver cancer of GIG40 cancer suppressor gene from these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:61 has an open reading frame (ORF) (terminator codon is represented in 3,677～3,679 base position) corresponding to 47～3,679 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 1,210 amino-acid residue, and it has the aminoacid sequence of SEQID NO:62 and the molecular weight of about 134kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:61.As another example, can use the random primer H-AP7 (5 '-AAGCTTAACGAGG-3 ') of SEQ ID NO:63 and the oligo-dT anchor primer of SEQ ID NO:64 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 275-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG40cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG40/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, heart and muscle overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.5kb size carry out overexpression.

17.GIG42

Gene of the present invention is the human tumor suppressor gene 42 (GIG42) with dna sequence dna of SEQ ID NO:65, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to the hsa gene that is deposited in database with the number of including of BC034023 with the number of including of AY550967.Yet find the expression during comprising the multiple human tumor of liver cancer of GIG42 cancer suppressor gene from these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:65 has an open reading frame (ORF) (terminator codon is represented in 1,835～1,837 base position) corresponding to 8～1,837 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 609 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:66 and the molecular weight of about 69kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:65.As another example, can use the random primer H-AP8 (5 '-AAGCTTTTACCGC-3 ') of SEQ ID NO:67 and the oligo-dT anchor primer of SEQ ID NO:68 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 327-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The present inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length GIG42cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG42/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.5kb size carry out overexpression.

18.GIG43

Gene of the present invention is the human tumor suppressor gene 43 (GIG43) with dna sequence dna of SEQ ID NO:69, its deposited in the number of including of AY550971 NIH (NIH) gene database (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in and the human phospholipase that is deposited in database with the number of including of BC028354 the similar of enzyme gene that creep.Yet it is closely related from these results of study discovery GIG43 genes and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from result of study discovery GIG43 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:69 has an open reading frame (ORF) (terminator codon is represented in 1,083～1,085 base position) corresponding to 96～1,085 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 329 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:70 and the molecular weight of about 37kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:69.As another example, can use the random primer H-AP10 (5 '-AAGCTTCCACGTA-3 ') of SEQ ID NO:71 and the oligo-dT anchor primer of SEQ ID NO:72 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 273-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, kidney, liver, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 3.5kb size carry out overexpression.

19.GIG46

Gene of the present invention is the human tumor suppressor gene 1 (GIG46) with dna sequence dna of SEQ ID NO:73, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on May 1st, 2006), (ACTA2) gene is similar for the dna sequence dna of the gene that this deposits in and the people's actin-like protein α 2 (unstriated muscle aorta) that is deposited in database with the number of including of NM_001613 with the number of including of AY692464.Yet it is, closely related by result of study discovery GIG46 gene and multiple human carcinogenesis with the functions reversed of report before it.Find the seldom expression during comprising the multiple human tumor of uterus carcinoma of GIG8 cancer suppressor gene from these results of study, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:73 has an open reading frame (ORF) (terminator codon is represented in 1,524～1,526 base position) corresponding to 393～1,526 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 377 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:74 and the molecular weight of about 42kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:73.As another example, can use the random primer H-AP16 (5 '-AAGCTTTAGAGCG-3 ') of SEQ ID NO:75 and the oligo-dT anchor primer of SEQ ID NO:76 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 255-bp cDNA fragment (corresponding to 1 by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), 323～1,577 base position), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in uterus, brain, heart, skeletal muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.5kb size carry out overexpression, except the mRNA transcript of 1.5kb, approximately the mRNA transcript of 2.0kb size is also expressed.

20.PIG33

Gene of the present invention is the human tumor suppressor gene (PIG33) with dna sequence dna of SEQ ID NO:77, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY513278, (mast9, hevin) gene is similar with the human SPARC sample 1 that is deposited in database with the number of including of BC033721 for the dna sequence dna of the gene that this deposits in.Yet find the seldom expression in comprising the multiple human tumor of liver cancer of PIG35 cancer suppressor gene by these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:77 has an open reading frame (ORF) (terminator codon is represented in 2,073～2,075 base position) corresponding to 81～2,075 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 664 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:78 and the molecular weight of about 75kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:77.As another example, can use the random primer H-AP2 (5 '-AAGCTTCGACTGT-3 ') of SEQ ID NO:79 and the oligo-dT anchor primer of SEQ ID NO:80 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 256-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

The present inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length PIG33cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG33/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, small intestine, placenta and lung overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 3.0kb size carry out overexpression.

21.PIG35

Gene of the present invention is the human tumor suppressor gene (PIG35) with dna sequence dna of SEQ ID NO:81, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human Serine (or halfcystine) protease inhibitor that is deposited in database with the number of including of NM_002615 with the number of including of AY513280.Yet find the seldom expression in comprising the multiple human tumor of mammary cancer of PIG35 cancer suppressor gene by these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:81 has an open reading frame (ORF) (terminator codon is represented in 1,304～1,306 base position) corresponding to 50～1,306 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 418 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:82 and the molecular weight of about 46kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:81.As another example, can use the random primer H-AP9 (5 '-AAGCTTCATTCCG-3 ') of SEQ ID NO:83 and the oligo-dT anchor primer of SEQ ID NO:84 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 312-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

The present inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length PIG35cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG35/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, heart, muscle, brain, small intestine, lung and placenta overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.7kb size carry out overexpression.

22.PIG36

Gene of the present invention is the human tumor suppressor gene (PIG36) with dna sequence dna of SEQ ID NO:85, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY544129, the dna sequence dna of the gene that this deposits in and the human ATP synthetic enzyme that is deposited in database with the number of including of NM_001685, H ⁺Transhipment, plastosome F0 complex body, subunit F6's (ATP5J) is similar.Yet find the seldom expression in comprising the multiple human tumor of liver cancer of PIG36 cancer suppressor gene by these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:85 has an open reading frame (ORF) (terminator codon is represented in 426～428 base position) corresponding to 102～428 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 108 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:86 and the molecular weight of about 13kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:85.As another example, can use the random primer H-AP9 (5 '-AAGCTTCATTCCG-3 ') of SEQ ID NO:87 and the oligo-dT anchor primer of SEQ ID NO:88 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 162-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length PIG36cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG36/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, heart, muscle, kidney and placenta overexpression to suppress carcinogenesis.Think that also its genetic expression is suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.0kb size carry out overexpression.

23.MIG20

The dna sequence dna of SEQ ID NO:89 deposited in the number of including of AY871271 NIH (NIH) gene database (date of publication of regulation: on October 1st, 2006), the dna sequence dna of the gene that this deposits in and the human mRNA who is deposited in database with the number of including of BX537651; CDNA DKFZp686C0390 gene similar.Yet find the expression in comprising the multiple human tumor of uterus carcinoma of MIG20 cancer suppressor gene by these results of study, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:89 has an open reading frame (ORF) (terminator codon is represented in 200～202 base position) corresponding to 8～202 base position of dna sequence dna.And the dna sequence dna of SEQ IDNO:89 has another open reading frame (ORF) (terminator codon is represented in 440～442 base position) corresponding to 233～442 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 64 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:90 and the molecular weight of about 7kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:89.As another example, can use the random primer H-AP32 (5 '-AAGCTTCCTGCAA-3 ') of SEQ ID NO:91 and the oligo-dT anchor primer of SEQ ID NO:92 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 311-bp cDNA fragment (corresponding to 2 by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), 067～2,377 base position), this fragment in cancerous tissue or cancerous cell line, do not express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in uterus, heart, skeletal muscle, kidney and liver overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 4.4kb size carry out overexpression, except the mRNA transcript of 4.4kb, approximately the mRNA transcript of 2.4kb and 1.5kb size is also expressed.

24.PIG49

Gene of the present invention is the human tumor suppressor gene (GIG49) with dna sequence dna of SEQ ID NO:93, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human ERBB2 transducer 1 (TOB1) gene that is deposited in database with the number of including of NM_005749 with the number of including of AY524047.Yet it is closely related by these results of study discovery GIG49 genes and multiple human oncogene.Result of study discovery GIG49 cancer suppressor gene is seldom expressed in comprising the multiple human tumor of mammary cancer or is not expressed, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:93 has an open reading frame (ORF) (terminator codon is represented in 1,046～1,048 base position) corresponding to 11～1,048 base position of dna sequence dna.Yet, because codon degeneracy, perhaps consider the codon-bias of organism expressing gene, gene of the present invention can carry out multiple modification in the coding region and not have to change a aminoacid sequence by the coding region expressed proteins, and can also be in the scope that does not influence genetic expression except carrying out multiple modification or change in the zone of coding region.The gene of this modification can also be within the scope of the invention.Therefore, the present invention also comprises polynucleotide and the gene fragment that has with the basic identical dna sequence dna of said gene.Term " essentially identical polynucleotide " refers to have the dna sequence dna of at least 80%, preferred at least 90% and most preferably at least 95% sequence homology.

Protein by genetic expression of the present invention is made up of 345 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:94 and the molecular weight of about 38kDa.And, even replace in the protein amino acid sequence in the scope that does not influence protein function, add or lack one or more amino acid, and can only use some protein according to their purposes.The aminoacid sequence of this change also comprises within the scope of the invention.Therefore, the present invention also comprises polypeptide and the fragment thereof with aminoacid sequence identical substantially with described protein.Term " essentially identical polypeptide " refers to have the polypeptide of at least 80%, preferred at least 90% and most preferably at least 95% sequence homology.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:93.As another example, can use the random primer H-AP10 (5 '-AAGCTTCCACGTA-3 ') of SEQ ID NO:95 and the oligo-dT anchor primer of SEQ ID NO:96 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 272-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Zhi Bei gene can insert as known in the art being used in the carrier that microorganism or zooblast are expressed thus, to obtain expression vector, then the DNA of described gene can massive duplication or by with the expression vector introducing as in the suitable host cell of intestinal bacteria (Escherichia coli), MCF-7 clone etc. and produce its protein with dimensions of market.When construction of expression vector, can suitably select and make up as the expression of promotor and terminator, autonomously replicating sequence, secretion signal etc. according to the kind of producer gene or proteinic host cell and regulate sequence.

Think gene of the present invention in healthy tissues, preferably in mammary gland, muscle, heart, kidney, liver and placenta overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 2.4kb size carry out overexpression.And except the mRNA transcript of 2.4kb, approximately the mRNA transcript of 1.5kb size is also expressed.

25.PIG51

Gene of the present invention is the human tumor suppressor gene (PIG51) with dna sequence dna of SEQ ID NO:97, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on December 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to human TBC1 territory family member 7 genes that deposited in database with the number of including of BC007054 with the number of including of AY542308.Yet it is closely related by these results of study discovery PIG51 genes and multiple human oncogene.Result of study discovery PIG51 cancer suppressor gene is seldom expressed in comprising the multiple human tumor of mammary cancer or is not expressed, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:97 has an open reading frame (ORF) (terminator codon is represented in 800～802 base position) corresponding to 59～802 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 247 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:98 and the molecular weight of about 28kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:97.As another example, can use the random primer H-AP22 (5 '-AAGCTTTTGATCC-3 ') of SEQ ID NO:99 and the oligo-dT anchor primer of SEQ ID NO:100 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 211-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, muscle, thymus gland, spleen, kidney, liver, placenta and peripheral blood leucocyte overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.0kb size carry out overexpression.

26.MIG12

Gene of the present invention is the human tumor suppressor gene (MIG12) with dna sequence dna of SEQ ID NO:101, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on March 31st, 2005), the dna sequence dna of the gene that this deposits in is similar to the human extrasin beta-10 gene that is deposited in database with the number of including of BC016731 with the number of including of AY453400.Yet find the seldom expression in comprising the multiple human tumor of lung cancer of MIG12 cancer suppressor gene by these results of study, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:101 has an open reading frame (ORF) (terminator codon is represented in 161～163 base position) corresponding to 29～163 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 44 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:102 and the molecular weight of about 5kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:101.As another example, can use the random primer H-AP12 (5 '-AAGCTTGAGTGCT-3 ') of SEQ ID NO:103 and the oligo-dT anchor primer of SEQ ID NO:104 (5 '-AAGCTTTTTTTTTTTC-3 ') to obtain 211-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in lung, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta and peripheral blood leucocyte overexpression to suppress carcinogenesis.

Gene of the present invention mainly in these tissues the mRNA transcript with about 0.5kb size carry out overexpression, except the mRNA transcript of 0.5kb, approximately the mRNA transcript of 1.0kb and 0.8kb size is also expressed.

27.PIG37

Gene of the present invention is the human tumor suppressor gene (PIG37) with dna sequence dna of SEQ ID NO:105, it is deposited in the gene database (date of publication of regulation: on December 31st, 2005) of NIH (NIH) with the number of including of AY513281, the dna sequence dna of the gene that this deposits in and the mankind 1 that deposited in database with the number of including of NM_002221,4,5-InsP3 3-kinase b (ITPKB) gene similar.Yet find the seldom expression in comprising the multiple human tumor of liver cancer of PIG37 cancer suppressor gene by these results of study, and its expression significantly improves in normal liver tissue.

The dna sequence dna of SEQ ID NO:105 has an open reading frame (ORF) (terminator codon is represented in 1,420～1,422 base position) corresponding to 4～1,422 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 472 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:106 and the molecular weight of about 53kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:105.As another example, can use the random primer H-AP10 (5 '-AAGCTTCCACGTA-3 ') of SEQ ID NO:107 and the oligo-dT anchor primer of SEQ ID NO:108 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 263-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.The inventor inserts expression vector pBAD/Thio-Topo (Invitrogen with total length PIG33cDNA, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG33/pBAD/Thio-Topo.

Think gene of the present invention in healthy tissues, preferably in liver, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, small intestine, placenta and lung overexpression to suppress carcinogenesis.Think that also gene of the present invention is suppressed in leukemia, uterus carcinoma, colorectal carcinoma, lung cancer and skin carcinoma, thereby cause carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 7.0kb size carry out overexpression.

28.GIG44

Gene of the present invention is the human tumor suppressor gene 44 (GIG44) with dna sequence dna of SEQ ID NO:109, its deposited in the number of including of AY971350 NIH (NIH) gene database (date of publication of regulation: on May 31st, 2006), the insulin like growth factor-1 I related protein gene that the dna sequence dna of the gene that this deposits in and the mankind that deposited in database with the number of including of BC042127 infer similar.Yet it is closely related by result of study discovery GIG44 gene and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from these results of study discoveries GIG44 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:109 has an open reading frame (ORF) (terminator codon is represented in 398～400 base position) corresponding to 59～400 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 113 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:110 and the molecular weight of about 12kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:109.As another example, can use the random primer H-AP12 (5 '-AAGCTTGAGTGCT-3 ') of SEQ ID NO:111 and the oligo-dT anchor primer of SEQ ID NO:112 (5 '-AAGCTTTTTTTTTTTG-3 ') to obtain 221-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, kidney, liver, placenta and lung overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.0kb size carry out overexpression.

29.GIG31

Gene of the present invention is the human tumor suppressor gene 31 (GIG31) with dna sequence dna of SEQ ID NO:113, it is deposited in the gene database of NIH (NIH), and (date of publication of regulation: on May 31st, 2006), the dna sequence dna of the gene that this deposits in is similar to human G-protein signal adjusting protein 2 genes that deposited in database with the number of including of NM_002923 with the number of including of AY971351.Yet it is closely related by result of study discovery GIG31 gene and multiple human carcinogenesis.During comprising the multiple human tumor of mammary cancer, seldom express or do not express from these results of study discoveries GIG31 cancer suppressor gene, and its expression significantly improves in multiple healthy tissues.

The dna sequence dna of SEQ ID NO:113 has an open reading frame (ORF) (terminator codon is represented in 647～649 base position) corresponding to 14～649 base position of dna sequence dna.

Protein by genetic expression of the present invention is made up of 211 amino-acid residues, and it has the aminoacid sequence of SEQ IDNO:114 and the molecular weight of about 24kDa.

Gene of the present invention can separate from tissue with protein, or can also synthesize according to the currently known methods that is used for synthetic DNA or peptide.For example, can screen and clone gene of the present invention according to conventional methods based on the information of dna sequence dna listed among the SEQ ID NO:113.As another example, can use the random primer H-AP4 (5 '-AAGCTTCTCAACG-3 ') of SEQ ID NO:115 and the oligo-dT anchor primer of SEQ ID NO:116 (5 '-AAGCTTTTTTTTTTTA-3 ') to obtain 223-bp cDNA fragment by using the total RNA that from healthy tissues and cancerous tissue or cancerous cell line, extracts to carry out inverse transcription polymerase chain reaction (RT-PCR), this fragment in cancerous tissue or cancerous cell line, do not express or seldom express and in healthy tissues differential expression, can carry out plaque hybridization to obtain full length cDNA clone with the cDNA library as the gained fragment of probe.

Think gene of the present invention in healthy tissues, preferably in mammary gland, heart, large intestine, spleen, small intestine, placenta, lung and peripheral blood leucocyte overexpression to suppress carcinogenesis.Gene of the present invention mainly in these tissues the mRNA transcript with about 1.4kb size carry out overexpression.

Simultaneously, because codon degeneracy, perhaps consider the codon-bias of organism expressing gene, gene of the present invention can carry out multiple modification in the coding region and not have to change a aminoacid sequence by the coding region expressed proteins, and can also be in the scope that does not influence genetic expression except carrying out multiple modification or change in the zone of coding region.The gene of this modification can also be within the scope of the invention.Therefore, the present invention also comprises polynucleotide and the gene fragment that has with the basic identical dna sequence dna of said gene.Term " essentially identical polynucleotide " refers to have the dna sequence dna of at least 80%, preferred at least 90% and most preferably at least 95% sequence homology.

And, even replace in the protein amino acid sequence in the scope that does not influence protein function, add or lack one or more amino acid, and can only use some protein according to their purposes.The aminoacid sequence of this modification also comprises within the scope of the invention.Therefore, the present invention also comprises polypeptide and the fragment thereof with aminoacid sequence identical substantially with described protein.Term " essentially identical polypeptide " refers to have the polypeptide of at least 80%, preferred at least 90% and most preferably at least 95% sequence homology.

In some embodiments, Zhi Bei gene of the present invention can insert as known in the art being used in the carrier that microorganism or zooblast are expressed thus, to obtain expression vector, the DNA of described gene can massive duplication or by expression vector being introduced as in the suitable host cell of intestinal bacteria, MCF-7 clone etc. and produce its protein with dimensions of market then.When construction of expression vector, can suitably select and make up as the expression of promotor and terminator, autonomously replicating sequence, secretion signal etc. according to the kind of producer gene or proteinic host cell and regulate sequence.

Particularly, gene of the present invention differential expression in healthy tissues only.For example, at cancerous tissue or cancer cells, as breast cancer tissue, breast cancer cell line MCF-7, leukemia cell, leukemia cell is the genetic expression that detects a little or detect in K562, liver cancer tissue, hepatoma cell line HepG2, cervical cancer, cervical cancer cell system, cancerous lung tissue, transfer cancerous lung tissue and the lung cancer cell line (A549 and NCI-H358) less than them, and only otherness ground raising in normal uterine tissue.

The cancerous cell line of introducing gene of the present invention presents high mortality, and therefore gene of the present invention can be used for the treatment of and anti-curing cancers effectively.

Hereinafter describe the present invention in detail with reference to preferred embodiment.Therefore, the description of Ti Chuing here only is the preferred embodiment that only is used for the illustrative purpose, and does not plan to limit the scope of the invention.

Reference example: the separation of total RNA

Use the total RNA test kit of RNeasy (Qiagen company, Germany) from flesh tissue or culturing cell, to separate total RNA sample, use message clean test kit (GenHunter company, MA, the U.S.) from the RNA sample, to remove contaminating dna then.

Embodiment 1: the separation of total RNA and mRNA otherness show

It is graphic as follows to observe the differential expression of gene in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line.

Normal galactophore tissue's sample is obtained by the patient with breast cancer during mastectomy, and the primary breast cancer tissue sample is being obtained by the patient with breast cancer who did not carry out radiotherapy and/or anticancer chemotherapy before surgical operation therapy during the radical mastectomy.Use MCF-7 (U.S. representative microbial DSMZ, ATCC HTB-22) as MCF-7.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

For the mRNA otherness of carrying out GIG15 shows, also from the normal human, obtain myeloid tissue, and when bone marrow biopsy, do not obtain primary leukemia myeloid tissue from carrying out anticancer chemotherapy and/or radiocurable leukaemic in the past.In the otherness display packing, use K-562 (U.S. representative microbial DSMZ, ATCC CCL-243) as people's chronic granulocytic leukemia clone.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

Simultaneously, under the situation of liver cancer related gene, the differential expression of observing gene in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line is graphic, as follows.

Normal liver tissue sample and liver cancer tissue sample are obtained by the liver cancer patient when the biopsy, use hepatoma cell line HepG2 (U.S. representative microbial DSMZ, ATCC HB-8065) as the Bel7402.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

The differential expression of also observing goal gene in normal ectocervix tissue, primary cervical cancer tissue and cervical cancer cell system is graphic, as follows.Normal ectocervix tissue sample is obtained by the patient who suffers from hysteromyoma during uterectomy, and primary cervical cancer tissue sample and transitivity iliac lymph nodes cancerous tissue sample are being obtained by the patient with breast cancer who did not carry out radiotherapy and/or anticancer chemotherapy before surgical operation therapy during the radical hysterectomy.Use CUMC-6 (Kim, people such as J.W., Gynecol.Oncol.62:230-240,1996) to be as human cervical carcinoma cell.According to from these tissues and cell, separating total RNA with same procedure described in reference example.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

Also in normal lung tissue, primary pulmonary cancerous tissue, transitivity cancerous lung tissue and lung cancer cell line, measure the differential expression of goal gene, as follows.Normal lung tissue's sample, cancerous lung tissue sample, transitivity cancerous lung tissue sample are obtained by the patients with lung cancer during surgical procedures.Use lung cancer cell line A549 (U.S. representative microbial DSMZ, ATCC CCL-185) and NCI-H358 (U.S. representative microbial DSMZ, ATCC CRL-5807) as the human lung cancer cell line.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

According to open text (Liang, P. and Pardee, A.B., Science, 257, 967-971 (1992); And Liang, people such as P., Cancer Res., 52, 6966-6968 (1993)) described in the method revised, use from tissue and cell isolating each total RNA sample to carry out RT-PCR and react, as follows.

1-1.GIG8

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:4 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:3 '-13-mer random primer H-AP33 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 1 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:3 '-13-mer random primer H-AP33 and SEQ ID NO:4.In Fig. 1,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in fig. 1, confirm that 163-bp cDNA fragment (total length GIG8 gene order 317～479 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal lung tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC33.

Remove the 163-bp band from dried glue, the FC33 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC33cDNA that increases again.The cDNA fragment FC33 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-2.GIG10

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:8 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:7 '-13-mer random primer H-AP10 (RNAimage primer to 2, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 2 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:7 '-13-mer random primer H-AP10 and SEQ ID NO:8.In Fig. 2,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 2, confirm that 321-bp cDNA fragment (total length GIG10 gene order 1,716～2,036 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal lung tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC42.

Remove the 321-bp band from dried glue, the FC42 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC42cDNA that increases again.The cDNA fragment FC42 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-3.GIG13

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:12 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:11 '-13-mer random primer H-AP5 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 3 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:11 '-13-mer random primer H-AP5 and SEQ ID NO:12.In Fig. 3,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 3, confirm that 347-bp cDNA fragment (total length GIG13 gene order 3,253～3,599 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC59.

Remove the 347-bp band from dried glue, the FC59 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC59cDNA that increases again.The cDNA fragment FC59 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-4.GIG15

Show for carrying out the mRNA otherness, also from the normal human, obtain myeloid tissue, and when bone marrow biopsy, do not obtain primary leukemia myeloid tissue from carrying out anticancer chemotherapy and/or radiocurable leukaemic in the past.In the otherness display packing, use K-562 (U.S. representative microbial DSMZ, ATCC CCL-243) as people's chronic granulocytic leukemia clone.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

According to open text (Liang, P. and Pardee, A.B., Science, 257, 967-971 (1992); And Liang, people such as P., CancerRes., 52, 6966-6968 (1993)) described in the method revised, use from tissue and cell isolating each total RNA sample to carry out RT-PCR and react, as follows.Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:16 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:15 '-13-mer random primer H-AP2 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 4 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:15 '-13-mer random primer H-AP2 and SEQ ID NO:16.As shown in Figure 4, usage variance show (DD) method confirm this gene in normal bone marrow tissue and leukemia cell and K-562 cell with the otherness horizontal expression.As shown in Figure 4,133-bp cDNA fragment, GV2 (total length GIG15 gene order 212～344 base position) seldom expresses in leukemia and K-562 cell, and only expresses in the normal bone marrow tissue higherly.This cDNA fragment is called GV2.Remove the 133-bp band from dried glue, the GV2 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the GV2cDNA that increases again.The cDNA fragment GV2 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-5.GIG16

The differential expression of observing gene in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line is graphic, as follows.

According to open text (Liang, P. and Pardee, A.B., Science, 257, 967-971 (1992); And Liang, people such as P., Cancer Res., 52, 6966-6968 (1993)) described in the method revised, use from tissue and cell isolating each total RNA sample to carry out RT-PCR and react, as follows.Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:20 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:19 '-13-mer random primer H-AP8 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 5 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:19 '-13-mer random primer H-AP8 and SEQ ID NO:20.In Fig. 5,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression liver gland cell system HepG2.As shown in Figure 5, confirm that 213-bp cDNA fragment (total length GIG16 gene order 867～1,079 base position) do not express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP8.

Remove the 213-bp band from dried glue, the HP8 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP8cDNA that increases again.The cDNA fragment HP8 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-6.GIG24

According to open text (Liang, P. and Pardee, A.B., Science, 257, 967-971 (1992); And Liang, people such as P., Cancer Res., 52, 6966-6968 (1993)) described in the method revised, use from tissue and cell isolating each total RNA sample to carry out RT-PCR and react, as follows.Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:24 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:23 '-13-mer random primer H-AP7 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 6 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:23 '-13-mer random primer H-AP7 and SEQ ID NO:24.In Fig. 6,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression liver gland cell system HepG2.As shown in Figure 6, confirm that 221-bp cDNA fragment (total length GIG42 gene order 1,057～1,277 base position) do not express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP71.

Remove the 221-bp band from dried glue, the HP71 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP71cDNA that increases again.The cDNA fragment HP71 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-7.GIG26

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:28 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:27 '-13-mer random primer H-AP11 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 7 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:27 '-13-mer random primer H-AP11 and SEQ ID NO:28.In Fig. 7,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression liver gland cell system HepG2.As shown in Figure 7, confirm that 204-bp cDNA fragment (total length GIG26 gene order 1,036～1,239 base position) do not express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP115.

Remove the 204-bp band from dried glue, the HP115 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP115cDNA that increases again.The cDNA fragment HP115 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-8.GIG29

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:32 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:31 '-13-mer random primer H-AP3 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 8 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:31 '-13-mer random primer H-AP3 and SEQ ID NO:32.In Fig. 8,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression liver gland cell system HepG2.As shown in Figure 8, confirm that 277-bp cDNA fragment (total length

GIG26 gene order

8,23～1,099 base position) do not express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP3.

Remove the 277-bp band from dried glue, the HP3 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP3cDNA that increases again.The cDNA fragment HP3 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-9.GIG30

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:36 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:35 '-13-mer random primer H-AP4 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Fig. 9 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:35 '-13-mer random primer H-AP4 and SEQ ID NO:36.In Fig. 9,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 9, confirm that 278-bp cDNA fragment (total length GIG30 gene order 1,452～1,739 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC48.

Remove the 278-bp band from dried glue, the FC48 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC48cDNA that increases again.The cDNA fragment FC48 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-10.GIG32

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:40 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:39 '-13-mer random primer H-AP8 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 10 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:39 '-13-mer random primer H-AP8 and SEQ ID NO:40.In Figure 10,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 10, confirm that 172-bp cDNA fragment (total length GIG32 gene order 428～599 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal breast, express with the level error opposite sex that improves.This cDNA fragment is called FC82.

Remove the 172-bp band from dried glue, the FC82 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC82cDNA that increases again.The cDNA fragment FC82 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-11.GIG33

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:44 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:43 '-13-mer random primer H-AP33 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 11 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:43 '-13-mer random primer H-AP33 and SEQ IDNO:44.In Figure 11,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 11, confirm that 182-bp cDNA fragment (total length GIG32 gene order 216～397 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC86.

Remove the 182-bp band from dried glue, the FC86 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC86cDNA that increases again.The cDNA fragment FC86 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-12.GIG34

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:48 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:47 '-13-mer random primer H-AP35 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 12 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:47 '-13-mer random primer H-AP35 and SEQ IDNO:48.In Figure 12,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 12, confirm that 205-bp cDNA fragment (total length GIG34 gene order 343～547 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC35.

Remove the 205-bp band from dried glue, the FC42 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC35cDNA that increases again.The cDNA fragment FC35 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-13.GIG35

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:52 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:51 '-13-mer random primer H-AP3 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 13 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:51 '-13-mer random primer H-AP3 and SEQ ID NO:52.In Figure 13,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 13, confirm that 212-bp cDNA fragment (total length GIG35 gene order 1,108～1,319 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC38.

Remove the 212-bp band from dried glue, the FC38 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC38cDNA that increases again.The cDNA fragment FC38 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-14.GIG38

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:56 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:55 '-13-mer random primer H-AP12 (RNAimage primer to 2, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 14 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:55 '-13-mer random primer H-AP12 and SEQ IDNO:56.In Figure 14,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 14, confirm that 172-bp cDNA fragment (total length GIG38 gene order 328～499 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC122.

Remove the 172-bp band from dried glue, the FC122 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC122cDNA that increases again.The cDNA fragment FC122 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-15.GIG39

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:60 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:59 '-13-mer random primer H-AP12 (RNAimage primer to 2, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 15 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:59 '-13-mer random primer H-AP12 and SEQ IDNO:60.In Figure 15,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 15, confirm that 327-bp cDNA fragment (total length GIG39 gene order 2,553～2,859 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC126.

Remove the 327-bp band from dried glue, FC 126 fragments are boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC126cDNA that increases again.The cDNA fragment FC126 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-16.GIG40

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:64 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:63 '-13-mer random primer H-AP7 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 16 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:63 '-13-mer random primer H-AP7 and SEQ ID NO:64.In Figure 16,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression liver gland cell system HepG2.As shown in Figure 16, confirm that 275-bp cDNA fragment (total length GIG40 gene order 3,112～3,386 base position) seldom expresses in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP79.

Remove the 275-bp band from dried glue, the HP79 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP79cDNA that increases again.The cDNA fragment HP79 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-17.GIG42

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:68 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:67 '-13-mer random primer H-AP8 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 17 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:67 '-13-mer random primer H-AP8 and SEQ ID NO:68.In Figure 17,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression hepatoma cell line HepG2.As shown in Figure 17, confirm that 327-bp cDNA fragment (total length GIG42 gene order 1,473～1,799 base position) do not express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP85.

Remove the 327-bp band from dried glue, the HP85 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP85cDNA that increases again.The cDNA fragment HP85 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-18.GIG43

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:72 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:71 '-13-mer random primer H-AP10 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 18 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:71 '-13-mer random primer H-AP10 and SEQ IDNO:72.In Figure 18,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 18, confirm that 273-bp cDNA fragment (total length GIG43 gene order 727～999 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC102.

Remove the 273-bp band from dried glue, the FC102 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC102cDNA that increases again.The cDNA fragment FC102 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-19.GIG46

In normal ectocervix tissue, primary cervical cancer tissue and cervical cancer cell system, observe the differential expression of goal gene, as follows.Normal ectocervix tissue sample is obtained by the patient who suffers from hysteromyoma during uterectomy, and primary cervical cancer tissue sample and transitivity iliac lymph nodes cancerous tissue sample are being obtained by the patient with breast cancer who did not carry out radiotherapy and/or anticancer chemotherapy before surgical operation therapy during the radical hysterectomy.Use CUMC-6 (Kim, people such as J.W., Gynecol.Oncol.62:230-240,1996) to be as human cervical carcinoma cell.According to from these tissues and cell, separating total RNA with same procedure described in reference example.

According to open text (Liang, P. and Pardee, A.B., Science, 257, 967-971 (1992); And Liang, people such as P., CancerRes., 52, 6966-6968 (1993)) described in the method revised, use from tissue and cell isolating each total RNA sample to carry out RT-PCR and react, as follows.Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:76 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:75 '-13-mer random primer H-AP16 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 19 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:75 '-13-mer random primer H-AP16 and SEQ IDNO:76.In Figure 19, the normal ectocervix tissue of swimming lane 1 expression; Swimming lane 2 expression cervical cancer tissues; Swimming lane 3 expression transitivity iliac lymph nodes tissues; And swimming lane 4 expression cervical cancer cells are CUMC-6.As shown in Figure 19, confirm that 255-bp cDNA fragment is not express among the CUMC-6 at cervical cancer tissue, transitivity iliac lymph nodes tissue and cervical cancer cell, and differential expression in normal ectocervix tissue only.This cDNA fragment is called CA161.

Remove the 255-bp band from dried glue, the CA161 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the CA161cDNA that increases again.The cDNA fragment CA161 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-20.PIG33

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:80 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:79 '-13-mer random primer H-AP2 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 20 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:79 '-13-mer random primer H-AP2 and SEQ ID NO:80.In Figure 20,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression hepatoma cell line HepG2.As shown in Figure 20, confirm that 256-bp cDNA fragment (total length PIG33 gene order 1,623～1,878 base position) do not express or seldom express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP29.

Remove the 256-bp band from dried glue, the HP29 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP29cDNA that increases again.The cDNA fragment HP29 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-21.PIG35

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:84 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:83 '-13-mer random primer H-AP9 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 21 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:83 '-13-mer random primer H-AP9 and SEQ ID NO:84.In Figure 21,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression hepatoma cell line HepG2.As shown in Figure 21, confirm that 312-bp cDNA fragment (total length PIG35 gene order 966～1,277 base position) do not express or seldom express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP95.

Remove the 312-bp band from dried glue, the HP95 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP95cDNA that increases again.The cDNA fragment HP95 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-22.PIG36

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:88 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:87 '-13-mer random primer H-AP9 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 22 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:87 '-13-mer random primer H-AP9 and SEQ ID NO:88.In Figure 22,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression hepatoma cell line HepG2.As shown in Figure 22, confirm that 162-bp cDNA fragment (total length PIG36 gene order 238～399 base position) do not express or seldom express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP96.

Remove the 162-bp band from dried glue, the HP96 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP96cDNA that increases again.The cDNA fragment HP96 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemicai company) to measure its dna sequence dna then.

1-23.MIG20

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:92 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:91 '-13-mer random primer H-AP32 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 23 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:91 '-13-mer random primer H-AP32 and SEQ IDNO:92.In Figure 23, the normal ectocervix tissue of swimming lane 1 expression; Swimming lane 2 expression cervical cancer tissues; Swimming lane 3 expression transitivity iliac lymph nodes tissues; And swimming lane 4 expression cervical cancer cells are CUMC-6.As shown in Figure 23, confirm that 311-bp cDNA fragment is not express among the CUMC-6 at cervical cancer tissue, transitivity iliac lymph nodes tissue and cervical cancer cell, and differential expression in normal ectocervix tissue only.This cDNA fragment is called CA324.

Remove the 311-bp band from dried glue, the CA324 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the CA324cDNA that increases again.The cDNA fragment CA324 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-24.PIG49

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:96 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:95 '-13-mer random primer H-AP10 (RNAimage primer to 2, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 24 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:95 '-13-mer random primer H-AP10 and SEQ IDNO:96.In Figure 24,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 24, confirm that 272-bp cDNA fragment (total length PIG49 gene order 767～1,038 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC101.

Remove the 272-bp band from dried glue, the FC101 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC101cDNA that increases again.The cDNA fragment FC101 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-25.PIG51

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:100 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:99 '-13-mer random primer H-AP22 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 25 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:99 '-13-mer random primer H-AP22 and SEQ IDNO:100.In Figure 25,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 25, confirm that 211-bp cDNA fragment (total length PIG51 gene order 519～729 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC22.

Remove the 211-bp band from dried glue, the FC22 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC22cDNA that increases again.The cDNA fragment FC22 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-26.MIG12

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:104 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:103 '-13-mer random primer H-AP12 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 26 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:103 '-13-mer random primer H-AP12 and SEQ IDNO:104.In Figure 26, swimming lane 1 expression normal lung tissue; Swimming lane 2 expression cancerous lung tissues; Swimming lane 3 expression transitivity cancerous lung tissues; And swimming lane 4 expression lung cancer cell line A549.As shown in Figure 26, confirm that 161-bp cDNA fragment (total length MIG12 gene order 35～195 base position) seldom expresses in cancerous lung tissue, transitivity cancerous lung tissue and lung cancer cell line, and differential expression in normal lung tissue only.This cDNA fragment is called L927.

Remove the 161-bp band from dried glue, the L927 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the L927cDNA that increases again.The cDNA fragment L927 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-27.PIG37

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:108 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:107 '-13-mer random primer H-AP10 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 27 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:107 '-13-mer random primer H-AP10 and SEQ IDNO:108.In Figure 27,

swimming lane

1,2 and 3 expression normal liver tissues;

Swimming lane

4,5 and 6 expression liver cancer tissues; And swimming lane 7 expression hepatoma cell line HepG2.As shown in Figure 27, confirm that 263-bp cDNA fragment (total length PIG37 gene order 1,217～1,479 base position) do not express or seldom express in liver cancer tissue and hepatoma cell line, and differential expression in normal liver tissue only.This cDNA fragment is called HP102.

Remove the 263-bp band from dried glue, the HP102 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the HP102cDNA that increases again.The cDNA fragment HP102 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-28.GIG44

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:112 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:111 '-13-mer random primer H-AP12 (RNAimage primer to 5, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 28 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:111 '-13-mer random primer H-AP12 and SEQ IDNO:112.In Figure 28,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 28, confirm that 221-bp cDNA fragment (total length GIG44 gene order 179～399 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC123.

Remove the 221-bp band from dried glue, the FC123 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC123cDNA that increases again.The cDNA fragment FC123 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

1-29.GIG31

Use test kit (the RNAimage test kit, GenHunter) the oligo-dT anchor primer by SEQ ID NO:116 is the total RNA reverse transcription of 0.2 μ g, then 0.5mM[α- ³⁵S] mark dATP (1, under existence 200Ci/mmol), use 5 of identical oligo-dT anchor primer and SEQ ID NO:115 '-13-mer random primer H-AP4 (RNAimage primer to 1, GenHunter company, the U.S.) to carry out the PCR reaction.Carry out PCR reaction below under the condition: 40 amplification cycles altogether, each circulation is made up of 95 ℃ of following denaturing steps of 40 seconds, 40 ℃ of following annealing steps of 2 minutes and 72 ℃ of extension steps of following 40 seconds, follows one 72 ℃ following 5 minutes extension steps.Amplified fragments is in 6% the polyacrylamide gel electrophoresis that is used for the DNA base sequence, radioautograph then.

Figure 29 represents to use the PCR result of the oligo-dT anchor primer of 5 of SEQ ID NO:115 '-13-mer random primer H-AP4 and SEQ IDNO:116.In Figure 29,

swimming lane

1,2 and 3 expression normal galactophore tissues;

Swimming lane

4,5 and 6 expression breast cancer tissues; And swimming lane 7 expression breast cancer cell line MCF-7.As shown in Figure 29, confirm that 223-bp cDNA fragment (total length GIG31 gene order 445～667 base position) seldom expresses in breast cancer tissue and breast cancer cell line, and only in normal galactophore tissue, express with the level error opposite sex that improves.This cDNA fragment is called FC47.

Remove the 223-bp band from dried glue, the FC47 fragment is boiled 15 minutes with wash-out cDNA, then except here do not use [α- ³⁵S] outside the dATP and 20 μ M dNTP of mark, under identical described condition, use aforesaid same primers as to carrying out the PCR reaction, with the FC47cDNA that increases again.The cDNA fragment FC47 that uses TA cloning system (Promega) to increase again clones among the expression vector pGEM-T Easy, uses Sequenase Version 2.0DNA sequencing system (U.S. Biochemical company) to measure its dna sequence dna then.

Embodiment 2: the cDNA library screening

According to open text (Feinberg, A.P. and Vogelstein, B., Anal.Biochem., 132, 6-13 (1983)) method respectively with the cDNA fragment FC33, FC42, FC59, GV2, H-AP8, HP71, HP115, HP3, FC48, FC82, FC86, FC35, FC38, FC122, FC126, HP79, HP85, FC102, CA161, HP29, HP95, HP96, CA324, FC101, FC22, L927, HP102, FC123 and the FC47 mark that obtain among the embodiment 1-1 to obtain ³²Probe FC33, FC42, FC59, GV2, H-AP8, HP71, HP115, HP3, FC48, FC82, FC86, FC35, FC38, FC122, FC126, HP79, HP85, FC102, CA161, HP29, HP95, HP96, CA324, FC101, FC22, L927, HP102, FC123 and the FC47cDNA of P mark, according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, the method described in the NewYork:Cold Spring Harbor Laboratory (1989) will ³²The probe of P mark and phage gt11 human embryonic lung fibroblast cDNA library (Miki, people such as T., Gene, 83,137-146 (1989)) carry out plaque hybridization to obtain the full length cDNA clone of human tumor suppressor gene GIG.

With the full length cDNA clone order-checking, so the DNA base sequencing result of GIG8 is consistent with SEQ ID NO:1.The dna sequence dna of GIG8 has the open reading frame of 134 amino-acid residues of coding, and is consistent with SEQ ID NO:2 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 15kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG8 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 30 illustrates the figure that the proteic SDS-PAGE of GIG8 analyzes.In Figure 30, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG8 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 30, the GIG8 protein of expression has the molecular weight of about 15kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG10 is consistent with SEQ ID NO:5.The dna sequence dna of GIG10 has the open reading frame of 665 amino-acid residues of coding, and is consistent with SEQ ID NO:6 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 73kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG10 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 31 illustrates the figure that the proteic SDS-PAGE of GIG10 analyzes.In Figure 31, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG10 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 31, the GIG10 protein of expression has the molecular weight of about 73kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG13 is consistent with SEQ ID NO:9.The dna sequence dna of GIG13 has the open reading frame of 1,201 amino-acid residue of coding, and is consistent with SEQ ID NO:10 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 132kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG13 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 32 illustrates the figure that the proteic SDS-PAGE of GIG13 analyzes.In Figure 32, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG13 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 32, the GIG13 protein of expression has the molecular weight of about 132kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG15 is consistent with SEQ ID NO:13.The dna sequence dna of GIG15 has the open reading frame of 106 amino-acid residues of coding, and is consistent with SEQ ID NO:14 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 12kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG15 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 33 illustrates the figure that the proteic SDS-PAGE of GIG15 analyzes.In Figure 33, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG15 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 33, the GIG15 protein of expression has the molecular weight of about 12kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG16 is consistent with SEQ ID NO:17.The dna sequence dna of GIG16 has the open reading frame of 351 amino-acid residues of coding, and is consistent with SEQ ID NO:18 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 39kDa.The total length GIG 16cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG16/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG16 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 34 illustrates the figure that the proteic SDS-PAGE of GIG16 analyzes.In Figure 34, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG16 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 34, the GIG16 protein of expression has the molecular weight of about 39kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG24 is consistent with SEQ ID NO:21.The dna sequence dna of GIG24 has the open reading frame of 423 amino-acid residues of coding, and is consistent with SEQ ID NO:22 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 47kDa.The total length GIG24cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG24/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG24 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 35 illustrates the figure that the proteic SDS-PAGE of GIG24 analyzes.In Figure 35, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG24 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 35, the GIG24 protein of expression has the molecular weight of about 47kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG26 is consistent with SEQ ID NO:25.The dna sequence dna of GIG26 has the open reading frame of 442 amino-acid residues of coding, and is consistent with SEQ ID NO:26 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 50kDa.The total length GIG26cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG26/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG26 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 36 illustrates the figure that the proteic SDS-PAGE of GIG24 analyzes.In Figure 36, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG26 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 36, the GIG26 protein of expression has the molecular weight of about 50kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG29 is consistent with SEQ ID NO:29.The dna sequence dna of GIG29 has the open reading frame of 349 amino-acid residues of coding, and is consistent with SEQ ID NO:30 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 38kDa.The total length GIG29cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG29/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG29 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 37 illustrates the figure that the proteic SDS-PAGE of GIG29 analyzes.In Figure 37, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG29 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 37, the GIG29 protein of expression has the molecular weight of about 38kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG30 is consistent with SEQ ID NO:33.The dna sequence dna of GIG30 has the open reading frame of 540 amino-acid residues of coding, and is consistent with SEQ ID NO:34 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 61kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG30 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 38 illustrates the figure that the proteic SDS-PAGE of GIG30 analyzes.In Figure 38, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG30 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 38, the GIG30 protein of expression has the molecular weight of about 61kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG32 is consistent with SEQ ID NO:37.The dna sequence dna of GIG32 has the open reading frame of 178 amino-acid residues of coding, and is consistent with SEQ ID NO:38 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 20kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG32 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 39 illustrates the figure that the proteic SDS-PAGE of GIG32 analyzes.In Figure 39, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG32 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 39, the GIG32 protein of expression has the molecular weight of about 20kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG33 is consistent with SEQ ID NO:41.The dna sequence dna of GIG33 has the open reading frame of 110 amino-acid residues of coding, and is consistent with SEQ ID NO:42 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 12kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG34 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 40 illustrates the figure that the proteic SDS-PAGE of GIG33 analyzes.In Figure 40, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG33 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 10, the GIG33 protein of expression has the molecular weight of about 12kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG34 is consistent with SEQ ID NO:45.The dna sequence dna of GIG34 has the open reading frame of 177 amino-acid residues of coding, and is consistent with SEQ ID NO:46 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 20kDa.

Figure 41 illustrates the figure that the proteic SDS-PAGE of GIG34 analyzes.In Figure 41, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG34 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 41, the GIG34 protein of expression has the molecular weight of about 20kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG35 is consistent with SEQ ID NO:49.The dna sequence dna of GIG35 has the open reading frame of 437 amino-acid residues of coding, and is consistent with SEQ ID NO:50 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 50kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG35 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 42 illustrates the figure that the proteic SDS-PAGE of GIG35 analyzes.In Figure 42, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG35 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 42, the GIG35 protein of expression has the molecular weight of about 50kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG38 is consistent with SEQ ID NO:53.The dna sequence dna of GIG38 has the open reading frame of 153 amino-acid residues of coding, and is consistent with SEQ ID NO:54 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 17kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG38 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 43 illustrates the figure that the proteic SDS-PAGE of GIG38 analyzes.In Figure 43, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG38 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 43, the GIG38 protein of expression has the molecular weight of about 17kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG39 is consistent with SEQ ID NO:57.The dna sequence dna of GIG39 has the open reading frame of 928 amino-acid residues of coding, and is consistent with SEQ ID NO:58 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 103kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG39 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 44 illustrates the figure that the proteic SDS-PAGE of GIG39 analyzes.In Figure 44, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG39 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 44, the GIG39 protein of expression has the molecular weight of about 103kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG40 is consistent with SEQ ID NO:61.The dna sequence dna of GIG40 has the open reading frame of 1,210 amino-acid residue of coding, and is consistent with SEQ ID NO:62 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 134kDa.The total length GIG40cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG40/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG40 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 45 illustrates the figure that the proteic SDS-PAGE of GIG40 analyzes.In Figure 45, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG40 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 45, the GIG40 protein of expression has the molecular weight of about 134kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG42 is consistent with SEQ ID NO:65.The dna sequence dna of GIG42 has the open reading frame of 609 amino-acid residues of coding, and is consistent with SEQ ID NO:66 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 69kDa.The total length GIG42cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/GIG42/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG42 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 46 illustrates the figure that the proteic SDS-PAGE of GIG42 analyzes.In Figure 46, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG42 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 46, the GIG42 protein of expression has the molecular weight of about 69kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG43 is consistent with SEQ ID NO:69.The dna sequence dna of GIG43 has the open reading frame of 329 amino-acid residues of coding, and is consistent with SEQ ID NO:70 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 37kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG43 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 47 illustrates the figure that the proteic SDS-PAGE of GIG43 analyzes.In Figure 47, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG43 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 47, the GIG43 protein of expression has the molecular weight of about 37kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG46 is consistent with SEQ ID NO:73.The dna sequence dna of GIG46 has the open reading frame of 377 amino-acid residues of coding, and is consistent with SEQ ID NO:74 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 42kDa.

The total length GIG46cDNA clone who obtains is inserted prokaryotic expression carrier pBAD/thio-Topo (Invitrogen, the U.S.) multiple clone site, to obtain carrier pBAD/Thio-Topo/GIG46, use the pBAD/thio-Topo/GIG46 transformed into escherichia coli Top10 (Invitrogen, the U.S.) of gained then.Expressing protein HT-Trx inserts the upstream of carrier pBAD/thio-Topo multiple clone site.The coli strain shaking culture in the LB liquid nutrient medium that transforms with the substratum dilution 1/100 of gained, and then was cultivated 3 hours.In the substratum of cultivating, add the generation of 0.5mM L-arabinose (Sigma, the U.S.) with induced protein.Bacillus coli cells in the substratum before L-arabinose is induced and ultrasonication afterwards, is carried out 12% SDS-PAGE (SDS-PAGE) with the homogenate of ultrasonication then.Figure 48 is the figure that the protein expression of the intestinal bacteria Top10 strain of using carrier pBAD/thio-Topo/GIG46 conversion of using SDS-PAGE is shown, and wherein obviously observes a fusion rotein band with molecular weight of about 57kDa after L-arabinose is induced.The fusion rotein of 57kDa comprises the HT-Trx albumen of the about 15kDa that inserts carrier pBAD/thio-Topo/GIG46 and GIG 46 albumen of about 42kDa.

Figure 48 illustrates the figure that the proteic SDS-PAGE of GIG46 analyzes.In Figure 48, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG46 genes are by the protein example behind the L-arabinose abduction delivering.

The DNA base sequencing result of PIG33 is consistent with SEQ ID NO:77.The dna sequence dna of PIG33 has the open reading frame of 664 amino-acid residues of coding, and is consistent with SEQ ID NO:78 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 75kDa.The total length PIG33cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG33/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG33 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 49 illustrates the figure that the proteic SDS-PAGE of PIG33 analyzes.In Figure 49, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG33 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 49, the PIG33 protein of expression has the molecular weight of about 75kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of PIG35 is consistent with SEQ ID NO:81.The dna sequence dna of PIG35 has the open reading frame of 418 amino-acid residues of coding, and is consistent with SEQ ID NO:82 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 46kDa.The total length PIG35cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG35/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG35 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 50 illustrates the figure that the proteic SDS-PAGE of PIG35 analyzes.In Figure 50, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG35 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 50, the PIG35 protein of expression has the molecular weight of about 46kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of PIG36 is consistent with SEQ ID NO:85.The dna sequence dna of PIG36 has the open reading frame of 108 amino-acid residues of coding, and is consistent with SEQ ID NO:86 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 13kDa.The total length PIG36cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG36/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG36 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 51 illustrates the figure that the proteic SDS-PAGE of PIG36 analyzes.In Figure 51, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG36 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 51, the PIG36 protein of expression has the molecular weight of about 13kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of MIG20 is consistent with SEQ ID NO:89.The dna sequence dna of MIG20 has the open reading frame of 64 amino-acid residues of coding, and is consistent with SEQ ID NO:90 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 7kDa.

The total length MIG20cDNA clone who obtains is inserted prokaryotic expression carrier pBAD/thio-Topo (Invitrogen, the U.S.) multiple clone site, to obtain carrier pBAD/thio-Topo/MIG20, use the pBAD/thio-Topo/MIG20 transformed into escherichia coli Top10 (Invitrogen, the U.S.) of gained then.Expressing protein HT-Trx inserts the upstream of carrier pBAD/thio-Topo multiple clone site.The coli strain shaking culture in the LB liquid nutrient medium that transforms with the substratum dilution 1/100 of gained, and then was cultivated 3 hours.In the substratum of cultivating, add the generation of 0.5mM L-arabinose (Sigma, the U.S.) with induced protein.Bacillus coli cells in the substratum before L-arabinose is induced and ultrasonication afterwards, is carried out 12% SDS-PAGE (SDS-PAGE) with the homogenate of ultrasonication then.Figure 52 is the figure that the protein expression of the intestinal bacteria Top10 strain of using carrier pBAD/thio-Topo/MIG20 conversion of using SDS-PAGE is shown, and wherein obviously observes a fusion rotein band with molecular weight of about 22kDa after L-arabinose is induced.The fusion rotein of 22kDa comprises the HT-Trx albumen of the about 15kDa that inserts carrier pBAD/thio-Topo/MIG20 and the MIG20 albumen of about 7kDa.

Figure 52 illustrates the figure that the proteic SDS-PAGE of MIG20 analyzes.In Figure 52, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression MIG20 genes are by the protein example behind the L-arabinose abduction delivering.

The DNA base sequencing result of PIG49 is consistent with SEQ ID NO:93.The dna sequence dna of PIG49 has the open reading frame of 345 amino-acid residues of coding, and is consistent with SEQ ID NO:94 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 38kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG49 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 53 illustrates the figure that the proteic SDS-PAGE of PIG49 analyzes.In Figure 53, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG49 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 53, the PIG49 protein of expression has the molecular weight of about 38kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of PIG51 is consistent with SEQ ID NO:97.The dna sequence dna of PIG51 has the open reading frame of 247 amino-acid residues of coding, and is consistent with SEQ ID NO:98 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 28kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG51 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 54 illustrates the figure that the proteic SDS-PAGE of PIG51 analyzes.In Figure 54, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG51 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 54, the PIG51 protein of expression has the molecular weight of about 28kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of MIG12 is consistent with SEQ ID NO:101.The dna sequence dna of MIG12 has the open reading frame of 44 amino-acid residues of coding, and is consistent with SEQ ID NO:102 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 5kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the MIG12 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 55 illustrates the figure that the proteic SDS-PAGE of MIG12 analyzes.In Figure 55, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression MIG12 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 55, the MIG12 protein of expression has the molecular weight of about 5kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of PIG37 is consistent with SEQ ID NO:105.The dna sequence dna of PIG37 has the open reading frame of 472 amino-acid residues of coding, and is consistent with SEQ ID NO:106 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 53kDa.The total length PIG37cDNA that obtains is inserted prokaryotic expression carrier pBAD/Thio-Topo (Invitrogen, the U.S.), the expression vector transformed into escherichia coli DH5 α that uses gained then is to obtain transformant, and it is called bacillus coli DH 5 alpha/PIG37/pBAD/Thio-Topo.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the PIG37 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 56 illustrates the figure that the proteic SDS-PAGE of PIG37 analyzes.In Figure 56, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression PIG37 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 56, the PIG37 white matter of expression has the molecular weight of about 53kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG44 is consistent with SEQ ID NO:109.The dna sequence dna of GIG44 has the open reading frame of 113 amino-acid residues of coding, and is consistent with SEQ ID NO:110 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 12kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG44 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 57 illustrates the figure that the proteic SDS-PAGE of GIG44 analyzes.In Figure 57, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG44 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 57, the GIG44 protein of expression has the molecular weight of about 12kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

The DNA base sequencing result of GIG31 is consistent with SEQ ID NO:113.The dna sequence dna of GIG31 has the open reading frame of 211 amino-acid residues of coding, and is consistent with SEQ ID NO:114 from the aminoacid sequence of this open reading frame.The protein that obtains also has the molecular weight of about 24kDa.

The coli strain that transforms is cultivated in the LB liquid nutrient medium, then 1mM sec.-propyl-β-D-thio-galactose pyran-glucoside (IPTG) is added in the substratum, and reacts 3 hours to express the GIG31 gene at 37 ℃.Obtain protein example from substratum, then according to open text (Sambrook, J. wait the people, Molecular Cloning:A Laboratory manual, New York:Cold Spring HarborLaboratory (1989)) method described in is carried out the SDS-PAGE electrophoresis with this protein example.

Figure 58 illustrates the figure that the proteic SDS-PAGE of GIG31 analyzes.In Figure 58, the protein example before swimming lane 1 expression IPTG induces, swimming lane 2 expression GIG31 genes are by the protein example behind the IPTG abduction delivering.As shown in Figure 58, the GIG31 protein of expression has the molecular weight of about 24kDa, and it is corresponding to the proteinic molecular weight from its dna sequence dna.

Embodiment 3: the RNA trace of GIG gene

3-1.GIG8, GIG10, GIG13, GIG30, GIG32, GIG33, GIG34, GIG35, GIG38, GIG39, GIG43, PIG49, PIG51, GIG44 and GIG31

For estimating GIG and PIG expression of gene level, carry out the RNA trace, as follows.

Respectively each total RNA sample sex change that 20 μ g are obtained from three normal galactophore tissues, three primary breast cancerous tissues and breast cancer cell line MCF-7 in

embodiment

1 and 1% formaldehyde agarose gel electrophoresis, the sepharose that obtains is transferred on the nylon membrane (Boehringer-Mannheim, Germany) then.Then with nylon membrane preparation with using Rediprime II random primer labelling system (Amersham, Britain) by partial sequence FC33, the FC42 of total length GIG cDNA, FC59, FC48, FC82, FC86, FC35, FC38, FC122, FC126, FC102, FC101, FC22, FC123 and FC47 ³²The hybridization under 42 ℃ of the random primer probe of P mark is spent the night.RNA trace step repeats twice, and one of them is to use photodensitometer that trace is quantitative, and another is to make trace and beta-actin probe hybridization to determine the total amount of mRNA.

Figure 59 shows the RNA trace result of GIG8 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 59 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in the bottom of Figure 59 and Figure 59, confirm that GIG8 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Carry out the RNA trace at a plurality of tissues of normal people (Clontech) and human carcinoma cell line (Clontech).In other words, by with identical as mentioned above method, the trace of each total RNA sample transfer above it that extracts from healthy tissues and cancerous cell line hybridized carry out the RNA trace, wherein said trace can be commercial available from Clontech company (U.S.), healthy tissues for example is selected from by brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta, the group that lung and peripheral blood leucocyte are formed, and cancerous cell line for example is selected from by promyelocytic leukemia cell HL-60, the HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4 (lymphoblastoidleukemia MOLT-4), Burkitt lymphoma Raji cell, the SW480 colon cancer cell, the group that A549 lung carcinoma cell and G361 melanoma cell are formed.

Figure 88 shows the RNA trace result of GIG8 gene differential expression in multiple healthy tissues, and the bottom of Figure 88 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 88, has main GIG8mRNA transcript overexpression in of about 1.3kb size as the healthy tissues of brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.Simultaneously, has the GIG8mRNA transcript of about 2.5kb size also at normal tissue expression as liver and peripheral blood.Figure 117 shows the RNA trace result of GIG8 gene differential expression in multiple cancerous cell line, and the bottom of Figure 117 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 117, the GIG8 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG8 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta, lung, large intestine and peripheral blood.

Figure 60 shows the RNA trace result of GIG10 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 60 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 60, confirm that GIG10 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Carry out the RNA trace at a plurality of tissues of normal people (Clontech) and human carcinoma cell line (Clontech).In other words, by with identical as mentioned above method, the trace of each total RNA sample transfer above it that extracts from healthy tissues and cancerous cell line hybridized carry out the RNA trace, wherein said trace can be commercial available from Clontech company (U.S.), healthy tissues for example is selected from by brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta, the group that lung and peripheral blood leucocyte are formed, and cancerous cell line for example is selected from by promyelocytic leukemia cell HL-60, the HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, the SW480 colon cancer cell, the group that A549 lung carcinoma cell and G361 melanoma cell are formed.

Figure 89 shows the RNA trace result of GIG10 gene differential expression in multiple healthy tissues, and the bottom of Figure 89 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 89, have main GIG10mRNA transcript overexpression in of about 3.5kb size, and in big intestinal tissue, do not express as the healthy tissues of brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.Simultaneously, has the GIG10mRNA transcript of about 2.2kb size also at normal tissue expression as heart and placenta.Figure 118 shows the RNA trace result of GIG10 gene differential expression in multiple cancerous cell line, and the bottom of Figure 118 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 118, the GIG8 gene is not expressed in the tissue as HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, A549 lung carcinoma cell and G361 melanoma cell, and detects its expression in promyelocytic leukemia cell HL-60, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell and SW480 colon cancer cell.

From these results as can be seen, GIG10 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.

Figure 61 shows the RNA trace result of GIG13 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 61 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 61, confirm that GIG13 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 90 shows the RNA trace result of GIG13 gene differential expression in multiple healthy tissues, and the bottom of Figure 90 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 90, the main GIG13mRNA transcript with about 1.3kb size is overexpression in normal liver tissue only.Figure 119 shows the RNA trace result of GIG13 gene differential expression in multiple cancerous cell line, and the bottom of Figure 119 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 119, the GIG13 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG13 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland and liver.

Figure 67 shows the RNA trace result of GIG30 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 67 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 67, confirm that GIG30 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 96 shows the RNA trace result of GIG30 gene differential expression in multiple healthy tissues, and the bottom of Figure 96 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 96, has main GIG30mRNA transcript overexpression in of about 1.9kb size as the healthy tissues of heart, muscle and liver.Simultaneously, has the GIG30mRNA transcript of about 1.0kb size also at normal tissue expression as liver and peripheral blood.Figure 125 shows the RNA trace result of GIG30 gene differential expression in multiple cancerous cell line, and the bottom of Figure 125 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 125, the GIG30 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG30 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, heart, muscle and liver.

Figure 68 shows the RNA trace result of GIG32 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 68 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 68, confirm that GIG32 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 97 shows the RNA trace result of GIG32 gene differential expression in multiple healthy tissues, and the bottom of Figure 97 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 97, has main GIG32mRNA transcript overexpression in of about 4.0kb size as the healthy tissues of muscle, large intestine, thymus gland, spleen, kidney, placenta, lung and peripheral blood.Simultaneously, has the GIG32mRNA transcript of about 1.0kb size also at normal tissue expression as muscle and large intestine.Figure 126 shows the RNA trace result of GIG32 gene differential expression in multiple cancerous cell line, and the bottom of Figure 126 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 126, the GIG32 gene is expressed in the tissue as HeLa cervical cancer cell, A549 lung carcinoma cell and G361 melanoma cell, and does not express in promyelocytic leukemia cell HL-60, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell and SW480 colon cancer cell.

From these results as can be seen, GIG32 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, muscle, large intestine, thymus gland, spleen, kidney, placenta and peripheral blood.

Figure 70 shows the RNA trace result of GIG34 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 70 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 70, confirm that GIG34 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 99 shows the RNA trace result of GIG34 gene differential expression in multiple healthy tissues, and the bottom of Figure 99 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 99, has main GIG34mRNA transcript overexpression in of about 0.6kb size as the healthy tissues of brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.Figure 128 shows the RNA trace result of GIG34 gene differential expression in multiple cancerous cell line, and the bottom of Figure 128 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 128, the GIG34 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.

From these results as can be seen, GIG34 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.

Figure 71 shows the RNA trace result of GIG35 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 71 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 71, confirm that GIG35 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 100 shows the RNA trace result of GIG35 gene differential expression in multiple healthy tissues, and the bottom of Figure 100 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 100, the GIG35mRNA transcript with about 1.3kb size is overexpression in as the healthy tissues of brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood equally.Figure 129 shows the RNA trace result of GIG35 gene differential expression in multiple cancerous cell line, and the bottom of Figure 129 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 129, the GIG35 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG35 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta, lung, large intestine and peripheral blood.

Figure 72 shows the RNA trace result of GIG38 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 72 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 72, confirm that GIG38 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 101 shows the RNA trace result of GIG38 gene differential expression in multiple healthy tissues, and the bottom of Figure 101 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 101, has main GIG38mRNA transcript overexpression in of about 0.7kb size as the healthy tissues of heart, muscle, kidney, liver and placenta.Simultaneously, has the GIG38mRNA transcript of about 1.5kb and 2.0kb size also at normal tissue expression as heart and muscle.Figure 130 shows the RNA trace result of GIG38 gene differential expression in multiple cancerous cell line, and the bottom of Figure 130 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 130, the GIG38 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell or is expressed hardly.Prove GIG38mRNA transcript at normal tissue expression, and in cancerous cell line, all do not express with about 1.5kb and 2.0kb size.From these results as can be seen, GIG38 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, heart, muscle, kidney, liver and placenta.

Figure 73 shows the RNA trace result of GIG39 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 73 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 73, confirm that GIG39 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 102 shows the RNA trace result of GIG39 gene differential expression in multiple healthy tissues, and the bottom of Figure 102 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 102, the main GIG39mRNA transcript with about 2.4kb size is overexpression in normal liver tissue only.Figure 131 shows the RNA trace result of GIG39 gene differential expression in multiple cancerous cell line, and the bottom of Figure 131 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 131, the GIG39 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG39 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland and liver.

Figure 76 shows the RNA trace result of GIG43 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 76 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 76, confirm that GIG43 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 105 shows the RNA trace result of GIG43 gene differential expression in multiple healthy tissues, and the bottom of Figure 105 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 105, has main GIG43mRNA transcript overexpression in of about 3.5kb size as the healthy tissues of heart, kidney, liver, placenta and lung.Figure 134 shows the RNA trace result of GIG43 gene differential expression in multiple cancerous cell line, and the bottom of Figure 134 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 134, the GIG8 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG8 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, heart, kidney, liver, placenta and lung.

Figure 82 shows the RNA trace result of PIG49 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 82 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 82, confirm that PIG49 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 111 shows the RNA trace result of PIG49 gene differential expression in multiple healthy tissues, and the bottom of Figure 111 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 111, has main PIG49mRNA transcript overexpression in of about 2.4kb size as the healthy tissues of heart, muscle, kidney, liver and placenta.Simultaneously, the PIG49mRNA transcript with about 1.5kb size is also expressed in the normal muscle tissue.Figure 140 shows the RNA trace result of PIG49 gene differential expression in multiple cancerous cell line, and the bottom of Figure 140 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 140, the PIG49 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, lymphoblastoid leukemia cell MOLT-4, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell or is seldom expressed.

From these results as can be seen, PIG49 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, heart, muscle, kidney, liver and placenta.

Figure 83 shows the RNA trace result of PIG51 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 83 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 83, confirm that PIG51 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 112 shows the RNA trace result of PIG51 gene differential expression in multiple healthy tissues, and the bottom of Figure 112 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 112, has main PIG51mRNA transcript overexpression in of about 1.0kb size as the healthy tissues of heart, muscle, thymus gland, spleen, kidney, liver, placenta and peripheral blood.Figure 141 shows the RNA trace result of PIG51 gene differential expression in multiple cancerous cell line, and the bottom of Figure 141 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 141, the PIG51 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, PIG51 gene of the present invention has cancer suppressing function in the healthy tissues as mammary gland, heart, muscle, thymus gland, spleen, kidney, liver, placenta and peripheral blood.

Figure 86 shows the RNA trace result of GIG44 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 86 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 86, confirm that GIG44 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 115 shows the RNA trace result of GIG44 gene differential expression in multiple healthy tissues, and the bottom of Figure 115 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 115, the main GIG44mRNA transcript with about 1.0kb size is overexpression in as brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and leukocytic healthy tissues equally.Simultaneously, has the GIG44mRNA transcript of about 0.5kb size also at normal tissue expression.

Figure 144 shows the RNA trace result of GIG44 gene differential expression in multiple cancerous cell line, and the bottom of Figure 144 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 144, the GIG44 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG44 gene of the present invention has cancer suppressing function in as brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and leukocytic healthy tissues.

Figure 87 shows the RNA trace result of GIG31 gene differential expression in normal galactophore tissue, primary breast cancerous tissue and breast cancer cell line, and the bottom of Figure 87 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 87, confirm that GIG31 expression of gene level detects than the highland in whole three normal galactophore tissue's samples, and in three breast cancer tissue's samples its express obviously than healthy tissues low or detect less than, and perhaps in a breast cancer cell line sample, detect a little.

Figure 116 shows the RNA trace result of GIG31 gene differential expression in multiple healthy tissues, and the bottom of Figure 116 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 116, has main GIG31mRNA transcript overexpression in of about 1.4kb size as mammary gland, heart, large intestine, spleen, small intestine, placenta, lung and leukocytic healthy tissues.Figure 145 shows the RNA trace result of GIG31 gene differential expression in multiple cancerous cell line, and the bottom of Figure 145 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 145, the GIG31 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell and G361 melanoma cell, and seldom expresses in HeLa cervical cancer cell and A549 lung carcinoma cell.From these results as can be seen, GIG31 gene of the present invention has cancer suppressing function in as mammary gland, heart, large intestine, spleen, small intestine, placenta, lung and leukocytic healthy tissues.

3-5.GIG15

For estimating GIG15 expression of gene level, carry out the RNA trace, as follows.As described in example 1 above, from normal bone marrow tissue, leukemia myeloid tissue and K-562 cell, extract total RNA sample.Respectively with each total RNA sample sex change of 20 μ g and in 1% formaldehyde agarose gel electrophoresis, the sepharose that obtains is transferred on the nylon membrane (Boehringer-Mannheim, Germany) then.Then with nylon membrane preparation with using Rediprime II random primer labelling system (Amersham, Britain) by the partial sequence GV2 of total length GIG15cDNA ³²The hybridization under 42 ℃ of the random primer probe of P mark is spent the night.RNA trace step repeats twice, and one of them is to use photodensitometer that trace is quantitative, and another is to make trace and beta-actin probe hybridization to determine the total amount of mRNA.

Figure 62 shows the RNA trace result of GIG15 gene differential expression in normal bone marrow tissue, leukemia myeloid tissue and K-562 cell, and the bottom of Figure 62 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 62, confirm that GIG15 expression of gene level is all detecting than the highland in the normal bone marrow tissue sample, and its expression is obviously low than healthy tissues in leukemia myeloid tissue sample, and perhaps detects a little in the sample a leukemia cell.

Figure 91 shows the RNA trace result of GIG15 gene differential expression in multiple healthy tissues, and the bottom of Figure 91 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 91, has main GIG15mRNA transcript overexpression in of about 0.5kb size as the healthy tissues of brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.Simultaneously, the GIG15mRNA transcript with about 1.0kb size also as hepatic and/or renal normal tissue expression.Figure 120 shows the RNA trace result of GIG15 gene differential expression in multiple cancerous cell line, and the bottom of Figure 120 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 120, the GIG15 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG15 gene of the present invention has cancer suppressing function in the healthy tissues as marrow, brain, heart, muscle, thymus gland, spleen, kidney, liver, small intestine, placenta, lung, large intestine and peripheral blood.

3-3.GIG16，GIG24，GIG26，GIG29，GIG40，GIG42，PIG33，PIG35，PIG36， PIG37

Respectively each total RNA sample sex change that 20 μ g are obtained from three normal liver tissues, three primary hepatocarcinoma tissues and hepatoma cell line HepG2 in

embodiment

1 and 1% formaldehyde agarose gel electrophoresis, the sepharose that obtains is transferred on the nylon membrane (Boehringer-Mannheim, Germany) then.Then nylon membrane is prepared with using Rediprime II random primer labelling system (Amersham, Britain) by total length GIG and PIG cDNA ³²The hybridization under 42 ℃ of the random primer probe of P mark is spent the night.RNA trace step repeats twice, and one of them is to use photodensitometer that trace is quantitative, and another is to make trace and beta-actin probe hybridization to determine the total amount of mRNA.

Figure 63 shows the RNA trace result of GIG16 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 63 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 63, confirm that GIG16 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Figure 92 shows the RNA trace result of GIG16 gene differential expression in multiple healthy tissues, and the bottom of Figure 92 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 92, the main GIG16mRNA transcript with about 2.0kb size as hepatic and/or renal healthy tissues in overexpression.

Figure 121 shows the RNA trace result of GIG16 gene differential expression in multiple cancerous cell line, and the bottom of Figure 121 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 121, the GIG16 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG16 gene of the present invention has cancer suppressing function as in the hepatic and/or renal healthy tissues.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG16 gene of the present invention as can be seen has cancer suppressing function.

Figure 64 shows the RNA trace result of GIG24 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 64 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 64, confirm that GIG24 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and even in a hepatoma cell line sample detection less than.

Figure 93 shows the RNA trace result of GIG24 gene differential expression in multiple healthy tissues, and the bottom of Figure 93 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 93, has main GIG24mRNA transcript overexpression in of about 2.4kb size as the healthy tissues of liver, heart and muscle.

Figure 122 shows the RNA trace result of GIG24 gene differential expression in multiple cancerous cell line, and the bottom of Figure 122 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 122, the GIG24 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG24 gene of the present invention has cancer suppressing function in the healthy tissues as liver, heart and muscle.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG24 gene of the present invention as can be seen has cancer suppressing function.

Figure 65 shows the RNA trace result of GIG26 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 65 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 65, confirm that GIG26 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Figure 94 shows the RNA trace result of GIG26 gene differential expression in multiple healthy tissues, and the bottom of Figure 94 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 94, have main GIG26mRNA transcript overexpression in normal liver tissue of about 2.0kb size, and simultaneously, the GIG26mRNA transcript with about 2.5kb and 1.5kb size is expressed in kidney, brain and heart also.Figure 123 shows the RNA trace result of GIG26 gene differential expression in multiple cancerous cell line, and the bottom of Figure 123 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 123, the GIG26 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG26 gene of the present invention has cancer suppressing function in the healthy tissues as liver, kidney, brain and heart.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG16 gene of the present invention as can be seen has cancer suppressing function.

Figure 66 shows the RNA trace result of GIG29 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 66 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 66, confirm that GIG29 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Figure 95 shows the RNA trace result of GIG29 gene differential expression in multiple healthy tissues, and the bottom of Figure 95 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 92, has main GIG29mRNA transcript overexpression in normal liver tissue of about 1.4kb size.

Figure 124 shows the RNA trace result of GIG29 gene differential expression in multiple cancerous cell line, and the bottom of Figure 124 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 124, the GIG29 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG29 gene of the present invention has cancer suppressing function in normal liver tissue.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG29 gene of the present invention as can be seen has cancer suppressing function.

Figure 74 shows the RNA trace result of GIG40 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 74 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 74, confirm that GIG40 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and even in a hepatoma cell line sample detection less than.

Figure 103 shows the RNA trace result of GIG40 gene differential expression in multiple healthy tissues, and the bottom of Figure 103 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 103, has main GIG40mRNA transcript overexpression in of about 1.5kb size as the healthy tissues of liver, heart and muscle.And the GIG40mRNA transcript that has simultaneously, about 5.0kb size is expressed.

Figure 132 shows the RNA trace result of GIG40 gene differential expression in multiple cancerous cell line, and the bottom of Figure 132 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 132, the GIG40 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG40 gene of the present invention has cancer suppressing function in the healthy tissues as liver, heart and muscle.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG40 gene of the present invention as can be seen has cancer suppressing function.

Figure 75 shows the RNA trace result of GIG42 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 75 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 75, confirm that GIG42 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Figure 104 shows the RNA trace result of GIG42 gene differential expression in multiple healthy tissues, and the bottom of Figure 104 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 104, has main GIG42mRNA transcript overexpression in normal liver tissue of about 2.5kb size.

Figure 133 shows the RNA trace result of GIG42 gene differential expression in multiple cancerous cell line, and the bottom of Figure 133 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 133, the GIG42 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, GIG42 gene of the present invention has cancer suppressing function in normal liver tissue.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, GIG42 gene of the present invention as can be seen has cancer suppressing function.

Figure 78 shows the RNA trace result of PIG33 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 78 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 78, confirm that PIG33 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Figure 107 shows the RNA trace result of PIG33 gene differential expression in multiple healthy tissues, and the bottom of Figure 107 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 107, has main PIG33mRNA transcript overexpression in of about 3.0kb size as the healthy tissues of brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta and lung.

Figure 136 shows the RNA trace result of PIG33 gene differential expression in multiple cancerous cell line, and the bottom of Figure 136 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 136, the PIG33 gene is not expressed in as the tissue of HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell, and seldom expresses in promyelocytic leukemia cell HL-60 and Burkitt lymphoma Raji cell.From these results as can be seen, PIG33 gene of the present invention has cancer suppressing function in the healthy tissues as brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta and lung.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, PIG33 gene of the present invention as can be seen has cancer suppressing function.

Figure 79 shows the RNA trace result of PIG35 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 79 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 79, confirm that PIG35 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and even in a hepatoma cell line sample detection less than.

Figure 108 shows the RNA trace result of PIG35 gene differential expression in multiple healthy tissues, and the bottom of Figure 108 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 108, has main PIG35mRNA transcript overexpression in of about 1.7kb size as the healthy tissues of brain, heart, skeletal muscle, liver, small intestine, placenta and lung.

Figure 137 shows the RNA trace result of PIG35 gene differential expression in multiple cancerous cell line, and the bottom of Figure 137 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 137, the PIG35 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell, and seldom expresses in chronic granulocytic leukemia clone K-562.From these results as can be seen, PIG35 gene of the present invention has cancer suppressing function in the healthy tissues as brain, heart, skeletal muscle, liver, small intestine, placenta and lung.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, PIG35 gene of the present invention as can be seen has cancer suppressing function.

Figure 80 shows the RNA trace result of PIG36 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 80 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 80, confirm that PIG36 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and perhaps in a hepatoma cell line sample detection less than.

Figure 109 shows the RNA trace result of PIG36 gene differential expression in multiple healthy tissues, and the bottom of Figure 109 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 109, has main PIG36mRNA transcript overexpression in normal liver tissue of about 1.0kb size.

Figure 138 shows the RNA trace result of PIG36 gene differential expression in multiple cancerous cell line, and the bottom of Figure 138 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 138, the PIG36 gene is not expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell or is seldom expressed.From these results as can be seen, PIG36 gene of the present invention has cancer suppressing function in the healthy tissues as liver, heart, muscle, kidney and placenta.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, malignant lymphoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, PIG36 gene of the present invention as can be seen has cancer suppressing function.

Figure 85 shows the RNA trace result of PIG37 gene differential expression in normal liver tissue, primary hepatocarcinoma tissue and hepatoma cell line, and the bottom of Figure 85 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 85, confirm that PIG37 expression of gene level detects than the highland in whole three normal liver tissue samples, and its expressions is obviously low than healthy tissues in three liver cancer tissue samples, and in a hepatoma cell line sample detection less than.

Carry out the RNA trace at a plurality of tissues of normal people (Clontech) and human carcinoma cell line (Clontech).In other words, by with identical as mentioned above method, the trace of each total RNA sample transfer above it that extracts from healthy tissues and cancerous cell line hybridized carry out the RNA trace, wherein said trace can be commercial available from Clontech company (U.S.), healthy tissues for example is selected from by brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta, the group that lung and peripheral blood leucocyte are formed, and cancerous cell line for example is selected from by children's grain early from the sick cell HL-60 of blood, the HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, the SW480 colon cancer cell, the group that A549 lung carcinoma cell and G361 melanoma cell are formed.

Figure 114 shows the RNA trace result of PIG37 gene differential expression in multiple healthy tissues, and the bottom of Figure 114 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 114, has main PIG37mRNA transcript overexpression in of about 7.0kb size as the healthy tissues of brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta and lung.Simultaneously, have about 2.0 and PIG37mRNA transcript overexpression in healthy tissues of 1.0kb size.

Figure 143 shows the RNA trace result of PIG37 gene differential expression in multiple cancerous cell line, and the bottom of Figure 143 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 143, the PIG37 gene is expressed in as the tissue of promyelocytic leukemia cell HL-60, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, SW480 colon cancer cell and A549 lung carcinoma cell hardly, and seldom expresses in HeLa cervical cancer cell, Burkitt lymphoma Raji cell and G361 melanoma cell.From these results as can be seen, PIG37 gene of the present invention has cancer suppressing function in the healthy tissues as brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta and lung.And, by the following fact: even it is expressed in to be suppressed in leukemia, uterus carcinoma, colorectal carcinoma, lung cancer and the skin carcinoma and causes carcinogenesis, PIG37 gene of the present invention as can be seen has cancer suppressing function.

3-4.GIG46、MIG20

Respectively with 20 μ g as described in example 1 above each the total RNA sample sex change that obtains from three normal ectocervix tissues, three primary cervical cancer tissues and two sub-cervical cancer tumer lines and 1% formaldehyde agarose gel electrophoresis, the sepharose that obtains is transferred on the nylon membrane (Boehringer-Mannheim, Germany) then.Then with nylon membrane with use total length GIG46 and MIG20cDNA ³²The hybridization under 42 ℃ of the random primer probe of P mark is spent the night.RNA trace step repeats twice, and one of them is to use photodensitometer that trace is quantitative, and another is to make trace and beta-actin probe hybridization to determine the total amount of mRNA.

Figure 77 shows the RNA trace result of GIG46 gene differential expression in normal ectocervix tissue, primary cervical cancer tissue and cervical cancer cell system, and Figure 77 illustrates the RNA trace result that beta-actin is expressed.In Figure 77, the normal ectocervix tissue sample of swimming lane 1～3 expression, swimming lane 4～6 expression cervical cancer tissue samples, swimming lane 7 expression cervical cancer cells are the sample of HeLa, and swimming lane 8 expression cervical cancer cells are the sample of CUMC-6.As shown in Figure 77, confirm that GIG46 expression of gene level detects than the highland in whole three normal ectocervix tissue samples, and its expression level is obviously low than healthy tissues in the sample of three cervical cancer tissues, and in two sub-cervical cancer tumer line samples, detect less than.

Figure 106 shows the RNA trace result of GIG46 gene differential expression in multiple healthy tissues, and Figure 106 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 106, main GIG46mRNA transcript overexpression in about 1.5kb size as the healthy tissues of uterus, brain, heart, skeletal muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte, and except the GIG46mRNA transcript of 1.5kb, the transcript with about 2.0kb size is also expressed.

Figure 135 shows the RNA trace result of GIG46 gene differential expression in multiple cancerous cell line, and the bottom of Figure 135 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 135, the GIG46 gene is seldom expressed in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.Yet the mRNA transcript of the 2.0kb that is proved to be at normal tissue expression is not expressed in cancerous cell line.

From these results as can be seen, GIG46 gene of the present invention has cancer suppressing function in the healthy tissues as uterus, brain, heart, skeletal muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte.

Figure 81 shows the RNA trace result of MIG20 gene differential expression in normal ectocervix tissue, primary cervical cancer tissue and cervical cancer cell system, and Figure 81 illustrates the RNA trace result that beta-actin is expressed.In Figure 81, the normal ectocervix tissue sample of swimming lane 1～3 expression, swimming lane 4～6 expression cervical cancer tissue samples, swimming lane 7 expression cervical cancer cells are the sample of HeLa, and swimming lane 8 expression cervical cancer cells are the sample of CUMC-6.As shown in Figure 81, confirm that MIG20 expression of gene level detects than the highland in whole three normal ectocervix tissue samples, and its expression level is obviously low than healthy tissues in the sample of three cervical cancer tissues, and in two sub-cervical cancer tumer line samples, detect less than.

Figure 110 shows the RNA trace result of MIG20 gene differential expression in multiple healthy tissues, and Figure 110 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 110, main MIG20mRNA transcript overexpression in about 4.4kb size as the healthy tissues of heart, skeletal muscle and liver, and except the MIG20mRNA transcript of 4.4kb, the transcript with about 2.4kb and 1.5kb size is also expressed.

Figure 139 shows the RNA trace result of MIG20 gene differential expression in multiple cancerous cell line, and the bottom of Figure 139 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 139, the MIG20 gene is not expressed in the tissue as promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell.From these results as can be seen, MIG20 gene of the present invention has cancer suppressing function in the healthy tissues as uterine cervix, heart, skeletal muscle and liver.

3-5.MIG12

For estimating MIG12 expression of gene level, carry out the RNA trace, as follows.

With 20 μ g as described in example 1 above each the total RNA sample sex change that obtains from three normal lung tissues, two primary pulmonary cancerous tissues, two transitivity cancerous lung tissues and lung cancer cell line (A549 and NCI-H358) and 1% formaldehyde agarose gel electrophoresis, the sepharose that obtains is transferred on the nylon membrane (Boehringer-Mannheim, Germany) then.Then nylon membrane is prepared with using Rediprime II random primer labelling system (Amersham, Britain) by total length MIG12 cDNA ³²The hybridization under 42 ℃ of the random primer probe of P mark is spent the night.RNA trace step repeats twice, and one of them is to use photodensitometer that trace is quantitative, and another is to make trace and beta-actin probe hybridization to determine the total amount of mRNA.

Figure 84 shows the RNA trace result of MIG12 gene differential expression in normal lung tissue, primary pulmonary cancerous tissue, transitivity cancerous lung tissue and lung cancer cell line, and the bottom of Figure 84 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.Shown in Figure 84, confirm that MIG9 expression of gene level detects than the highland in whole three normal lung tissue's samples, and detect a little in two cancerous lung tissue samples, two transitivity cancerous lung tissue samples and two lung cancer cell line samples.

Figure 113 shows the RNA trace result of MIG12 gene differential expression in multiple healthy tissues, and the bottom of Figure 113 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 113, has main MIG12mRNA transcript overexpression in of about 0.5kb size as the healthy tissues of brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte.Except the MIG12mRNA transcript of 0.5kb, the transcript with about 1.0kb and 0.8kb size is also expressed in as heart, muscle, hepatic and/or renal healthy tissues.

Figure 142 shows the RNA trace result of MIG12 gene differential expression in multiple cancerous cell line, and the bottom of Figure 142 shows the RNA trace result by identical trace and beta-actin probe hybridization are obtained.As shown in Figure 142, in as the tissue of promyelocytic leukemia cell HL-60, HeLa cervical cancer cell, chronic granulocytic leukemia clone K-562, lymphoblastoid leukemia cell MOLT-4, Burkitt lymphoma Raji cell, SW480 colon cancer cell, A549 lung carcinoma cell and G361 melanoma cell, seldom express at the MIG12mRNA transcript of the main 0.5kb of normal tissue expression.From these results as can be seen, MIG12 gene of the present invention has cancer suppressing function in the healthy tissues as brain, heart, skeletal muscle, colon, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood leucocyte.

Embodiment 4: the structure of expression vector and transfection

4-1.GIG8、GIG10、GIG13、GIG30、GIG32、GIG33、GIG34、GIG35、 GIG38、GIG39、GIG43、PIG49、PIG51、GIG44、GIG31

Structure comprises the expression vector of the coding region of each GIG and PIG gene, and is as follows.At first, full length cDNA clone with preparation among the embodiment 2 inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen, the U.S.) to obtain expression vector pcDNA3.1/GIG8, pcDNA3.1/GIG10, pcDNA3.1/GIG13, pcDNA3.1/GIG30, pcDNA3.1/GIG32, pcDNA3.1/GIG33, pcDNA3.1/GIG34, pcDNA3.1/GIG35, pcDNA3.1/GIG38, pcDNA3.1/GIG39, pcDNA3.1/GIG43, pcDNA3.1/PIG49, pcDNA3.1/PIG51, pcDNA3.1/GIG44 and pcDNA3.1/GIG31 respectively.Use lipofectamine (Gibco BRL) that each expression vector transfection is advanced in the MCF-7 breast cancer cell line, in the DMEM substratum that contains the G418 of 0.6mg/ml (Gibco), cultivate with the screening cells transfected then.Simultaneously, use is organized in contrast with the MCF-7 cell of the expression vector pcDNA3.1 transfection that lacks GIG cDNA.

4-2.GIG15

Structure comprises the expression vector of the coding region of GIG15 gene, and is as follows.At first, the total length GIG15cDNA clone with preparation among the embodiment 2 inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen, the U.S.) to obtain expression vector pcDNA3.1/GIG15.Use lipofectamine (Gibco BRL) that the expression vector transfection is advanced in the K562 leukemia cell system, in the DMEM substratum that contains the G418 of 0.6mg/ml (Gibco), cultivate with the screening cells transfected then.Simultaneously, use is organized in contrast with the K562 cell of the expression vector pcDNA3.1 transfection that lacks GIG cDNA.

4-3.GIG16、GIG24、GIG26、GIG29、GIG40、GIG42、PIG33、PIG35、 PIG36、PIG37

Structure comprises the expression vector of the coding region of each GIG and PIG gene, and is as follows.At first, full length cDNA clone GIG16, GIG24, GIG26, GIG29, GIG40, GIG42, PIG33, PIG35, PIG36 and PIG37 with preparation among the embodiment 2 inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen, the U.S.) to obtain expression vector pcDNA3.1/GIG16, pcDNA3.1/GIG24, pcDNA3.1/GIG26, pcDNA3.1/GIG29, pcDNA3.1/GIG40, pcDNA3.1/GIG42, pcDNA3.1/PIG33, pcDNA3.1/PIG35, pcDNA3.1/PIG36 and pcDNA3.1/PIG37 respectively.Use lipofectamine (Gibco BRL) that each expression vector transfection is advanced in the HepG2 hepatoma cell line, in the DMEM substratum that contains the G418 of 0.6mg/ml (Gibco), cultivate with the screening cells transfected then.Simultaneously, use is organized in contrast with the HepG2 cell of the expression vector pcDNA3.1 transfection that lacks GIG cDNA.

4-4.GIG46、MIG20

Structure comprises the expression vector of the coding region of each GIG and MIG gene, and is as follows.Total length GIG46cDNA clone with preparation among the embodiment 2 inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen, the U.S.) to obtain expression vector pcDNA3.1/GIG46 and pcDNA3.1/MIG20 at first, respectively.Use lipofectamine (Gibco BRL) that each expression vector transfection is advanced in the HeLa cervical cancer cell system (ATCC CCL-2), in the DMEM substratum that contains the G418 of 0.6mg/ml (Gibco), cultivate with the screening cells transfected then.Simultaneously, use is organized in contrast with the HeLa cell of the expression vector pcDNA3.1 transfection that lacks GIG46 or MIG20cDNA.

4-5.MIG12

Structure comprises the expression vector of the coding region of MIG12 gene, and is as follows.At first, the total length MIG12cDNA clone with preparation among the embodiment 2 inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen, the U.S.) to obtain expression vector pcDNA3.1/MIG12.Use lipofectamine (Gibco BRL) that the expression vector transfection is advanced in the A549 lung cancer cell line, in the DMEM substratum that contains the G418 of 0.6mg/ml (Gibco), cultivate with the screening cells transfected then.Simultaneously, use is organized in contrast with the A549 cell of the expression vector pcDNA3.1 transfection that lacks MIG12cDNA.

Embodiment 5: the growth curve of using the breast cancer cell of GIG gene transfection

5-1.GIG8、GIG10、GIG13、GIG30、GIG32、GIG33、GIG34、GIG35、 GIG38、GIG39、GIG43、PIG49、PIG51、GIG44、GIG31

Be to detect the influence that GIG and PIG gene pairs breast cancer cell generate, respectively in the DMEM substratum with 1x10 ⁵The cell density of individual cell/ml is cultivated wild-type MCF-7 cell; Use the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG8, pcDNA3.1/GIG10, pcDNA3.1/GIG13, pcDNA3.1/GIG30, pcDNA3.1/GIG32, pcDNA3.1/GIG33, pcDNA3.1/GIG34, pcDNA3.1/GIG35, pcDNA3.1/GIG38, pcDNA3.1/GIG39, pcDNA3.1/GIG43, pcDNA3.1/PIG49, pcDNA3.1/PIG51, pcDNA3.1/GIG44 and the pcDNA3.1/GIG31 transfection of preparation among the embodiment 4 respectively; And the MCF-7 cell 9 days of only using carrier pcDNA3.1 transfection.Respectively by use trypsin Sigma) processing and from the culturing bottle of cell attachment the cell the separation and Culture liquid, then according to trypan blue dyeing discharge method (Freshney, I.R., Culture ofAnimal Cells, the 2nd edition .A.R.Liss, New York (1987)) respectively at the 1st, 3,5,7 and 9 day living cell counting.

Figure 146 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG8 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 146, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG8 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 30% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG8 transfection.From this result growth of GIG8 gene inhibition breast cancer cell as can be seen.

Figure 147 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG10 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 147, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG10 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 40% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG10 transfection.From this result growth of GIG10 gene inhibition breast cancer cell as can be seen.

Figure 148 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG13 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 148, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG13 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 30% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG13 transfection.From this result growth of GIG13 gene inhibition breast cancer cell as can be seen.

Figure 154 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG30 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 154, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG30 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 30% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG30 transfection.From this result growth of GIG30 gene inhibition breast cancer cell as can be seen.

Figure 155 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG32 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 155, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG32 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 50% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG32 transfection.From this result growth of GIG32 gene inhibition breast cancer cell as can be seen.

Figure 156 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG33 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 156, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG33 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 70% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG33 transfection.From this result growth of GIG33 gene inhibition breast cancer cell as can be seen.

Figure 157 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG34 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 157, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG34 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 80% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG34 transfection.From this result growth of GIG34 gene inhibition breast cancer cell as can be seen.

Figure 158 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG35 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 158, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG35 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 70% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG35 transfection.From this result growth of GIG35 gene inhibition breast cancer cell as can be seen.

Figure 159 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG38 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 159, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG38 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 60% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG38 transfection.From this result growth of GIG38 gene inhibition breast cancer cell as can be seen.

Figure 160 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG39 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 160, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG39 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 40% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG39 transfection.From this result growth of GIG39 gene inhibition breast cancer cell as can be seen.

Figure 163 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG43 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 163, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG43 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 60% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG43 transfection.From this result growth of GIG43 gene inhibition breast cancer cell as can be seen.

Figure 169 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/PIG49 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 169, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/PIG49 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 60% MCF-7 breast cancer cell survival with carrier pcDNA3.1/PIG49 transfection.From this result growth of PIG49 gene inhibition breast cancer cell as can be seen.

Figure 170 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/PIG51 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 170, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/PIG51 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 40% MCF-7 breast cancer cell survival with carrier pcDNA3.1/PIG51 transfection.From this result growth of PIG51 gene inhibition breast cancer cell as can be seen.

Figure 173 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG44 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 173, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG44 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 60% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG44 transfection.From this result growth of GIG44 gene inhibition breast cancer cell as can be seen.

Figure 174 is for illustrating wild-type MCF-7 cell; MCF-7 breast cancer cell with the carrier pcDNA3.1/GIG31 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the MCF-7 cell of expression vector pcDNA3.1 transfection.As shown in Figure 174, confirm to present than MCF-7 cell and the higher mortality ratio of wild-type MCF-7 cell with expression vector pcDNA3.1 transfection with the MCF-7 breast cancer cell of carrier pcDNA3.1/GIG31 transfection.Cultivate after 9 days, compare with wild-type MCF-7 cell and have only about 70% MCF-7 breast cancer cell survival with carrier pcDNA3.1/GIG31 transfection.From this result growth of GIG31 gene inhibition breast cancer cell as can be seen.

5-2.GIG15

Be to detect the influence that GIG gene pairs leukemia cell generates, respectively in the DMEM substratum with 1x10 ⁵The cell density of individual cell/ml is cultivated wild-type K562 cell; Use the K562 leukemia cell of the carrier pcDNA3.1/GIG15 transfection of preparation among the embodiment 4 respectively; And the K562 cell 9 days of only using carrier pcDNA3.1 transfection.Respectively by use trypsin Sigma) processing and from the culturing bottle of cell attachment the cell the separation and Culture liquid, then according to trypan blue dyeing discharge method (Freshney, I.R., Cultureof Animal Cells, the 2nd edition .A.R.Liss, New York (1987)) respectively at the 1st, 3,5,7 and 9 day living cell counting.

Figure 149 is for illustrating wild-type K562 cell; K562 leukemia cell with the carrier pcDNA3.1/GIG15 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the K562 cell of expression vector pcDNA3.1 transfection.As shown in Figure 149, confirm to present than K562 cell and the higher mortality ratio of wild-type K562 cell with expression vector pcDNA3.1 transfection with the K562 cell of carrier pcDNA3.1/GIG15 transfection.Cultivate after 9 days, compare with wild-type K562 cell and have only about 80% K562 cell survival with carrier pcDNA3.1/GIG15 transfection.From this result growth of GIG15 gene inhibition breast cancer cell as can be seen.

5-3.GIG16、GIG24、GIG26、GIG29、GIG40、GIG42、PIG33、PIG35、 PIG36、PIG37

Be to detect the influence that GIG and PIG gene pairs liver cancer cell generate, respectively in the DMEM substratum with 1x10 ⁵The cell density of individual cell/ml is cultivated wild-type HepG2 cell; Use the HepG2 liver cancer cell of carrier pcDNA3.1/GIG16, pcDNA3.1/GIG24, pcDNA3.1/GIG26, pcDNA3.1/GIG29, pcDNA3.1/GIG40, pcDNA3.1/GIG42, pcDNA3.1/PIG33, pcDNA3.1/PIG35, pcDNA3.1/PIG36 and the pcDNA3.1/PIG37 transfection of preparation among the embodiment 4 respectively; And the HepG2 cell 9 days of only using carrier pcDNA3.1 transfection.Respectively by use trypsin Sigma) processing and from the culturing bottle of cell attachment the cell the separation and Culture liquid, then according to trypan blue dyeing discharge method (Freshney, I.R., Culture of Animal Cells, the 2nd edition .A.R.Liss, New York (1987)) respectively at the 1st, 3,5,7 and 9 day living cell counting.

Figure 150 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG16 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 150, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG16 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 70% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG16 transfection.From this result growth of GIG16 gene inhibition liver cancer cell as can be seen.

Figure 151 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG24 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 151, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG24 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 60% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG24 transfection.From this result growth of GIG24 gene inhibition liver cancer cell as can be seen.

Figure 152 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG26 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 152, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG26 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 50% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG26 transfection.From this result growth of GIG26 gene inhibition liver cancer cell as can be seen.

Figure 153 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG29 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 153, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG29 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 70% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG29 transfection.From this result growth of GIG29 gene inhibition liver cancer cell as can be seen.

Figure 161 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG40 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 161, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG40 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 80% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG40 transfection.From this result growth of GIG40 gene inhibition liver cancer cell as can be seen.

Figure 162 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/GIG42 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 162, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/GIG42 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 60% HepG2 liver cancer cell survival with carrier pcDNA3.1/GIG42 transfection.From this result growth of GIG42 gene inhibition liver cancer cell as can be seen.

Figure 165 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/PIG33 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 165, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/PIG33 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 60% HepG2 liver cancer cell survival with carrier pcDNA3.1/PIG33 transfection.From this result growth of PIG33 gene inhibition liver cancer cell as can be seen.

Figure 166 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/PIG35 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 166, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/PIG35 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 70% HepG2 liver cancer cell survival with carrier pcDNA3.1/PIG35 transfection.From this result growth of PIG35 gene inhibition liver cancer cell as can be seen.

Figure 167 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/PIG36 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 167, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/PIG36 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 60% HepG2 liver cancer cell survival with carrier pcDNA3.1/PIG36 transfection.From this result growth of PIG36 gene inhibition liver cancer cell as can be seen.

Figure 172 is for illustrating wild-type HepG2 cell; HepG2 liver cancer cell with the carrier pcDNA3.1/PIG37 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HepG2 cell of expression vector pcDNA3.1 transfection.As shown in Figure 172, confirm to present than HepG2 cell and the higher mortality ratio of wild-type HepG2 cell with expression vector pcDNA3.1 transfection with the HepG2 liver cancer cell of carrier pcDNA3.1/PIG37 transfection.Cultivate after 9 days, compare with wild-type HepG2 cell and have only about 70% HepG2 liver cancer cell survival with carrier pcDNA3.1/PIG37 transfection.From this result growth of PIG37 gene inhibition liver cancer cell as can be seen.

5-4.GIG46、MIG20

Be to detect the influence of GIG and MIG gene pairs cervical cancer cell growth, respectively in the DMEM substratum with 1x10 ⁵The cell density of individual cell/ml is cultivated normal HeLa cell; HeLa cervical cancer cell with the GIG46 gene transfection of preparation among the embodiment 4; And the HeLa cell 9 days of only using carrier pcDNA3.1 transfection.Respectively by use trypsin Sigma) processing and from the culturing bottle of cell attachment the cell the separation and Culture liquid, then according to trypan blue dyeing discharge method (Freshney, I.R., Culture ofAnimal Cells, the 2nd edition .A.R.Liss, New York (1987)) respectively at the 1st, 3,5,7 and 9 day living cell counting.

Figure 164 is for illustrating normal HeLa cell; HeLa cervical cancer cell with the GIG46 gene transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HeLa cell of expression vector pcDNA3.1 transfection.As shown in Figure 164, confirm and compare with normal HeLa cell with the HeLa cell of expression vector pcDNA3.1 transfection, present higher mortality ratio with the HeLa cervical cancer cell of GIG46 gene transfection.Cultivate after 9 days, compare with normal HeLa cell and have only about 80% HeLa cervical cancer cell survival with the GIG46 gene transfection.From this result growth of GIG46 gene inhibition liver cancer cell as can be seen.

Figure 168 is for illustrating normal HeLa cell; HeLa cervical cancer cell with the MIG20 gene transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the HeLa cell of expression vector pcDNA3.1 transfection.As shown in Figure 168, confirm and compare with normal HeLa cell with the HeLa cell of expression vector pcDNA3.1 transfection, present higher mortality ratio with the HeLa cervical cancer cell of MIG20 gene transfection.Cultivate after 9 days, compare with normal HeLa cell and have only about 80% HeLa cervical cancer cell survival with the MIG20 gene transfection.From this result growth of MIG20 gene inhibition liver cancer cell as can be seen.

5-5.MIG12

Be to detect the influence of MIG12 gene pairs lung carcinoma cell growth, respectively in the DMEM substratum with 1x10 ⁵The cell density of individual cell/ml is cultivated wild-type A549 cell; A549 lung carcinoma cell with the carrier pcDNA3.1/MIG12 transfection of preparation among the embodiment 4; And the A549 cell 9 days of only using carrier pcDNA3.1 transfection.Respectively by use trypsin Sigma) processing and from the culturing bottle of cell attachment the cell the separation and Culture liquid, then according to trypan blue dyeing discharge method (Freshney, I.R., Culture ofAnimal Cells, the 2nd edition .A.R.Liss, New York (1987)) respectively at the 1st, 3,5,7 and 9 day living cell counting.

Figure 171 is for illustrating wild-type A549 cell; A549 lung carcinoma cell with the carrier pcDNA3.1/MIG12 transfection of preparation among the embodiment 4; And the figure of growth curve that only uses the A549 cell of expression vector pcDNA3.1 transfection.As shown in Figure 171, confirm to compare with wild-type A549 cell with A549 cell with expression vector pcDNA3.1 transfection, present higher mortality ratio with the A549 lung carcinoma cell of carrier pcDNA3.1/MIG12 transfection.Cultivate after 9 days, compare with wild-type A549 cell and have only about 70% A549 lung carcinoma cell survival with carrier pcDNA3.1/MIG12 transfection.From this result growth of MIG12 gene inhibition liver cancer cell as can be seen.

Industrial applicability

GIG of the present invention, PIG or MIG gene can be used for diagnosis, prevention and treatment people cancer effectively Disease.

Sequence table

＜110〉Jin Xian rises

＜120〉human tumor suppressor gene, its encoded protein matter

<130>PCT06-025

<150>KR10-2005-0026254

<151>2005-03-30

<160>116

<170>Kopatentln?1.71

<210>1

<211>531

<212>DNA

＜213〉mankind

<400>1

tcgggcttca?ttctgagccg?agcccggtgc?caagcgcagc?tagctcagca?ggcggcagcg 60

gcggcctgag?cttcagggca?gccagctccc?tcccggtctc?gccttccctc?gcggtcagca 120

tgaaagcctt?cagtcccgtg?aggtccgtta?ggaaaaacag?cctgtcggac?cacagcctgg 180

gcatctcccg?gagcaaaacc?cctgtggacg?acccgatgag?cctgctatac?aacatgaacg 240

actgctactc?caagctcaag?gagctggtgc?ccagcatccc?ccagaacaag?aaggtgagca 300

agatggaaat?cctgcagcac?gtcatcgact?acatcttgga?cctgcagatc?gccctggact 360

cgcatcccac?tattgtcagc?ctgcatcacc?agagacccgg?gcagaaccag?gcgtccagga 420

cgccgctgac?caccctcaac?acggatatca?gcatcctgtc?cttgcaggct?tctgaattcc 480

cttctgagtt?aatgtcaaat?gacagcaaag?cactgtgtgg?ctgaataagc?g 531

<210>2

<211>134

<212>PRT

＜213〉mankind

<400>2

Met?Lys?Ala?Phe?Ser?Pro?Val?Arg?Ser?Val?Arg?Lys?Asn?Ser?Leu?Ser

1 5 10 15

Asp?His?Ser?Leu?Gly?Ile?Ser?Arg?Ser?Lys?Thr?Pro?Val?Asp?Asp?Pro

20 25 30

Met?Ser?Leu?Leu?Tyr?Asn?Met?Asn?Asp?Cys?Tyr?Ser?Lys?Leu?Lys?Glu

35 40 45

Leu?Val?Pro?Ser?Ile?Pro?Gln?Asn?Lys?Lys?Val?Ser?Lys?Met?Glu?Ile

50 55 60

Leu?Gln?His?Val?Ile?Asp?Tyr?Ile?Leu?Asp?Leu?Gln?Ile?Ala?Leu?Asp

65 70 75 80

Ser?His?Pro?Thr?Ile?Val?Ser?Leu?His?His?Gln?Arg?Pro?Gly?Gln?Asn

85 90 95

Gln?Ala?Ser?Arg?Thr?Pro?Leu?Thr?Thr?Leu?Asn?Thr?Asp?Ile?Ser?Ile

100 105 110

Leu?Ser?Leu?Gln?Ala?Ser?Glu?Phe?Pro?Ser?Glu?Leu?Met?Ser?Asn?Asp

115 120 125

Ser?Lys?Ala?Leu?Cys?Gly

130

<210>3

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP33 of GIG8

<400>3

aagcttgctg?ctc 13

<210>4

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG8

<400>4

aagctttttt?ttttta 16

<210>5

<211>2090

<212>DNA

＜213〉mankind

<400>5

gcctccgcca?actttcacgc?tgcctcggcg?gcccggcccg?gctcgacgcc?aatggtggag 60

gccatagtgg?agtttgacta?ccaggcccag?cacgatgatg?agctgacgat?cagcgtgggt 120

gaaatcatca?ccaacatcag?gaaggaggat?ggaggctggt?gggagggaca?gatcaacggc 180

aggagaggtt?tgttccctga?caactttgta?agagaaataa?agaaagagat?gaagaaagac 240

cctctcacca?acaaagctcc?agaaaagccc?ctgcacgaag?tgcccagtgg?aaactctttg 300

ctgtcttctg?aaacgatttt?aagaaccaat?aagagaggcg?agcgacggag?gcgccggtgc 360

caggtggcat?tcagctacct?gccccagaat?gacgatgaac?ttgagctgaa?agttggcgac 420

atcatagagg?tggtaggaga?ggtagaggaa?ggatggtggg?aaggtgttct?caacgggaag 480

actggaatgt?ttccttccaa?cttcatcaag?gagctgtcag?gggagtcgga?tgagcttggc 540

atttcccagg?atgagcagct?atccaagtca?agtttaaggg?aaaccacagg?ctccgagagt 600

gatgggggtg?actcaagcag?caccaagtct?gaaggtgcca?acgggacagt?ggcaactgca 660

gcaatccagc?ccaagaaagt?taagggagtg?ggctttggag?acattttcaa?agacaagcca 720

atcaaactaa?gaccaaggtc?aattgaagta?gaaaatgact?ttctgccggt?agaaaagact 780

attgggaaga?agttacctgc?aactacagca?actccagact?catcaaaaac?agaaatggac 840

agcaggacaa?agagcaagga?ttactgcaaa?gtaatatttc?catatgaggc?acagaatgat 900

gatgaattga?caatcaaaga?aggagatata?gtcactctca?tcaataagga?ctgcatcgac 960

gtaggctggt?gggaaggaga?gctgaacggc?agacgaggcg?tgttccccga?taacttcgtg 1020

aagttacttc?caccggactt?tgaaaaggaa?gggaatagac?ccaagaagcc?accgcctcca 1080

tccgctcctg?tcatcaaaca?aggggcaggc?accactgaga?gaaaacatga?aattaaaaag 1140

atacctcctg?aaagaccaga?aatgcttcca?aacagaacag?aagaaaaaga?aagaccagag 1200

agagagccaa?aactggattt?acagaagccc?tccgttcctg?ccataccgcc?aaaaaagcct 1260

cggccaccta?agaccaattc?tctcagcaga?cctggcgcac?tgcccccgag?aaggccggag 1320

agaccggtgg?gtccgctgac?acacaccagg?ggtgacagtc?caaagattga?cttggccggc 1380

agttcgctat?ctggcatcct?ggacaaagat?ctctcggacc?gcagcaatga?cattgactta 1440

gaaggttttg?actccgtggt?atcatctact?gagaaactca?gtcatccgac?cacaagcaga 1500

ccaaaagcta?cagggaggcg?gcctccgtcc?cagtccctca?catcttcatc?cctttcaagc 1560

cctgatatct?tcgactcccc?aagtcccgaa?gaggataagg?aggaacacat?ttcacttgcg 1620

cacagaggag?tggacgcgtc?aaagaaaact?tccaagactg?ttaccatatc?ccaagtgtct 1680

gacaacaaag?catccctgcc?gcccaagccg?gggaccatgg?cagcaggtgg?cggtgggcca 1740

gcccctctgt?cctcagcggc?gccctccccc?ctgtcatcct?ctttgggaac?agctggacac 1800

agagccaact?ccccgtctct?gttcggcacg?gaaggaaaac?caaagatgga?gcctgcggcc 1860

agcagccagg?cggccgtgga?ggagctaagg?acacaggtcc?gcgagctgag?gagcatcatc 1920

gagaccatga?aggaccagca?gaaacgagag?attaaacagt?tattgtctga?gttggatgaa 1980

gagaagaaaa?tccggcttcg?gttgcagatg?gaagtgaacg?acataaagaa?agctctacaa 2040

tcaaaatgaa?tacttgatca?atgaaatgtc?acattattca?tcctgagtcc 2090

<210>6

<211>665

<212>PRT

＜213〉mankind

<400>6

Met?Val?Glu?Ala?Ile?Val?Glu?Phe?Asp?Tyr?Gln?Ala?Gln?His?Asp?Asp

1 5 10 15

Glu?Leu?Thr?Ile?Ser?Val?Gly?Glu?Ile?Ile?Thr?Asn?Ile?Arg?Lys?Glu

20 25 30

Asp?Gly?Gly?Trp?Trp?Glu?Gly?Gln?Ile?Asn?Gly?Arg?Arg?Gly?Leu?Phe

35 40 45

Pro?Asp?Asn?Phe?Val?Arg?Glu?Ile?Lys?Lys?Glu?Met?Lys?Lys?Asp?Pro

50 55 60

Leu?Thr?Asn?Lys?Ala?Pro?Glu?Lys?Pro?Leu?His?Glu?Val?Pro?Ser?Gly

65 70 75 80

Asn?Ser?Leu?Leu?Ser?Ser?Glu?Thr?Ile?Leu?Arg?Thr?Asn?Lys?Arg?Gly

85 90 95

Glu?Arg?Arg?Arg?Arg?Arg?Cys?Gln?Val?Ala?Phe?Ser?Tyr?Leu?Pro?Gln

100 105 110

Asn?Asp?Asp?Glu?Leu?Glu?Leu?Lys?Val?Gly?Asp?Ile?Ile?Glu?Val?Val

115 120 125

Gly?Glu?Val?Glu?Glu?Gly?Trp?Trp?Glu?Gly?Val?Leu?Asn?Gly?Lys?Thr

130 135 140

Gly?Met?Phe?Pro?Ser?Asn?Phe?Ile?Lys?Glu?Leu?Ser?Gly?Glu?Ser?Asp

145 150 155 160

Glu?Leu?Gly?Ile?Ser?Gln?Asp?Glu?Gln?Leu?Ser?Lys?Ser?Ser?Leu?Arg

165 170 175

Glu?Thr?Thr?Gly?Ser?Glu?Ser?Asp?Gly?Gly?Asp?Ser?Ser?Ser?Thr?Lys

180 185 190

Ser?Glu?Gly?Ala?Asn?Gly?Thr?Val?Ala?Thr?Ala?Ala?Ile?Gln?Pro?Lys

195 200 205

Lys?Val?Lys?Gly?Val?Gly?Phe?Gly?Asp?Ile?Phe?Lys?Asp?Lys?Pro?Ile

210 215 220

Lys?Leu?Arg?Pro?Arg?Ser?Ile?Glu?Val?Glu?Asn?Asp?Phe?Leu?Pro?Val

225 230 235 240

Glu?Lys?Thr?Ile?Gly?Lys?Lys?Leu?Pro?Ala?Thr?Thr?Ala?Thr?Pro?Asp

245 250 255

Ser?Ser?Lys?Thr?Glu?Met?Asp?Ser?Arg?Thr?Lys?Ser?Lys?Asp?Tyr?Cys

260 265 270

Lys?Val?Ile?Phe?Pro?Tyr?Glu?Ala?Gln?Asn?Asp?Asp?Glu?Leu?Thr?Ile

275 280 285

Lys?Glu?Gly?Asp?Ile?Val?Thr?Leu?Ile?Asn?Lys?Asp?Cys?Ile?Asp?Val

290 295 300

Gly?Trp?Trp?Glu?Gly?Glu?Leu?Asn?Gly?Arg?Arg?Gly?Val?Phe?Pro?Asp

305 310 315 320

Asn?Phe?Val?Lys?Leu?Leu?Pro?Pro?Asp?Phe?Glu?Lys?Glu?Gly?Asn?Arg

325 330 335

Pro?Lys?Lys?Pro?Pro?Pro?Pro?Ser?Ala?Pro?Val?Ile?Lys?Gln?Gly?Ala

340 345 350

Gly?Thr?Thr?Glu?Arg?Lys?His?Glu?Ile?Lys?Lys?Ile?Pro?Pro?Glu?Arg

355 360 365

Pro?Glu?Met?Leu?Pro?Asn?Arg?Thr?Glu?Glu?Lys?Glu?Arg?Pro?Glu?Arg

370 375 380

Glu?Pro?Lys?Leu?Asp?Leu?Gln?Lys?Pro?Ser?Val?Pro?Ala?Ile?Pro?Pro

385 390 395 400

Lys?Lys?Pro?Arg?Pro?Pro?Lys?Thr?Asn?Ser?Leu?Ser?Arg?Pro?Gly?Ala

405 410 415

Leu?Pro?Pro?Arg?Arg?Pro?Glu?Arg?Pro?Val?Gly?Pro?Leu?Thr?His?Thr

420 425 430

Arg?Gly?Asp?Ser?Pro?Lys?Ile?Asp?Leu?Ala?Gly?Ser?Ser?Leu?Ser?Gly

435 440 445

Ile?Leu?Asp?Lys?Asp?Leu?Ser?Asp?Arg?Ser?Asn?Asp?Ile?Asp?Leu?Glu

450 455 460

Gly?Phe?Asp?Ser?Val?Val?Ser?Ser?Thr?Glu?Lys?Leu?Ser?His?Pro?Thr

465 470 475 480

Thr?Ser?Arg?Pro?Lys?Ala?Thr?Gly?Arg?Arg?Pro?Pro?Ser?Gln?Ser?Leu

485 490 495

Thr?Ser?Ser?Ser?Leu?Ser?Ser?Pro?Asp?Ile?Phe?Asp?Ser?Pro?Ser?Pro

500 505 510

Glu?Glu?Asp?Lys?Glu?Glu?His?Ile?Ser?Leu?Ala?His?Arg?Gly?Val?Asp

515 520 525

Ala?Ser?Lys?Lys?Thr?Ser?Lys?Thr?Val?Thr?Ile?Ser?Gln?Val?Ser?Asp

530 535 540

Asn?Lys?Ala?Ser?Leu?Pro?Pro?Lys?Pro?Gly?Thr?Met?Ala?Ala?Gly?Gly

545 550 555 560

Gly?Gly?Pro?Ala?Pro?Leu?Ser?Ser?Ala?Ala?Pro?Ser?Pro?Leu?Ser?Ser

565 570 575

Ser?Leu?Gly?Thr?Ala?Gly?His?Arg?Ala?Asn?Ser?Pro?Ser?Leu?Phe?Gly

580 585 590

Thr?Glu?Gly?Lys?Pro?Lys?Met?Glu?Pro?Ala?Ala?Ser?Ser?Gln?Ala?Ala

595 600 605

Val?Glu?Glu?Leu?Arg?Thr?Gln?Val?Arg?Glu?Leu?Arg?Ser?Ile?Ile?Glu

610 615 620

Thr?Met?Lys?Asp?Gln?Gln?Lys?Arg?Glu?Ile?Lys?Gln?Leu?Leu?Ser?Glu

625 630 635 640

Leu?Asp?Glu?Glu?Lys?Lys?Ile?Arg?Leu?Arg?Leu?Gln?Met?Glu?Val?Asn

645 650 655

Asp?Ile?Lys?Lys?Ala?Leu?Gln?Ser?Lys

660 665

<210>7

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP10 of GlG10

<400>7

aagcttccac?gta 13

<210>8

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG10

<400>8

aagctttttt?tttttc 16

<210>9

<211>3718

<212>DNA

＜213〉mankind

<400>9

gactgcaaag?tgagcgagaa?gcaggctgcg?ggccgtccca?gcacgacgtg?gagccccgcg 60

gagacctcga?gatgccccgc?ggggaagctc?ctggccccgg?gagacggggg?gctaaggacg 120

aggccctggg?cgaagaatcg?ggggagcggt?ggagccccga?gttccatctg?cagaggaaat 180

tggcggacag?cagccacagt?gaacagcaag?atcgaaacag?agtttctgaa?gaacttatca 240

tggttgtcca?agaaatgaaa?aaatacttcc?cctcggagag?acgcaataaa?ccaagcactc 300

tagatgccct?caactatgct?ctccgctgtg?tccacagcgt?tcaagcaaac?agtgagtttt 360

tccagattct?cagtcagaat?ggagcacctc?aggcagatgt?gagcatgtac?agtcttgagg 420

agctggccac?tatcgcttca?gaacacactt?ccaaaaacac?agataccttt?gtggcagtat 480

tttcatttct?gtctggaagg?ttagtgcaca?tttctgaaca?ggctgctttg?atcctgaatc 540

gtaagaaaga?tgtcctggcg?tcttctcact?ttgttgacct?gcttgcacct?caagacatga 600

gggtattcta?cgcgcacact?gccagagctc?agcttccttt?ctggaacaac?tggacccaaa 660

gagctgcacg?gtatgaatgt?gctccggtga?aacctttttt?ctgcaggatc?cgtggaggtg 720

aagacagaaa?gcaagagaag?tgtcactccc?cattccggat?catcccctat?ctgattcatg 780

tacatcaccc?tgcccagcca?gaattggaat?cggaaccttg?ctgtctcact?gtggttgaaa 840

agattcactc?tggttatgaa?gctcctcgga?tcccagtgaa?taaaagaatc?ttcaccacca 900

cacacacccc?agggtgtgtt?tttcttgaag?tagatgaaaa?agcagtgcct?ttgctgggtt 960

acctacctca?ggacctgatt?ggaacatcga?tcctaagcta?cctgcaccct?gaagatcgtt 1020

ctctgatggt?tgccatacac?caaaaagttt?tgaagtatgc?agggcatcct?ccctttgaac 1080

attctcccat?tcgattttgt?actcaaaacg?gagactacat?catactggat?tccagttggt 1140

ccagctttgt?gaatccctgg?agccggaaga?tttctttcat?cattggtcgg?cataaagttc 1200

gaacgagccc?actaaatgag?gatgtttttg?ctaccaaaat?taaaaagatg?aacgataatg 1260

acaaagacat?aacagaatta?caagaacaaa?tttacaaact?tctcttacag?ccagttcacg 1320

tgagcgtgtc?cagcggctac?gggagcctgg?ggagcagcgg?gtcgcaggag?cagcttgtca 1380

gcatcgcctc?ctccagtgag?gccagtgggc?accgtgtgga?ggagacgaag?gcggagcaga 1440

tgaccttgca?gcaggtctat?gccagtgtga?acaaaattaa?aaatctgggt?cagcagctct 1500

acattgagtc?aatgaccaaa?tcatcattca?agccagtgac?ggggacacgc?acagaaccga 1560

atggtggtgg?tgaatgtaag?acctttactt?ccttccacca?aacactgaaa?aacaatagtg 1620

tgtacactga?gccctgtgag?gatttgagga?acgatgagca?cagcccatcc?tatcaacaga 1680

tcaactgtat?cgacagtgtc?atcagatacc?tgaagagcta?caacattcca?gctttgaaaa 1740

gaaagtgtat?ctcctgtaca?aatacaactt?cttcctcctc?agaagaagac?aaacagaacc 1800

acaaggcaga?tgatgtccaa?gccttacaag?ctggtttgca?aatcccagcc?atacctaaat 1860

cagaaatgcc?aacaaatgga?cggtccatag?acacaggagg?aggagctcca?cagatcctgt 1920

ccacggcgat?gctgagcttg?gggtcgggca?taagccaatg?cggttacagc?agcaccattg 1980

tccatgtccc?acccccagag?acagccaggg?atgctaccct?cttctgtgag?ccctggaccc 2040

tgaacatgca?gccagcccct?ttgacctcgg?aagaatttaa?acacgtgggg?ctcacagcgg 2100

ctgttctgtc?agcgcacacc?cagaaggaag?agcagaatta?tgttgataaa?ttccgagaaa 2160

agatcctgtc?atcaccctac?agctcctatc?ttcagcaaga?aagcaggagc?aaagctaaat 2220

attcatattt?tcaaggagat?tctacttcca?agcagacgcg?gtcggccggc?tgcaggaaag 2280

ggaagcacaa?gcggaagaag?ctgccggagc?cgccagacag?cagcagctcg?aacaccggct 2340

ctggtccccg?caggggagcg?catcagaacg?cacagccctg?ctgcccctcc?gcggcctcct 2400

ctccgcacac?ctcgagcccg?accttcccac?ctgccgccat?ggtgcccagc?caggcccctt 2460

acctcgtccc?agcttttccc?ctcccagccg?cgacctcacc?cggaagagaa?tacgcagccc 2520

ccggaactgc?accggaaggc?ctgcatgggc?tgcccttgtc?cgagggcttg?cagccttacc 2580

cagctttccc?ttttccttac?ttggatactt?ttatgaccgt?tttcctgcct?gacccccctg 2640

tctgtcctct?gttgtcgcca?tcgtttttgc?catgtccatt?cctgggggcg?acagcctctt 2700

ctgcgatatc?accctcaatg?tcgtcagcaa?tgagtccaac?tctggaccca?cccccttcag 2760

tcaccagcca?aaggagagag?gaggaaaagt?gggaggcaca?aagcgagggg?cacccgttca 2820

ttacttcgag?aagcagctca?cccttgcagt?taaacttact?tcaggaagag?atgcccagac 2880

cctctgaatc?tccagatcag?atgagaagga?acacgtgccc?acaaactgag?tattgtgtta 2940

caggcaacaa?tggcagtgag?agcagtcctg?ctactaccgg?tgcactgtcc?acggggtcac 3000

ctcccaggga?gaatccatcc?catcctactg?ccagcgctct?gtccacagga?tcgcctccca 3060

tgaagaatcc?atcccatcct?actgccagcg?ctctgtccac?aggatcgcct?cccatgaaga 3120

atccatccca?tcctactgcc?agcacactgt?ccatgggat?tgcctcccagc?aggactccat 3180

cccatcctac?tgccactgtt?ctgtccacgg?ggtcacctcc?cagcgaatcc?ccatccagaa 3240

ctggttcagc?agcatcagga?agcagcgaca?gcagtatata?ccttactagt?agtgtttatt 3300

cttctaaaat?ctcccaaaat?gggcagcaat?ctcaggacgt?acagaaaaaa?gaaacatttc 3360

ctaatgtcgc?cgaagagccc?atctggagaa?tgatacggca?gacacctgag?cgcattctca 3420

tgacatacca?ggtacctgag?agggttaaag?aagttgtact?aaaagaagac?ctggaaaagc 3480

tagaaagtat?gaggcagcag?cagccccagt?tttctcatgg?gcaaaaggag?gagctggcta 3540

aggtgtataa?ttggattcaa?agccagactg?tcactcaaga?aatcgacatt?caagcctgtg 3600

tcacttgtga?aaatgaagat?tcagctgatg?gtgcggccac?atcctgtggt?caggttctgg 3660

tagaagacag?ctgttgagtg?actgtgagga?tgaaccttca?taccctttcc?aagacgtg 3718

<210>10

<211>1201

<212>PRT

＜213〉mankind

<400>10

Met?Pro?Arg?Gly?Glu?Ala?Pro?Gly?Pro?Gly?Arg?Arg?Gly?Ala?Lys?Asp

1 5 10 15

Glu?Ala?Leu?Gly?Glu?Glu?Ser?Gly?Glu?Arg?Trp?Ser?Pro?Glu?Phe?His

20 25 30

Leu?Gln?Arg?Lys?Leu?Ala?Asp?Ser?Ser?His?Ser?Glu?Gln?Gln?Asp?Arg

35 40 45

Asn?Arg?Val?Ser?Glu?Glu?Leu?Ile?Met?Val?Val?Gln?Glu?Met?Lys?Lys

50 55 60

Tyr?Phe?Pro?Ser?Glu?Arg?Arg?Asn?Lys?Pro?Ser?Thr?Leu?Asp?Ala?Leu

65 70 75 80

Asn?Tyr?Ala?Leu?Arg?Cys?Val?His?Ser?Val?Gln?Ala?Asn?Ser?Glu?Phe

85 90 95

Phe?Gln?Ile?Leu?Ser?Gln?Asn?Gly?Ala?Pro?Gln?Ala?Asp?Val?Ser?Met

100 105 110

Tyr?Ser?Leu?Glu?Glu?Leu?Ala?Thr?Ile?Ala?Ser?Glu?His?Thr?Ser?Lys

115 120 125

Asn?Thr?Asp?Thr?Phe?Val?Ala?Val?Phe?Ser?Phe?Leu?Ser?Gly?Arg?Leu

130 135 140

Val?His?Ile?Ser?Glu?Gln?Ala?Ala?Leu?Ile?Leu?Asn?Arg?Lys?Lys?Asp

145 150 155 160

Val?Leu?Ala?Ser?Ser?His?Phe?Val?Asp?Leu?Leu?Ala?Pro?Gln?Asp?Met

165 170 175

Arg?Val?Phe?Tyr?Ala?His?Thr?Ala?Arg?Ala?Gln?Leu?Pro?Phe?Trp?Asn

180 185 190

Asn?Trp?Thr?Gln?Arg?Ala?Ala?Arg?Tyr?Glu?Cys?Ala?Pro?Val?Lys?Pro

195 200 205

Phe?Phe?Cys?Arg?Ile?Arg?Gly?Gly?Glu?Asp?Arg?Lys?Gln?Glu?Lys?Cys

210 215 220

His?Ser?Pro?Phe?Arg?Ile?Ile?Pro?Tyr?Leu?Ile?His?Val?His?His?Pro

225 230 235 240

Ala?Gln?Pro?Glu?Leu?Glu?Ser?Glu?Pro?Cys?Cys?Leu?Thr?Val?Val?Glu

245 250 255

Lys?Ile?His?Ser?Gly?Tyr?Glu?Ala?Pro?Arg?Ile?Pro?Val?Asn?Lys?Arg

260 265 270

Ile?Phe?Thr?Thr?Thr?His?Thr?Pro?Gly?Cys?Val?Phe?Leu?Glu?Val?Asp

275 280 285

Glu?Lys?Ala?Val?Pro?Leu?Leu?Gly?Tyr?Leu?Pro?Gln?Asp?Leu?Ile?Gly

290 295 300

Thr?Ser?Ile?Leu?Ser?Tyr?Leu?His?Pro?Glu?Asp?Arg?Ser?Leu?Met?Val

305 310 315 320

Ala?Ile?His?Gln?Lys?Val?Leu?Lys?Tyr?Ala?Gly?His?Pro?Pro?Phe?Glu

325 330 335

His?Ser?Pro?Ile?Arg?Phe?Cys?Thr?Gln?Asn?Gly?Asp?Tyr?Ile?Ile?Leu

340 345 350

Asp?Ser?Ser?Trp?Ser?Ser?Phe?Val?Asn?Pro?Trp?Ser?Arg?Lys?Ile?Ser

355 360 365

Phe?Ile?Ile?Gly?Arg?His?Lys?Val?Arg?Thr?Ser?Pro?Leu?Asn?Glu?Asp

370 375 380

Val?Phe?Ala?Thr?Lys?Ile?Lys?Lys?Met?Asn?Asp?Asn?Asp?Lys?Asp?Ile

385 390 395 400

Thr?Glu?Leu?Gln?Glu?Gln?Ile?Tyr?Lys?Leu?Leu?Leu?Gln?Pro?Val?His

405 410 415

Val?Ser?Val?Ser?Ser?Gly?Tyr?Gly?Ser?Leu?Gly?Ser?Ser?Gly?Ser?Gln

420 425 430

Glu?Gln?Leu?Val?Ser?Ile?Ala?Ser?Ser?Ser?Glu?Ala?Ser?Gly?His?Arg

435 440 445

Val?Glu?Glu?Thr?Lys?Ala?Glu?Gln?Met?Thr?Leu?Gln?Gln?Val?Tyr?Ala

450 455 460

Ser?Val?Asn?Lys?Ile?Lys?Asn?Leu?Gly?Gln?Gln?Leu?Tyr?Ile?Glu?Ser

465 470 475 480

Met?Thr?Lys?Ser?Ser?Phe?Lys?Pro?Val?Thr?Gly?Thr?Arg?Thr?Glu?Pro

485 490 495

Asn?Gly?Gly?Gly?Glu?Cys?Lys?Thr?Phe?Thr?Ser?Phe?His?Gln?Thr?Leu

500 505 510

Lys?Asn?Asn?Ser?Val?Tyr?Thr?Glu?Pro?Cys?Glu?Asp?Leu?Arg?Asn?Asp

515 520 525

Glu?His?Ser?Pro?Ser?Tyr?Gln?Gln?Ile?Asn?Cys?Ile?Asp?Ser?Val?Ile

530 535 540

Arg?Tyr?Leu?Lys?Ser?Tyr?Asn?Ile?Pro?Ala?Leu?Lys?Arg?Lys?Cys?Ile

545 550 555 560

Ser?Cys?Thr?Asn?Thr?Thr?Ser?Ser?Ser?Ser?Glu?Glu?Asp?Lys?Gln?Asn

565 570 575

His?Lys?Ala?Asp?Asp?Val?Gln?Ala?Leu?Gln?Ala?Gly?Leu?Gln?Ile?Pro

580 585 590

Ala?Ile?Pro?Lys?Ser?Glu?Met?Pro?Thr?Asn?Gly?Arg?Ser?Ile?Asp?Thr

595 600 605

Gly?Gly?Gly?Ala?Pro?Gln?Ile?Leu?Ser?Thr?Ala?Met?Leu?Ser?Leu?Gly

610 615 620

Ser?Gly?Ile?Ser?Gln?Cys?Gly?Tyr?Ser?Ser?Thr?Ile?Val?His?Val?Pro

625 630 635 640

Pro?Pro?Glu?Thr?Ala?Arg?Asp?Ala?Thr?Leu?Phe?Cys?Glu?Pro?Trp?Thr

645 650 655

Leu?Asn?Met?Gln?Pro?Ala?Pro?Leu?Thr?Ser?Glu?Glu?Phe?Lys?His?Val

660 665 670

Gly?Leu?Thr?Ala?Ala?Val?Leu?Ser?Ala?His?Thr?Gln?Lys?Glu?Glu?Gln

675 680 685

Asn?Tyr?Val?Asp?Lys?Phe?Arg?Glu?Lys?Ile?Leu?Ser?Ser?Pro?Tyr?Ser

690 695 700

Ser?Tyr?Leu?Gln?Gln?Glu?Ser?Arg?Ser?Lys?Ala?Lys?Tyr?Ser?Tyr?Phe

705 710 715 720

Gln?Gly?Asp?Ser?Thr?Ser?Lys?Gln?Thr?Arg?Ser?Ala?Gly?Cys?Arg?Lys

725 730 735

Gly?Lys?His?Lys?Arg?Lys?Lys?Leu?Pro?Glu?Pro?Pro?Asp?Ser?Ser?Ser

740 745 750

Ser?Asn?Thr?Gly?Ser?Gly?Pro?Arg?Arg?Gly?Ala?His?Gln?Asn?Ala?Gln

755 760 765

Pro?Cys?Cys?Pro?Ser?Ala?Ala?Ser?Ser?Pro?His?Thr?Ser?Ser?Pro?Thr

770 775 780

Phe?Pro?Pro?Ala?Ala?Met?Val?Pro?Ser?Gln?Ala?Pro?Tyr?Leu?Val?Pro

785 790 795 800

Ala?Phe?Pro?Leu?Pro?Ala?Ala?Thr?Ser?Pro?Gly?Arg?Glu?Tyr?Ala?Ala

805 810 815

Pro?Gly?Thr?Ala?Pro?Glu?Gly?Leu?His?Gly?Leu?Pro?Leu?Ser?Glu?Gly

820 825 830

Leu?Gln?Pro?Tyr?Pro?Ala?Phe?Pro?Phe?Pro?Tyr?Leu?Asp?Thr?Phe?Met

835 840 845

Thr?Val?Phe?Leu?Pro?Asp?Pro?Pro?Val?Cys?Pro?Leu?Leu?Ser?Pro?Ser

850 855 860

Phe?Leu?Pro?Cys?Pro?Phe?Leu?Gly?Ala?Thr?Ala?Ser?Ser?Ala?Ile?Ser

865 870 875 880

Pro?Ser?Met?Ser?Ser?Ala?Met?Ser?Pro?Thr?Leu?Asp?Pro?Pro?Pro?Ser

885 890 895

Val?Thr?Ser?Gln?Arg?Arg?Glu?Glu?Glu?Lys?Trp?Glu?Ala?Gln?Ser?Glu

900 905 910

Gly?His?Pro?Phe?Ile?Thr?Ser?Arg?Ser?Ser?Ser?Pro?Leu?Gln?Leu?Asn

915 920 925

Leu?Leu?Gln?Glu?Glu?Met?Pro?Arg?Pro?Ser?Glu?Ser?Pro?Asp?Gln?Met

930 935 940

Arg?Arg?Asn?Thr?Cys?Pro?Gln?Thr?Glu?Tyr?Cys?Val?Thr?Gly?Asn?Asn

945 950 955 960

Gly?Ser?Glu?Ser?Ser?Pro?Ala?Thr?Thr?Gly?Ala?Leu?Ser?Thr?Gly?Ser

965 970 975

Pro?Pro?Arg?Glu?Asn?Pro?Ser?His?Pro?Thr?Ala?Ser?Ala?Leu?Ser?Thr

980 985 990

Gly?Ser?Pro?Pro?Met?Lys?Asn?Pro?Ser?His?Pro?Thr?Ala?Ser?Ala?Leu

995 1000 1005

Ser?Thr?Gly?Ser?Pro?Pro?Met?Lys?Asn?Pro?Ser?His?Pro?Thr?Ala?Ser

1010 1015 1020

Thr?Leu?Ser?Met?Gly?Leu?Pro?Pro?Ser?Arg?Thr?Pro?Ser?His?Pro?Thr

1025 1030 1035 1040

Ala?Thr?Val?Leu?Ser?Thr?Gly?Ser?Pro?Pro?Ser?Glu?Ser?Pro?Ser?Arg

1045 1050 1055

Thr?Gly?Ser?Ala?Ala?Ser?Gly?Ser?Ser?Asp?Ser?Ser?Ile?Tyr?Leu?Thr

1060 1065 1070

Ser?Ser?Val?Tyr?Ser?Ser?Lys?Ile?Ser?Gln?Asn?Gly?Gln?Gln?Ser?Gln

1075 1080 1085

Asp?Val?Gln?Lys?Lys?Glu?Thr?Phe?Pro?Asn?Val?Ala?Glu?Glu?Pro?Ile

1090 1095 1100

Trp?Arg?Met?Ile?Arg?Gln?Thr?Pro?Glu?Arg?Ile?Leu?Met?Thr?Tyr?Gln

1105 1110 1115 1120

Val?Pro?Glu?Arg?Val?Lys?Glu?Val?Val?Leu?Lys?Glu?Asp?Leu?Glu?Lys

1125 1130 1135

Leu?Glu?Ser?Met?Arg?Gln?Gln?Gln?Pro?Gln?Phe?Ser?His?Gly?Gln?Lys

1140 1145 1150

Glu?Glu?Leu?Ala?Lys?Val?Tyr?Asn?Trp?Ile?Gln?Ser?Gln?Thr?Val?Thr

1155 1160 1165

Gln?Glu?Ile?Asp?Ile?Gln?Ala?Cys?Val?Thr?Cys?Glu?Asn?Glu?Asp?Ser

1170 1175 1180

Ala?Asp?Gly?Ala?Ala?Thr?Ser?Cys?Gly?Gln?Val?Leu?Val?Glu?Asp?Ser

1185 1190 1195 1200

Cys

<210>11

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP5 of GI G13

<400>11

aagcttagta?ggc 13

<210>12

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG13

<400>12

aagctttttt tttttc 16

<210>13

<211>351

<212>DNA

＜213〉mankind

<400>13

atagcgctca?cgcaagcatg?gttaacgtcc?ctaaaacccg?ccggactttc?tgtaagaagt 60

gtggcaagca?ccaaccccat?aaagtgacac?agtacaagaa?gggcaaggat?tctctgtacg 120

cccagggaaa?gcggcgttat?gacaggaagc?agagtggcta?tggtgggcaa?actaagccga 180

ttttccggaa?aaaggctaaa?actacaaaga?agattgtgct?aaggcttgag?tgcgttgagc 240

ccaactgcag?atctaagaga?atgctggcta?ttaaaagatg?caagcatttt?gaactgggag 300

gagataagaa?gagaaagggc?caagtgatcc?agttctaagt?gtcatctttt?a 351

<210>14

<211>106

<212>PRT

＜213〉mankind

<400>14

Met?Val?Asn?Val?Pro?Lys?Thr?Arg?Arg?Thr?Phe?Cys?Lys?Lys?Cys?Gly

1 5 10 15

Lys?His?Gln?Pro?His?Lys?Val?Thr?Gln?Tyr?Lys?Lys?Gly?Lys?Asp?Ser

20 25 30

Leu?Tyr?Ala?Gln?Gly?Lys?Arg?Arg?Tyr?Asp?Arg?Lys?Gln?Ser?Gly?Tyr

35 40 45

Gly?Gly?Gln?Thr?Lys?Pro?Ile?Phe?Arg?Lys?Lys?Ala?Lys?Thr?Thr?Lys

50 55 60

Lys?Ile?Val?Leu?Arg?Leu?Glu?Cys?Val?Glu?Pro?Asn?Cys?Arg?Ser?Lys

65 70 75 80

Arg?Met?Leu?Ala?Ile?Lys?Arg?Cys?Lys?His?Phe?Glu?Leu?Gly?Gly?Asp

85 90 95

Lys?Lys?Arg?Lys?Gly?Gln?Val?Ile?Gln?Phe

100 105

<210>15

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP2 of GIG15

<400>15

aagcttcgac?tgt 13

<210>16

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG15

<400>16

aagctttttt?tttttc 16

<210>17

<211>1131

<212>DNA

＜213〉mankind

<400>17

tttccctgag?gactggaaga?cattagaata?aggtccagaa?atgtccttgg?tgtgtctgac 60

agactttcag?gcccatgcgc?gagagcagct?gtctaagtca?actcgggatt?ttattgaagg 120

tggagcagat?gacagcatca?cgcgggatga?caacattgca?gcgtttaaaa?gaattcgcct 180

ccgtccgcgg?tacctgagag?atgtgtctga?ggtggacacc?agaaccacaa?tccaagggga 240

ggagatcagt?gcccctattt?gtatcgcacc?cacagggttc?cactgccttg?tctggcctga 300

tggggaaatg?agcaccgcaa?gagctgccca?agcggctggt?atctgctaca?tcaccagcac 360

atttgccagc?tgtagccttg?aagacattgt?cattgcagct?cccgaaggcc?tccgatggtt 420

ccaactctat?gtgcatccag?acctgcagct?gaacaaacag?ttgatccaga?gggtagaatc 480

cctaggtttc?aaagctttgg?taataacttt?ggatacacct?gtatgtggca?acaggcgaca 540

tgacattcga?aaccagttga?ggaggaactt?aacactaaca?gatcttcaat?cacctaaaaa 600

gggaaatgca?ataccttatt?tccagatgac?tcctatcagc?acttctctct?gctggaatga 660

tctctcctgg?tttcagagca?taactcgatt?gcccatcatc?ctgaaaggga?ttttgacaaa 720

agaggatgca?gagttagctg?tgaagcacaa?tgtccagggt?atcattgttt?ccaaccatgg 780

tgggaggcag?cttgatgagg?ttcttgcttc?aattgatgct?ttgacagaag?tggtggctgc 840

tgtaaagggg?aaaattgaag?tctacctgga?tggcggggtc?cgaactggca?atgatgtgct 900

gaaggctctg?gcccttggag?ctaagtgcat?ttttcttggg?agaccaatcc?tatggggcct 960

tgcctgcaag?ggtgaacatg?gtgttaagga?agttttgaac?attttaacaa?atgagttcca 1020

cacttccatg?gcccttacag?gctgccggtc?ggtcgctgag?atcaatcgaa?acttggtcca 1080

gttttccagg?ctgtaagaaa?aaagggccaa?caaccagact?gctgaggttg?c 1131

<210>18

<211>351

<212>PRT

＜213〉mankind

<400>18

Met?Ser?Leu?Val?Cys?Leu?Thr?Asp?Phe?Gln?Ala?His?Ala?Arg?Glu?Gln

1 5 10 15

Leu?Ser?Lys?Ser?Thr?Arg?Asp?Phe?Ile?Glu?Gly?Gly?Ala?Asp?Asp?Ser

20 25 30

Ile?Thr?Arg?Asp?Asp?Asn?Ile?Ala?Ala?Phe?Lys?Arg?Ile?Arg?Leu?Arg

35 40 45

Pro?Arg?Tyr?Leu?Arg?Asp?Val?Ser?Glu?Val?Asp?Thr?Arg?Thr?Thr?Ile

50 55 60

Gln?Gly?Glu?Glu?Ile?Ser?Ala?Pro?Ile?Cys?Ile?Ala?Pro?Thr?Gly?Phe

65 70 75 80

His?Cys?Leu?Val?Trp?Pro?Asp?Gly?Glu?Met?Ser?Thr?Ala?Arg?Ala?Ala

85 90 95

Gln?Ala?Ala?Gly?Ile?Cys?Tyr?Ile?Thr?Ser?Thr?Phe?Ala?Ser?Cys?Ser

100 105 110

Leu?Glu?Asp?Ile?Val?Ile?Ala?Ala?Pro?Glu?Gly?Leu?Arg?Trp?Phe?Gln

115 120 125

Leu?Tyr?Val?His?Pro?Asp?Leu?Gln?Leu?Asn?Lys?Gln?Leu?Ile?Gln?Arg

130 135 140

Val?Glu?Ser?Leu?Gly?Phe?Lys?Ala?Leu?Val?Ile?Thr?Leu?Asp?Thr?Pro

145 150 155 160

Val?Cys?Gly?Asn?Arg?Arg?His?Asp?Ile?Arg?Asn?Gln?Leu?Arg?Arg?Asn

165 170 175

Leu?Thr?Leu?Thr?Asp?Leu?Gln?Ser?Pro?Lys?Lys?Gly?Asn?Ala?Ile?Pro

180 185 190

Tyr?Phe?Gln?Met?Thr?Pro?Ile?Ser?Thr?Ser?Leu?Cys?Trp?Asn?Asp?Leu

195 200 205

Ser?Trp?Phe?Gln?Ser?Ile?Thr?Arg?Leu?Pro?Ile?Ile?Leu?Lys?Gly?Ile

210 215 220

Leu?Thr?Lys?Glu?Asp?Ala?Glu?Leu?Ala?Val?Lys?His?Asn?Val?Gln?Gly

225 230 235 240

Ile?Ile?Val?Ser?Asn?His?Gly?Gly?Arg?Gln?Leu?Asp?Glu?Val?Leu?Ala

245 250 255

Ser?Ile?Asp?Ala?Leu?Thr?Glu?Val?Val?Ala?Ala?Val?Lys?Gly?Lys?Ile

260 265 270

Glu?Val?Tyr?Leu?Asp?Gly?Gly?Val?Arg?Thr?Gly?Asn?Asp?Val?Leu?Lys

275 280 285

Ala?Leu?Ala?Leu?Gly?Ala?Lys?Cys?Ile?Phe?Leu?Gly?Arg?Pro?Ile?Leu

290 295 300

Trp?Gly?Leu?Ala?Cys?Lys?Gly?Glu?His?Gly?Val?Lys?Glu?Val?Leu?Asn

305 310 315 320

Ile?Leu?Thr?Asn?Glu?Phe?His?Thr?Ser?Met?Ala?Leu?Thr?Gly?Cys?Arg

325 330 335

Ser?Val?Ala?Glu?Ile?Asn?Arg?Asn?Leu?Val?Gln?Phe?Ser?Arg?Leu

340 345 350

<210>19

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP8 of GlG16

<400>19

aagcttttac?cgc 13

<210>20

<211>16

<212>0NA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GlG16

<400>20

aagctttttt?tttttc 16

<210>21

<211>1336

<212>DNA

＜213〉mankind

<400>21

agctacatcc?agctccctga?ggcagagttg?agaatggaga?gaatgttacc?tctcctgact 60

ctggggctct?tagcggctgg?gttctgccct?gctgtcctct?gccaccctaa?cagcccactt 120

gacgaggaga?atctgaccca?ggagaaccaa?gaccgaggga?cacacgtgga?cctcggatta 180

gcctccgcca?acgtggactt?cgctttcagc?ctgtacaagc?agttagtcct?gaaggcccct 240

gataagaatg?tcatcttctc?cccactgagc?atctccaccg?ccttggcctt?cctgtctctg 300

ggggcccata?ataccaccct?gacagagatt?ctcaaaggcc?tcaagttcta?cctcacggag 360

acttctgagg?cagaaattca?ccagagcttc?cagcacctcc?tgcgcaccct?caatcagtcc 420

agcgatgagc?tgcagctgag?tatgggaaat?gccatgtttg?tcaaagagca?actcagtctg 480

ctggacaggt?tcacggagga?tgccaagagg?ctgtatggct?ccgaggcctt?tgccactgac 540

tttcaggact?cagctgcagc?taagaagctc?atcaacgact?acgtgaagaa?tggaactagg 600

gggaaaatca?cagatctgat?caaggacctt?gactcgcaga?caatgatggt?cctggtgaat 660

tacatcttct?ttaaagccaa?atgggagatg?ccctttgacc?cccaagatac?tcatcagtca 720

aggttctact?tgagcaagaa?aaagtgggta?atggtgccta?tgatgagttt?gcatcacctg 780

actatacctt?acttccggga?cgaggagctg?tcctgcaccg?tggtggagct?gaagtacaca 840

ggcaatgcca?gcgcactctt?catcctccct?gatcaagaca?agatggagga?agtggaagcc 900

atgctgctcc?cagagaccct?gaagcggtgg?agagactctc?tggagttcag?agagataggt 960

gagctctacc?tgccaaagtt?ttccatctcg?agggactata?acctgaacga?catacttctc 1020

cagctgggca?ttgaggaagc?cttcaccggc?aaggctgacc?tgtcagggag?cacaggggcc 1080

aggaacctag?cagtctccca?ggtggtccat?aaggctgtgc?ttgatgtatt?tgaggagggc 1140

acagaagcat?ctgctgccac?agcagtcaaa?atcaccctcc?tttctgcatt?agtggagaca 1200

aggaccattg?tgcgtttcaa?caggcccttc?ctgatgatca?ttgtccctac?agacacccag 1260

aacatcttct?tcatgagcaa?agtcaccaat?cccaagcaag?cctagagctt?gccatcaagc 1320

agtggggctc?tcagta 1336

<210>22

<211>423

<212>PRT

＜213〉mankind

<400>22

Met?Glu?Arg?Met?Leu?Pro?Leu?Leu?Thr?Leu?Gly?Leu?Leu?Ala?Ala?Gly

1 5 10 15

Phe?Cys?Pro?Ala?Val?Leu?Cys?His?Pro?Asn?Ser?Pro?Leu?Asp?Glu?Glu

20 25 30

Asn?Leu?Thr?Gln?Glu?Asn?Gln?Asp?Arg?Gly?Thr?His?Val?Asp?Leu?Gly

35 40 45

Leu?Ala?Ser?Ala?Asn?Val?Asp?Phe?Ala?Phe?Ser?Leu?Tyr?Lys?Gln?Leu

50 55 60

Val?Leu?Lys?Ala?Pro?Asp?Lys?Asn?Val?Ile?Phe?Ser?Pro?Leu?Ser?Ile

65 70 75 80

Ser?Thr?Ala?Leu?Ala?Phe?Leu?Ser?Leu?Gly?Ala?His?Asn?Thr?Thr?Leu

85 90 95

Thr?Glu?Ile?Leu?Lys?Gly?Leu?Lys?Phe?Tyr?Leu?Thr?Glu?Thr?Ser?Glu

100 105 110

Ala?Glu?Ile?His?Gln?Ser?Phe?Gln?His?Leu?Leu?Arg?Thr?Leu?Asn?Gln

115 120 125

Ser?Ser?Asp?Glu?Leu?Gln?Leu?Ser?Met?Gly?Asn?Ala?Met?Phe?Val?Lys

130 135 140

Glu?Gln?Leu?Ser?Leu?Leu?Asp?Arg?Phe?Thr?Glu?Asp?Ala?Lys?Arg?Leu

145 150 155 160

Tyr?Gly?Ser?Glu?Ala?Phe?Ala?Thr?Asp?Phe?Gln?Asp?Ser?Ala?Ala?Ala

165 170 175

Lys?Lys?Leu?Ile?Asn?Asp?Tyr?Val?Lys?Asn?Gly?Thr?Arg?Gly?Lys?Ile

180 185 190

Thr?Asp?Leu?Ile?Lys?Asp?Leu?Asp?Ser?Gln?Thr?Met?Met?Val?Leu?Val

195 200 205

Asn?Tyr?Ile?Phe?Phe?Lys?Ala?Lys?Trp?Glu?Met?Pro?Phe?Asp?Pro?Gln

210 215 220

Asp?Thr?His?Gln?Ser?Arg?Phe?Tyr?Leu?Ser?Lys?Lys?Lys?Trp?Val?Met

225 230 235 240

Val?Pro?Met?Met?Ser?Leu?His?His?Leu?Thr?Ile?Pro?Tyr?Phe?Arg?Asp

245 250 255

Glu?Glu?Leu?Ser?Cys?Thr?Val?Val?Glu?Leu?Lys?Tyr?Thr?Gly?Asn?Ala

260 265 270

Ser?Ala?Leu?Phe?Ile?Leu?Pro?Asp?Gln?Asp?Lys?Met?Glu?Glu?Val?Glu

275 280 285

Ala?Met?Leu?Leu?Pro?Glu?Thr?Leu?Lys?Arg?Trp?Arg?Asp?Ser?Leu?Glu

290 295 300

Phe?Arg?Glu?Ile?Gly?Glu?Leu?Tyr?Leu?Pro?Lys?Phe?Ser?Ile?Ser?Arg

305 310 315 320

Asp?Tyr?Asn?Leu?Asn?Asp?Ile?Leu?Leu?Gln?Leu?Gly?Ile?Glu?Glu?Ala

325 330 335

Phe?Thr?Gly?Lys?Ala?Asp?Leu?Ser?Gly?Ser?Thr?Gly?Ala?Arg?Asn?Leu

340 345 350

Ala?Val?Ser?Gln?Val?Val?His?Lys?Ala?Val?Leu?Asp?Val?Phe?Glu?Glu

355 360 365

Gly?Thr?Glu?Ala?Ser?Ala?Ala?Thr?Ala?Val?Lys?Ile?Thr?Leu?Leu?Ser

370 375 380

Ala?Leu?Val?Glu?Thr?Arg?Thr?Ile?Val?Arg?Phe?Asn?Arg?Pro?Phe?Leu

385 390 395 400

Met?Ile?Ile?Val?Pro?Thr?Asp?Thr?Gln?Asn?Ile?Phe?Phe?Met?Ser?Lys

405 410 415

Val?Thr?Asn?Pro?Lys?Gln?Ala

420

<210>23

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP7 of GIG24

<400>23

aagcttaacg?agg 13

<210>24

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG24

<400>24

aagctttttt?tttttc 16

<210>25

<211>1402

<212>DNA

＜213〉mankind

<400>25

tgatgcacag?aagctcctag?aaaaaatggg?tggctcagca?ccaccagata?gcagctggag 60

aggaagtctc?aaagtgtcct?acaatgttgg?acctggcttt?actggaaact?tttctacaca 120

aaaagtcaag?atgcacatcc?actctaccaa?tgaagtgacg?agaatttaca?atgtgatagg 180

tactctcaga?ggagcagtgg?aaccagacag?atatgtcatt?ctgggaggtc?accgggactc 240

atgggtgttt?ggtggtattg?accctcagag?tggagcagct?gttgttcatg?aaactgtgag 300

gagctttgga?acactgaaaa?aggaagggtg?gagacctaga?agaacaattt?tgtttgcaag 360

ctgggatgca?gaagaatttg?gtcttcttgg?ttctactgag?tgggcagagg?ataattcaag 420

actccttcaa?gagcgtggcg?tggcttatat?taatgctgac?tcatctatag?aaggaaacta 480

cactctgaga?gttgattgta?caccactgat?gtacagcttg?gtatacaacc?taacaaaaga 540

gctgaaaagc?cctgatgaag?gctttgaagg?caaatctctt?tatgaaagtt?ggactaaaaa 600

aagtccttcc?ccagagttca?gtggcatgcc?caggataagc?aaattgggat?ctggaaatga 660

ttttgaggtg?ttcttccaac?gacttggaat?tgcttcaggc?agagcacggt?atactaaaaa 720

ttgggaaaca?aacaaattca?gcggctatcc?actgtatcac?agtgtctatg?aaacatatga 780

gttggtggaa?aagttttatg?atccaatgtt?taaatatcac?ctcactgtgg?cccaggttcg 840

aggagggatg?gtgtttgagc?tagccaattc?catagtgctc?ccttttgatt?gtcgagatta 900

tgctgtagtt?ttaagaaagt?atgctgacaa?aatctacaat?atttctatga?aacatccaca 960

ggaaatgaag?acatacagtt?tatcatttga?ttcacttttt?tctgcagtaa?aaaattttac 1020

agaaattgct?tccaagttca?gcgagagact?ccaggacttt?gacaaaagca?acccaatatt 1080

gttaagaatg?atgaatgatc?aactcatgtt?tctggaaaga?gcatttattg?atccattagg 1140

gttaccagac?agaccttttt?ataggcatgt?catctatgct?ccaagcagcc?acaacaagta 1200

tgcaggggag?tcattcccag?gaatttatga?tgctctgttt?gatattgaaa?gcaaagtgga 1260

cccttccaag?gcctggggag?atgtgaagag?acagatttct?gttgcagcct?tcacagtgca 1320

ggcagctgca?gagactttga?gtgaagtagc?ctaagaggat?tctttagaga?ctctgtattg 1380

aatttgtgtg?gtatgtcact?ca 1402

<210>26

<211>442

<212>pRT

＜213〉mankind

<400>26

Met?Gly?Gly?Ser?Ala?Pro?Pro?Asp?Ser?Ser?Trp?Arg?Gly?Ser?Leu?Lys

1 5 10 15

Val?Ser?Tyr?Asn?Val?Gly?Pro?Gly?Phe?Thr?Gly?Asn?Phe?Ser?Thr?Gln

20 25 30

Lys?Val?Lys?Met?His?Ile?His?Ser?Thr?Asn?Glu?Val?Thr?Arg?Ile?Tyr

35 40 45

Asn?Val?Ile?Gly?Thr?Leu?Arg?Gly?Ala?Val?Glu?Pro?Asp?Arg?Tyr?Val

50 55 60

Ile?Leu?Gly?Gly?His?Arg?Asp?Ser?Trp?Val?Phe?Gly?Gly?Ile?Asp?Pro

65 70 75 80

Gln?Ser?Gly?Ala?Ala?Val?Val?His?Glu?Thr?Val?Arg?Ser?Phe?Gly?Thr

85 90 95

Leu?Lys?Lys?Glu?Gly?Trp?Arg?Pro?Arg?Arg?Thr?Ile?Leu?Phe?Ala?Ser

100 105 110

Trp?Asp?Ala?Glu?Glu?Phe?Gly?Leu?Leu?Gly?Ser?Thr?Glu?Trp?Ala?Glu

115 120 125

Asp?Asn?Ser?Arg?Leu?Leu?Gln?Glu?Arg?Gly?Val?Ala?Tyr?Ile?Asn?Ala

130 135 140

Asp?Ser?Ser?Ile?Glu?Gly?Asn?Tyr?Thr?Leu?Arg?Val?Asp?Cys?Thr?Pro

145 150 155 160

Leu?Met?Tyr?Ser?Leu?Val?Tyr?Asn?Leu?Thr?Lys?Glu?Leu?Lys?Ser?Pro

165 170 175

Asp?Glu?Gly?Phe?Glu?Gly?Lys?Ser?Leu?Tyr?Glu?Ser?Trp?Thr?Lys?Lys

180 185 190

Ser?Pro?Ser?Pro?Glu?Phe?Ser?Gly?Met?Pro?Arg Ile?Ser?Lys?Leu?Gly

195 200 205

Ser?Gly?Asn?Asp?Phe?Glu?Val?Phe?Phe?Gln?Arg?Leu?Gly Ile?Ala?Ser

210 215 220

Gly?Arg?Ala?Arg?Tyr?Thr?Lys?Asn?Trp?Glu?Thr?Asn?Lys?Phe?Ser?Gly

225 230 235 240

Tyr?Pro?Leu?Tyr?His?Ser?Val?Tyr?Glu?Thr?Tyr?Glu?Leu?Val?Glu?Lys

245 250 255

Phe?Tyr?Asp?Pro?Met?Phe?Lys?Tyr?His?Leu?Thr?Val?Ala?Gln?Val?Arg

260 265 270

Gly?Gly?Met?Val?Phe?Glu?Leu?Ala?Asn?Ser Ile?Val?Leu?Pro?Phe?Asp

275 280 285

Cys?Arg?Asp?Tyr?Ala?Val?Val?Leu?Arg?Lys?Tyr?Ala?Asp?Lys?Ile?Tyr

290 295 300

Asn?Ile?Ser?Met?Lys?His?Pro?Gln?Glu?Met?Lys?Thr?Tyr?Ser?Leu?Ser

305 310 315 320

Phe?Asp?Ser?Leu?Phe?Ser?Ala?Val?Lys?Asn?Phe?Thr?Glu?Ile?Ala?Ser

325 330 335

Lys?Phe?Ser?Glu?Arg?Leu?Gln?Asp?Phe?Asp?Lys?Ser?Asn?Pro?Ile?Leu

340 345 350

Leu?Arg?Met?Met?Asn?Asp?Gln?Leu?Met?Phe?Leu?Glu?Arg?Ala?Phe?Ile

355 360 365

Asp?Pro?Leu?Gly?Leu?Pro?Asp?Arg?Pro?Phe?Tyr?Arg?His?Val?Ile?Tyr

370 375 380

Ala?Pro?Ser?Ser?His?Asn?Lys?Tyr?Ala?Gly?Glu?Ser?Phe?Pro?Gly?Ile

385 390 395 400

Tyr?Asp?Ala?Leu?Phe?Asp?Ile?Glu?Ser?Lys?Val?Asp?Pro?Ser?Lys?Ala

405 410 415

Trp?Gly?Asp?Val?Lys?Arg?Gln?Ile?Ser?Val?Ala?Ala?Phe?Thr?Val?Gln

420 425 430

Ala?Ala?Ala?Glu?Thr?Leu?Ser?Glu?Val?Ala

435 440

<210>27

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP11 of GIG26

<400>27

aagcttcggg?taa 13

<210>28

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG26

<400>28

aagctttttt?tttttg 16

<210>29

<211>1160

<212>DNA

＜213〉mankind

<400>29

ctgcacaaga?aacggagtca?gccggagaac?aaggagtggt?cttccactgc?ctcacaggag 60

gatggaggcc?cacaacgcgt?ctgccccatt?caacttcacc?ctgccaccca?actttggcaa 120

gcgccccaca?gacctggcac?tgagcgtcat?cctggtgttc?atgttgttct?tcatcatgct 180

ctcgctgggc?tgcaccatgg?agttcagcaa?gatcaaggct?cacttatgga?agcctaaagg 240

gctggccatc?gccctggtgg?cacagtatgg?catcatgccc?ctcacggcct?ttgtgctggg 300

caaggtcttc?cggctgaaga?acattgaggc?actggccatc?ttggtctgtg?gctgctcacc 360

tggagggaac?ctgtccaatg?tcttcagtct?ggccatgaag?ggggacatga?acctcagcat 420

tgtgatgacc?acctgctcca?ccttctgtgc?ccttggcatg?atgcctctcc?tcctgtacat 480

ctactccagg?gggatctatg?atggggacct?gaaggacaag?gtgccctata?aaggcatcgt 540

gatatcactg?gtcctggttc?tcattccttg?caccataggg?atcgtcctca?aatccaaacg 600

gccacaatac?atgcgctatg?tcatcaaggg?agggatgatc?atcattctct?tgtgcagtgt 660

ggccgtcaca?gttctctctg?ccatcaatgt?ggggaagagc?atcatgtttg?ccatgacacc 720

actcttgatt?gccacctcct?ccctgatgcc?ttttattggc?tttctgctgg?gttatgttct 780

ctctgctctc?ttctgcctca?atggacggtg?cagacgcact?gtcagcatgg?agactggatg 840

ccaaaatgtc?caactctgtt?ccaccatcct?caatgtggcc?tttccacctg?aagtcattgg 900

accacttttc?ttctttcccc?tcctctacat?gattttccag?cttggagaag?ggcttctcct 960

cattgccata?ttttggtgct?atgagaaatt?caagactccc?aaggataaaa?caaaaatgat 1020

ctacacagct?gccacaactg?aagaaacaat?tccaggagct?ctgggaaatg?gcacctacaa 1080

aggggaggac?tgctcccctt?gcacagccta?gcccttcccc?tggtggcctg?gattctggtc 1140

ccaaagcaat?tctgaaagcc 1160

<210>30

<211>349

<212>PRT

＜213〉mankind

<400>30

Met?Glu?Ala?His?Asn?Ala?Ser?Ala?Pro?Phe?Asn?Phe?Thr?Leu?Pro?Pro

1 5 10 15

Asn?Phe?Gly?Lys?Arg?Pro?Thr?Asp?Leu?Ala?Leu?Ser?Val?Ile?Leu?Val

20 25 30

Phe?Met?Leu?Phe?Phe?Ile?Met?Leu?Ser?Leu?Gly?Cys?Thr?Met?Glu?Phe

35 40 45

Ser?Lys?Ile?Lys?Ala?His?Leu?Trp?Lys?Pro?Lys?Gly?Leu?Ala?Ile?Ala

50 55 60

Leu?Val?Ala?Gln?Tyr?Gly?Ile?Met?Pro?Leu?Thr?Ala?Phe?Val?Leu?Gly

65 70 75 80

Lys?Val?Phe?Arg?Leu?Lys?Asn?Ile?Glu?Ala?Leu?Ala?Ile?Leu?Val?Cys

85 90 95

Gly?Cys?Ser?Pro?Gly?Gly?Asn?Leu?Ser?Asn?Val?Phe?Ser?Leu?Ala?Met

100 105 110

Lys?Gly?Asp?Met?Asn?Leu?Ser?Ile?Val?Met?Thr?Thr?Cys?Ser?Thr?Phe

115 120 125

Cys?Ala?Leu?Gly?Met?Met?Pro?Leu?Leu?Leu?Tyr?Ile?Tyr?Ser?Arg?Gly

130 135 140

Ile?Tyr?Asp?Gly?Asp?Leu?Lys?Asp?Lys?Val?Pro?Tyr?Lys?Gly?Ile?Val

145 150 155 160

Ile?Ser?Leu?Val?Leu?Val?Leu?Ile?Pro?Cys?Thr?Ile?Gly?Ile?Val?Leu

165 170 175

Lys?Ser?Lys?Arg?Pro?Gln?Tyr?Met?Arg?Tyr?Val?Ile?Lys?Gly?Gly?Met

180 185 190

Ile?Ile?Ile?Leu?Leu?Cys?Ser?Val?Ala?Val?Thr?Val?Leu?Ser?Ala?Ile

195 200 205

Asn?Val?Gly?Lys?Ser?Ile?Met?Phe?Ala?Met?Thr?Pro?Leu?Leu?Ile?Ala

210 215 220

Thr?Ser?Ser?Leu?Met?Pro?Phe?Ile?Gly?Phe?Leu?Leu?Gly?Tyr?Val?Leu

225 230 235 240

Ser?Ala?Leu?Phe?Cys?Leu?Asn?Gly?Arg?Cys?Arg?Arg?Thr?Val?Ser?Met

245 250 255

Glu?Thr?Gly?Cys?Gln?Asn?Val?Gln?Leu?Cys?Ser?Thr?Ile?Leu?Asn?Val

260 265 270

Ala?Phe?Pro?Pro?Glu?Val?Ile?Gly?Pro?Leu?Phe?Phe?Phe?Pro?Leu?Leu

275 280 285

Tyr?Met?Ile?Phe?Gln?Leu?Gly?Glu?Gly?Leu?Leu?Leu?Ile?Ala?Ile?Phe

290 295 300

Trp?Cys?Tyr?Glu?Lys?Phe?Lys?Thr?Pro?Lys?Asp?Lys?Thr?Lys?Met?Ile

305 310 315 320

Tyr?Thr?Ala?Ala?Thr?Thr?Glu?Glu?Thr?Ile?Pro?Gly?Ala?Leu?Gly?Asn

325 330 335

Gly?Thr?Tyr?Lys?Gly?Glu?Asp?Cys?Ser?Pro?Cys?Thr?Ala

340 345

<210>31

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP3 of GIG29

<400>31

aagctttggt?cag 13

<210>32

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG29

<400>32

aagctttttt?ttttta 16

<210>33

<211>1825

<212>DNA

＜213〉mankind

<400>33

gtatctgggc?gcctgagcgc?ggcgtgggag?ccttgggagc?cgccgcagca?gggggcacac 60

ccggaaccgg?cctgagcgcc?cgggaccatg?aacggggagg?ccatctgcag?cgccctgccc 120

accattccct?accacaaact?cgccgacctg?cgctacctga?gccgcggcgc?ctctggcact 180

gtgtcgtccg?cccgccacgc?agactggcgc?gtccaggtgg?ccgtgaagca?cctgcacatc 240

cacactccgc?tgctcggcag?tgaaagaaag?gatgtcttaa?gagaagctga?aattttacac 300

aaagctagat?ttagttacat?tcttccaatt?ttgggaattt?gcaatgagcc?tgaatttttg 360

ggaatagtta?ctgaatacat?gccaaatgga?tcattaaatg?aactcctaca?taggaaaact 420

gaatatcctg?atgttgcttg?gccattgaga?tttcgcatcc?tgcatgaaat?tgcccttggt 480

gtaaattacc?tgcacaatat?gactcctcct?ttacttcatc?atgacttgaa?gactcagaat 540

atcttattgg?acaatgaatt?tcatgttaag?attgcagatt?ttggtttatc?aaagtggcgc 600

atgatgtccc?tctcacagtc?acgaagtagc?aaatctgcac?cagaaggagg?gacaattatc 660

tatatgccac?ctgaaaacta?tgaacctgga?caaaaatcaa?gggccagtat?caagcacgat 720

atatatagct?atgcagttat?cacatgggaa?gtgttatcca?gaaaacagcc?ttttgaagat 780

gtcaccaatc?ctttgcagat?aatgtatagt?gtgtcacaag?gacatcgacc?tgttattaat 840

gaagaaagtt?tgccatatga?tatacctcac?cgagcacgta?tgatctctct?aatagaaagt 900

ggatgggcac?aaaatccaga?tgaaagacca?tctttcttaa?aatgtttaat?agaacttgaa 960

ccagttttga?gaacatttga?agagataact?tttcttgaag?ctgttattca?gctaaagaaa 1020

acaaagttac?agagtgtttc?aagtgccatt?cacctatgtg?acaagaagaa?aatggaatta 1080

tctctgaaca?tacctgtaaa?tcatggtcca?caagaggaat?catgtggatc?ctctcagctc 1140

catgaaaata?gtggttctcc?tgaaacttca?aggtccctgc?cagctcctca?agacaatgat 1200

tttttatcta?gaaaagctca?agactgttat?tttatgaagc?tgcatcactg?tcctggaaat 1260

cacagttggg?atagcaccat?ttctggatct?caaagggctg?cattctgtga?tcacaagacc 1320

actccatgct?cttcagcaat?aataaatcca?ctctcaactg?caggaaactc?agaacgtctg 1380

cagcctggta?tagcccagca?gtggatccag?agcaaaaggg?aagacattgt?gaaccaaatg 1440

acagaagcct?gccttaacca?gtcgctagat?gcccttctgt?ccagggactt?gatcatgaaa 1500

gaggactatg?aacttgttag?taccaagcct?acaaggacct?caaaagtcag?acaattacta 1560

gacactactg?acatccaagg?agaagaattt?gccaaagtta?tagtacaaaa?attgaaagat 1620

aacaaacaaa?tgggtcttca?gccttacccg?gaaatacttg?tggtttctag?atcaccatct 1680

ttaaatttac?ttcaaaataa?aagcatgtaa?gtgactgttt?ttcaagaaga?aatgtgtttc 1740

ataaaaggat?atttatatct?ctgttgcttt?gacttttttt?atataaaatc?cgtgagtatt 1800

aaagctttat?tgaaggttct?ttggg 1825

<210>34

<211>540

<212>PRT

＜213〉mankind

<400>34

Met?Asn?Gly?Glu?Ala?Ile?Cys?Ser?Ala?Leu?Pro?Thr?Ile?Pro?Tyr?His

1 5 10 15

Lys?Leu?Ala?Asp?Leu?Arg?Tyr?Leu?Ser?Arg?Gly?Ala?Ser?Gly?Thr?Val

20 25 30

Ser?Ser?Ala?Arg?His?Ala?Asp?Trp?Arg?Val?Gln?Val?Ala?Val?Lys?His

35 40 45

Leu?His?Ile?His?Thr?Pro?Leu?Leu?Gly?Ser?Glu?Arg?Lys?Asp?Val?Leu

50 55 60

Arg?Glu?Ala?Glu?Ile?Leu?His?Lys?Ala?Arg?Phe?Ser?Tyr?Ile?Leu?Pro

65 70 75 80

Ile?Leu?Gly?Ile?Cys?Asn?Glu?Pro?Glu?Phe?Leu?Gly?Ile?Val?Thr?Glu

85 90 95

Tyr?Met?Pro?Asn?Gly?Ser?Leu?Asn?Glu?Leu?Leu?His?Arg?Lys?Thr?Glu

100 105 110

Tyr?Pro?Asp?Val?Ala?Trp?Pro?Leu?Arg?Phe?Arg?Ile?Leu?His?Glu?Ile

115 120 125

Ala?Leu?Gly?Val?Asn?Tyr?Leu?His?Asn?Met?Thr?Pro?Pro?Leu?Leu?His

130 135 140

His?Asp?Leu?Lys?Thr?Gln?Asn?Ile?Leu?Leu?Asp?Asn?Glu?Phe?His?Val

145 150 155 160

Lys?Ile?Ala?Asp?Phe?Gly?Leu?Ser?Lys?Trp?Arg?Met?Met?Ser?Leu?Ser

165 170 175

Gln?Ser?Arg?Ser?Ser?Lys?Ser?Ala?Pro?Glu?Gly?Gly?Thr?Ile?Ile?Tyr

180 185 190

Met?Pro?Pro?Glu?Asn?Tyr?Glu?Pro?Gly?Gln?Lys?Ser?Arg?Ala?Ser?Ile

195 200 205

Lys?His?Asp?Ile?Tyr?Ser?Tyr?Ala?Val?Ile?Thr?Trp?Glu?Val?Leu?Ser

210 215 220

Arg?Lys?Gln?Pro?Phe?Glu?Asp?Val?Thr?Asn?Pro?Leu?Gln?Ile?Met?Tyr

225 230 235 240

Ser?Val?Ser?Gln?Gly?His?Arg?Pro?Val?Ile?Asn?Glu?Glu?Ser?Leu?Pro

245 250 255

Tyr?Asp?Ile?Pro?His?Arg?Ala?Arg?Met?Ile?Ser?Leu?Ile?Glu?Ser?Gly

260 265 270

Trp?Ala?Gln?Asn?Pro?Asp?Glu?Arg?Pro?Ser?Phe?Leu?Lys?Cys?Leu?Ile

275 280 285

Glu?Leu?Glu?Pro?Val?Leu?Arg?Thr?Phe?Glu?Glu?Ile?Thr?Phe?Leu?Glu

290 295 300

Ala?Val?Ile?Gln?Leu?Lys?Lys?Thr?Lys?Leu?Gln?Ser?Val?Ser?Ser?Ala

305 310 315 320

Ile?His?Leu?Cys?Asp?Lys?Lys?Lys?Met?Glu?Leu?Ser?Leu?Asn?Ile?Pro

325 330 335

Val?Asn?His?Gly?Pro?Gln?Glu?Glu?Ser?Cys?Gly?Ser?Ser?Gln?Leu?His

340 345 350

Glu?Asn?Ser?Gly?Ser?Pro?Glu?Thr?Ser?Arg?Ser?Leu?Pro?Ala?Pro?Gln

355 360 365

Asp?Asn?Asp?Phe?Leu?Ser?Arg?Lys?Ala?Gln?Asp?Cys?Tyr?Phe?Met?Lys

370 375 380

Leu?His?His?Cys?Pro?Gly?Asn?His?Ser?Trp?Asp?Ser?Thr?Ile?Ser?Gly

385 390 395 400

Ser?Gln?Arg?Ala?Ala?Phe?Cys?Asp?His?Lys?Thr?Thr?Pro?Cys?Ser?Ser

405 410 415

Ala?Ile?Ile?Asn?Pro?Leu?Ser?Thr?Ala?Gly?Asn?Ser?Glu?Arg?Leu?Gln

420 425 430

Pro?Gly?Ile?Ala?Gln?Gln?Trp?Ile?Gln?Ser?Lys?Arg?Glu?Asp?Ile?Val

435 440 445

Asn?Gln?Met?Thr?Glu?Ala?Cys?Leu?Asn?Gln?Ser?Leu?Asp?Ala?Leu?Leu

450 455 460

Ser?Arg?Asp?Leu?Ile?Met?Lys?Glu?Asp?Tyr?Glu?Leu?Val?Ser?Thr?Lys

465 470 475 480

Pro?Thr?Arg?Thr?Ser?Lys?Val?Arg?Gln?Leu?Leu?Asp?Thr?Thr?Asp?Ile

485 490 495

Gln?Gly?Glu?Glu?Phe?Ala?Lys?Val?Ile?Val?Gln?Lys?Leu?Lys?Asp?Asn

500 505 510

Lys?Gln?Met?Gly?Leu?Gln?Pro?Tyr?Pro?Glu?Ile?Leu?Val?Val?Ser?Arg

515 520 525

Ser?Pro?Ser?Leu?Asn?Leu?Leu?Gln?Asn?Lys?Ser?Met

530 535 540

<210>35

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP4 of GIG30

<400>35

aagcttctca?acg 13

<210>36

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG30

<400>36

aagctttttt?tttttg 16

<210>37

<211>648

<212>DNA

＜213〉mankind

<400>37

cagggaaacc?tcctcacagt?tttcatccag?ccacgggcca?gcatgtctgg?gggcaaatac 60

gtagactcgg?agggacatct?ctacaccgtt?cccatccggg?aacagggcaa?catctacaag 120

cccaacaaca?aggccatggc?agacgagctg?agcgagaagc?aagtgtacga?cgcgcacacc 180

aaggagatcg?acctggtcaa?ccgcgaccct?aaacacctca?acgatgacgt?ggtcaagatt 240

gactttgaag?atgtgattgc?agaaccagaa?gggacacaca?gttttgacgg?catttggaag 300

gccagcttca?ccaccttcac?tgtgacgaaa?tactggtttt?accgcttgct?gtctgccctc 360

tttggcatcc?cgatggcact?catctggggc?atttacttcg?ccattctctc?tttcctgcac 420

atctgggcag?ttgtaccatg?cattaagagc?ttcctgattg?agattcagtg?catcagccgt 480

gtctattcca?tctacgtcca?caccgtctgt?gacccactct?ttgaagctgt?tgggaaaata 540

ttcagcaatg?tccgcatcaa?cttgcagaaa?gaaatataaa?tgacatttca?aggatagaag 600

tatacctgat?tttttttcct?tttaattttc?ctggtgccaa?tttcaagt 648

<210>38

<211>178

<212>PRT

＜213〉mankind

<400>38

Met?Ser?Gly?Gly?Lys?Tyr?Val?Asp?Ser?Glu?Gly?His?Leu?Tyr?Thr?Val

1 5 10 15

Pro?Ile?Arg?Glu?Gln?Gly?Asn?Ile?Tyr?Lys?Pro?Asn?Asn?Lys?Ala?Met

20 25 30

Ala?Asp?Glu?Leu?Ser?Glu?Lys?Gln?Val?Tyr?Asp?Ala?His?Thr?Lys?Glu

35 40 45

Ile?Asp?Leu?Val?Asn?Arg?Asp?Pro?Lys?His?Leu?Asn?Asp?Asp?Val?Val

50 55 60

Lys?Ile?Asp?Phe?Glu?Asp?Val?Ile?Ala?Glu?Pro?Glu?Gly?Thr?His?Ser

65 70 75 80

Phe?Asp?Gly?Ile?Trp?Lys?Ala?Ser?Phe?Thr?Thr?Phe?Thr?Val?Thr?Lys

85 90 95

Tyr?Trp?Phe?Tyr?Arg?Leu?Leu?Ser?Ala?Leu?Phe?Gly?Ile?Pro?Met?Ala

100 105 110

Leu?Ile?Trp?Gly?Ile?Tyr?Phe?Ala?Ile?Leu?Ser?Phe?Leu?His?Ile?Trp

115 120 125

Ala?Val?Val?Pro?Cys?Ile?Lys?Ser?Phe?Leu?Ile?Glu?Ile?Gln?Cys?Ile

130 135 140

Ser?Arg?Val?Tyr?Ser?Ile?Tyr?Val?His?Thr?Val?Cys?Asp?Pro?Leu?Phe

145 150 155 160

Glu?Ala?Val?Gly?Lys?Ile?Phe?Ser?Asn?Val?Arg?Ile?Asn?Leu?Gln?Lys

165 170 175

Glu Ile

<210>39

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP8 of GIG32

<400>39

aagcttttac?cgc 13

<210>40

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG32

<400>40

aagctttttt?tttttg 16

<210>41

<211>406

<212>DNA

＜213〉mankind

<400>41

ggcctcgtcc?ttctcttacc?gccatcttgg?ctcctgtgga?ggcctgctgg?gaacgggact 60

tctaaaagga?actatgtctg?gaaggctgtg?gtccaaggcc?atttttgctg?gctataagcg 120

gggtctccgg?aaccaaaggg?agcacacagc?tcttcttaaa?attgaaggtg?tttacgcccg 180

agatgaaaca?gaattctatt?tgggcaagag?atgcgcttat?gtatataaag?caaagaacaa 240

cacagtcact?cctggcggca?aaccaaacaa?aaccagagtc?atctggggaa?aagtaactcg 300

ggcccatgga?aacagtggca?tggttcgtgc?caaattccga?agcaatcttc?ctgccaaggc 360

cattggacac?agaatccgag?tgatgctgta?cccctcaagg?atttaa 406

<210>42

<211>110

<212>PRT

＜213〉mankind

<400>42

Met?Ser?Gly?Arg?Leu?Trp?Ser?Lys?Ala?Ile?Phe?Ala?Gly?Tyr?Lys?Arg

1 5 10 15

Gly?Leu?Arg?Asn?Gln?Arg?Glu?His?Thr?Ala?Leu?Leu?Lys?Ile?Glu?Gly

20 25 30

Val?Tyr?Ala?Arg?Asp?Glu?Thr?Glu?Phe?Tyr?Leu?Gly?Lys?Arg?Cys?Ala

35 40 45

Tyr?Val?Tyr?Lys?Ala?Lys?Asn?Asn?Thr?Val?Thr?Pro?Gly?Gly?Lys?Pro

50 55 60

Asn?Lys?Thr?Arg?Val?Ile?Trp?Gly?Lys?Val?Thr?Arg?Ala?His?Gly?Asn

65 70 75 80

Ser?Gly?Met?Val?Arg?Ala?Lys?Phe?Arg?Ser?Asn?Leu?Pro?Ala?Lys?Ala

85 90 95

Ile?Gly?His?Arg?Ile?Arg?Val?Met?Leu?Tyr?Pro?Ser?Arg?Ile

100 105 110

<210>43

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP33 of GIG33

<400>43

aagcttgctg?ctc 13

<210>44

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG33

<400>44

aagctttttt?tttttg 16

<210>45

<211>560

<212>DNA

＜213〉mankind

<400>45

catcatggcg?gatcaaggtg?aaaaggagaa?ccccatgcgg?gaacttcgca?tccgcaaact 60

ctgtctcaac?atctgtgttg?gggagagtgg?agacagactg?gcgcgagcag?ccaaggtgtt 120

ggagcagctc?acagggcaga?cccctgtgtt?ttccaaagct?agatacactg?tcagatcctt 180

tggcatccgg?agaaatgaaa?agattgctgt?ccactgcaca?gttcgagggg?ccaaggcaga 240

agaaatcttg?gagaagggtc?taaaggtgcg?ggagtatgag?ttaagaaaaa?acaacttctc 300

agatactgga?aactttggtt?ttgggatcca?ggaacacatc?gatctgggta?tcaaatatga 360

cccaagcatt?ggtatctacg?gcctggactt?ctatgtggtg?ctgggtaggc?caggtttcag 420

catcgcagac?aagaagcgca?ggacaggctg?cattggggcc?aaacacagaa?tcagcaaaga 480

ggaggccatg?cgctggttcc?agcagaagta?tgatgggatc?atcct?tcctg?gcaaataaat 540

tcccgtttct?atccaaaaga 560

<210>46

<211>177

<212>PRT

＜213〉mankind

<400>46

Met?Ala?Asp?Gln?Gly?Glu?Lys?Glu?Asn?Pro?Met?Arg?Glu?Leu?Arg?Ile

1 5 10 15

Arg?Lys?Leu?Cys?Leu?Asn?Ile?Cys?Val?Gly?Glu?Ser?Gly?Asp?Arg?Leu

20 25 30

Ala?Arg?Ala?Ala?Lys?Val?Leu?Glu?Gln?Leu?Thr?Gly?Gln?Thr?Pro?Val

35 40 45

Phe?Ser?Lys?Ala?Arg?Tyr?Thr?Val?Arg?Ser?Phe?Gly?Ile?Arg?Arg?Asn

50 55 60

Glu?Lys?Ile?Ala?Val?His?Cys?Thr?Val?Arg?Gly?Ala?Lys?Ala?Glu?Glu

65 70 75 80

Ile?Leu?Glu?Lys?Gly?Leu?Lys?Val?Arg?Glu?Tyr?Glu?Leu?Arg?Lys?Asn

85 90 95

Asn?Phe?Ser?Asp?Thr?Gly?Asn?Phe?Gly?Phe?Gly?Ile?Gln?Glu?His?Ile

100 105 110

Asp?Leu?Gly?Ile?Lys?Tyr?Asp?Pro?Ser?Ile?Gly?Ile?Tyr?Gly?Leu?Asp

115 120 125

Phe?Tyr?Val?Val?Leu?Gly?Arg?Pro?Gly?Phe?Ser?Ile?Ala?Asp?Lys?Lys

130 135 140

Arg?Arg?Thr?Gly?Cys?Ile?Gly?Ala?Lys?His?Arg?Ile?Ser?Lys?Glu?Glu

145 150 155 160

Ala?Met?Arg?Trp?Phe?Gln?Gln?Lys?Tyr?Asp?Gly?Ile?Ile?Leu?Pro?Gly

165 170 175

Lys

<210>47

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP35 of GIG34

<400>47

aagctcagg?gca 13

<210>48

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG34

<400>48

aagctttttt?tttttc 16

<210>49

<211>1398

<212>DNA

＜213〉mankind

<400>49

tttctttgcg?gaatcaccat?ggcggctggg?accctgtaca?cgtatcctga?aaactggagg 60

gccttcaagg?ctctcatcgc?tgctcagtac?agcggggctc?aggtccgcgt?gctctccgca 120

ccaccccact?tccattttgg?ccaaaccaac?cgcacccctg?aatttctccg?caaatttcct 180

gccggcaagg?tcccagcatt?tgagggtgat?gatggattct?gtgtgtttga?gagcaacgcc 240

attgcctact?atgtgagcaa?tgaggagctg?cggggaagta?ctccagaggc?agcagcccag 300

gtggtgcagt?gggtgagctt?tgctgattcc?gatatagtgc?ccccagccag?tacctgggtg 360

ttccccacct?tgggcatcat?gcaccacaac?aaacaggcca?ctgagaatgc?aaaggaggaa 420

gtgaggcgaa?ttctggggct?gctggatgct?tacttgaaga?cgaggacttt?tctggtgggc 480

gaacgagtga?cattggctga?catcacagtt?gtctgcaccc?tgttgtggct?ctataagcag 540

gttctagagc?cttctttccg?ccaggccttt?cccaatacca?accgctggtt?cctcacctgc 600

attaaccagc?cccagttccg?ggctgtcttg?ggcgaagtga?aactgtgtga?gaagatggcc 660

cagtttgatg?ctaaaaagtt?tgcagagacc?caacctaaaa?aggacacacc?acggaaagag 720

aagggttcac?gggaagagaa?gcagaagccc?caggctgagc?ggaaggagga?gaaaaaggcg 780

gctgcccctg?ctcctgagga?ggagatggat?gaatgtgagc?aggcgctggc?tgctgagccc 840

aaggccaagg?accccttcgc?tcacctgccc?aagagtacct?ttgtgttgga?tgaatttaag 900

cgcaagtact?ccaatgagga?cacactctct?gtggcactgc?catatttctg?ggagcacttt 960

gataaggacg?gctggtccct?gtggtactca?gagtatcgct?tccctgaaga?actcactcag 1020

accttcatga?gctgcaatct?catcactgga?atgttccagc?gactggacaa?gctgaggaag 1080

aatgccttcg?ccagtgtcat?cctttttgga?accaacaata?gcagctccat?ttctggagtc 1140

tgggtcttcc?gaggccagga?gcttgccttt?ccgctgagtc?cagattggca?ggtggactac 1200

gagtcataca?catggcggaa?actggatcct?ggcagcgagg?agacccagac?gctggttcga 1260

gagtactttt?cctgggaggg?ggccttccag?catgtgggca?aagccttcaa?tcagggcaag 1320

atcttcaagt?gaacatctct?tgccatcacc?tagctgcctg?cacctgccct?tcagggagat 1380

gggggtcatt?aaaggaaa 1398

<210>50

<211>437

<212>PRT

＜213〉mankind

<400>50

Met?Ala?Ala?Gly?Thr?Leu?Tyr?Thr?Tyr?Pro?Glu?Asn?Trp?Arg?Ala?Phe

1 5 10 15

Lys?Ala?Leu?Ile?Ala?Ala?Gln?Tyr?Ser?Gly?Ala?Gln?Val?Arg?Val?Leu

20 25 30

Ser?Ala?Pro?Pro?His?Phe?His?Phe?Gly?Gln?Thr?Asn?Arg?Thr?Pro?Glu

35 40 45

Phe?Leu?Arg?Lys?Phe?Pro?Ala?Gly?Lys?Val?Pro?Ala?Phe?Glu?Gly?Asp

50 55 60

Asp?Gly?Phe?Cys?Val?Phe?Glu?Ser?Asn?Ala?Ile?Ala?Tyr?Tyr?Val?Ser

65 70 75 80

Asn?Glu?Glu?Leu?Arg?Gly?Ser?Thr?Pro?Glu?Ala?Ala?Ala?Gln?Val?Val

85 90 95

Gln?Trp?Val?Ser?Phe?Ala?Asp?Ser?Asp?Ile?Val?Pro?Pro?Ala?Ser?Thr

100 105 110

Trp?Val?Phe?Pro?Thr?Leu?Gly?Ile?Met?His?His?Asn?Lys?Gln?Ala?Thr

115 120 125

Glu?Asn?Ala?Lys?Glu?Glu?Val?Arg?Arg?Ile?Leu?Gly?Leu?Leu?Asp?Ala

130 135 140

Tyr?Leu?Lys?Thr?Arg?Thr?Phe?Leu?Val?Gly?Glu?Arg?Val?Thr?Leu?Ala

145 150 155 160

Asp?Ile?Thr?Val?Val?Cys?Thr?Leu?Leu?Trp?Leu?Tyr?Lys?Gln?Val?Leu

165 170 175

Glu?Pro?Ser?Phe?Arg?Gln?Ala?Phe?Pro?Asn?Thr?Asn?Arg?Trp?Phe?Leu

180 185 190

Thr?Cys?Ile?Asn?Gln?Pro?Gln?Phe?Arg?Ala?Val?Leu?Gly?Glu?Val?Lys

195 200 205

Leu?Cys?Glu?Lys?Met?Ala?Gln?Phe?Asp?Ala?Lys?Lys?Phe?Ala?Glu?Thr

210 215 220

Gln?Pro?Lys?Lys?Asp?Thr?Pro?Arg?Lys?Glu?Lys?Gly?Ser?Arg?Glu?Glu

225 230 235 240

Lys?Gln?Lys?Pro?Gln?Ala?Glu?Arg?Lys?Glu?Glu?Lys?Lys?Ala?Ala?Ala

245 250 255

Pro?Ala?Pro?Glu?Glu?Glu?Met?Asp?Glu?Cys?Glu?Gln?Ala?Leu?Ala?Ala

260 265 270

Glu?Pro?Lys?Ala?Lys?Asp?Pro?Phe?Ala?His?Leu?Pro?Lys?Ser?Thr?Phe

275 280 285

Val?Leu?Asp?Glu?Phe?Lys?Arg?Lys?Tyr?Ser?Asn?Glu?Asp?Thr?Leu?Ser

290 295 300

Val?Ala?Leu?Pro?Tyr?Phe?Trp?Glu?His?Phe?Asp?Lys?Asp?Gly?Trp?Ser

305 310 315 320

Leu?Trp?Tyr?Ser?Glu?Tyr?Arg?Phe?Pro?Glu?Glu?Leu?Thr?Gln?Thr?Phe

325 330 335

Met?Ser?Cys?Asn?Leu?Ile?Thr?Gly?Met?Phe?Gln?Arg?Leu?Asp?Lys?Leu

340 345 350

Arg?Lys?Asn?Ala?Phe?Ala?Ser?Val?Ile?Leu?Phe?Gly?Thr?Asn?Asn?Ser

355 360 365

Ser?Ser?Ile?Ser?Gly?Val?Trp?Val?Phe?Arg?Gly?Gln?Glu?Leu?Ala?Phe

370 375 380

Pro?Leu?Ser?Pro?Asp?Trp?Gln?Val?Asp?Tyr?Glu?Ser?Tyr?Thr?Trp?Arg

385 390 395 400

Lys?Leu?Asp?Pro?Gly?Ser?Glu?Glu?Thr?Gln?Thr?Leu?Val?Arg?Glu?Tyr

405 410 415

Phe?Ser?Trp?Glu?Gly?Ala?Phe?Gln?His?Val?Gly?Lys?Ala?Phe?Asn?Gln

420 425 430

Gly?Lys?Ile?Phe?Lys

435

<210>51

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP3 of GIG35

<400>51

aagctttggt?cag 13

<210>52

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG35

<400>52

aagctttttt?tttttc 16

<210>53

<211>560

<212>DNA

＜213〉mankind

<400>53

aggccgtagg?aggaagatgg?cggtggagtc?gcgcgttacc?caggaggaaa?ttaagaagga 60

gccagagaaa?ccgatcgacc?gcgagaagac?atgcccactg?ttgctacggg?tcttcaccac 120

caataacggc?cgccaccacc?gaatggacga?gttctcccgg?ggaaatgtac?cgtccagcga 180

gttgcagatc?tacacttgga?tggatgcaac?tttgaaagaa?ctgacaagct?tagtaaaaga 240

agtctaccca?gaagctagaa?agaagggcac?tcacttcaat?tttgcaatcg?tttttacaga 300

tgttaaaaga?cctggctatc?gagttaagga?gattggcagc?accatgtctg?gcagaaaggg 360

gactgatgat?tccatgaccc?tgcagtcgca?gaagttccag?ataggagatt?acttggacat 420

agcaattacc?cctccaaatc?gggcaccacc?tccttcaggg?cgcatgagac?catattaaat 480

tctatttact?atttgttgaa?tttatttttc?cgtcagttat?gtaaaataaa?catactcttc 540

ttcctcccct?gattattgcc 560

<210>54

<211>153

<212>PRT

＜213〉mankind

<400>54

Met?Ala?Val?Glu?Ser?Arg?Val?Thr?Gln?Glu?Glu?Ile?Lys?Lys?Glu?Pro

1 5 10 15

Glu?Lys?Pro?Ile?Asp?Arg?Glu?Lys?Thr?Cys?Pro?Leu?Leu?Leu?Arg?Val

20 25 30

Phe?Thr?Thr?Asn?Asn?Gly?Arg?His?His?Arg?Met?Asp?Glu?Phe?Ser?Arg

35 40 45

Gly?Asn?Val?Pro?Ser?Ser?Glu?Leu?Gln?Ile?Tyr?Thr?Trp?Met?Asp?Ala

50 55 60

Thr?Leu?Lys?Glu?Leu?Thr?Ser?Leu?Val?Lys?Glu?Val?Tyr?Pro?Glu?Ala

65 70 75 80

Arg?Lys?Lys?Gly?Thr?His?Phe?Asn?Phe?Ala?Ile?Val?Phe?Thr?Asp?Val

85 90 95

Lys?Arg?Pro?Gly?Tyr?Arg?Val?Lys?Glu?Ile?Gly?Ser?Thr?Met?Ser?Gly

100 105 110

Arg?Lys?Gly?Thr?Asp?Asp?Ser?Met?Thr?Leu?Gln?Ser?Gln?Lys?Phe?Gln

115 120 125

Ile?Gly?Asp?Tyr?Leu?Asp?Ile?Ala?Ile?Thr?Pro?Pro?Asn?Arg?Ala?Pro

130 135 140

Pro?Pro?Ser?Gly?Arg?Met?Arg?Pro?Tyr

145 150

<210>55

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP12 of GIG38

<400>55

aagcttgagt?gct 13

<210>56

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG38

<400>56

aagctttttt?tttttc 16

<210>57

<211>2874

<212>DNA

＜213〉mankind

<400>57

caacctccag?gagctagcag?cgggcgcgga?ccgggcagtt?tccgcgctca?gcacaggcag 60

ctcgcggtca?tgggcggctc?agcctccagc?cagctggacg?agggcaagtg?cgcttacatc 120

cgagggaaaa?ctgaggctgc?catcaaagac?ttcagtccct?actacagtcg?tcagtactct 180

gtggctttct?gcaatcacgt?gcgcactgaa?gtagaacagc?aaagagattt?aacgtcacag 240

tttttgaaga?ccaagccacc?attggcgcct?ggaactattt?tgtatgaagc?agagctatca 300

caattttctg?aagacataaa?gaagtggaag?gagagatacg?ttgtagttaa?aaatgattat 360

gctgtggaga?gctatgagaa?taaagaggcc?tatcagagag?gagctgctcc?taaatgtcga 420

attcttccag?ccggtggcaa?ggtgttaacc?tcagaagatg?aatataatct?gttgtctgac 480

aggcatttcc?cagaccctct?tgcctccagt?gagaaggaga?acactcagcc?ctttgtggtc 540

ctgcccaagg?aattcccagt?gtacctgtgg?cagcccttct?tcagacacgg?ctacttctgc 600

ttccacgagg?ctgctgacca?gaagaggttt?agtgccctcc?tgagtgactg?cgtcaggcat 660

ctcaatcatg?attacatgaa?gcagatgaca?tttgaagccc?aagccttttt?agaagctgtg 720

caattcttcc?gacaggagaa?gggtcactat?ggttcctggg?aaatgatcac?tggggatgaa 780

atccagatcc?tgagtaacct?ggtgatggag?gagctcctgc?ccactcttca?gacagacctg 840

ctgcctaaga?tgaaggggaa?gaagaatgac?agaaagagga?cgtggcttgg?tctcctcgag 900

gaggcctaca?ccctggttca?gcatcaagtt?tcagaaggat?taagtgcctt?gaaggaggaa 960

tgcagagctc?tgacaaaggg?cctggaagga?acgatccgtt?ctgacatgga?tcagattgtg 1020

aactcaaaga?actatttaat?tggaaagatc?aaagcgatgg?tggcccagcc?ggcggagaaa 1080

agctgcttgg?agagtgtgca?gccattcctg?gcatccatcc?tggaggagct?catgggacca 1140

gtgagctcgg?gattcagtga?agtacgtgta?ctctttgaga?aagaggtgaa?tgaagtcagc 1200

cagaacttcc?agaccaccaa?agacagtgtc?cagctaaagg?agcatctaga?ccggcttatg 1260

aatcttccgc?tgcattccgt?gaagatggaa?ccttgttata?ctaaagtcaa?cctgcttcac 1320

gagcgcctgc?aggatctcaa?gagccgcttc?agattccccc?acattgatct?ggtggttcag 1380

aggacacaga?actacatgca?ggagctaatg?gagaatgcag?tgttcacttt?tgagcagttg 1440

ctttccccac?atctccaagg?agaggcctcc?aaaactgcag?ttgccattga?gaaggttaaa 1500

ctccgagtct?taaagcaata?tgattatgac?agcagcacca?tccgaaagaa?gatatttcaa 1560

gaggcactag?ttcaaatcac?acttcccact?gtgcagaagg?cactggcgtc?cacatgcaaa 1620

ccagagcttc?agaaatacga?gcagttcatc?tttgcagatc?ataccaatat?gattcacgtt 1680

gaaaatgtct?atgaggagat?tttacatcag?atcctgcttg?atgaaactct?gaaagtgata 1740

aaggaagctg?ctatcttgaa?gaaacacaac?ttatttgaag?ataacatggc?cttgcccagt 1800

gaaagtgtgt?ccagcttaac?agatctaaag?ccccccacag?ggtcaaacca?ggccagccct 1860

gccaggagag?cttctgccat?tctgccagga?gttctgggta?gtgagaccct?cagtaacgaa 1920

gtattccagg?agtcagagga?agagaagcag?cctgaggtcc?ctagctcgtt?ggccaaagga 1980

gaaagccttt?ctctccctgg?gccaagccca?cccccagatg?ggactgagca?ggtgattatt 2040

tcaagagtgg?atgaccccgt?ggtgaatcct?gtggcaacag?aggacacagc?aggactcccg 2100

ggcacatgct?catcagagct?ggagtttgga?gggacccttg?aggatgaaga?acccgcccag 2160

gaagagccag?aacccatcac?tgcctcgggt?tctttgaagg?cgctcagaaa?gttgctgaca 2220

gcgtccgtgg?aagtaccagt?ggactctgct?ccagtgatgg?aagaagatac?gaatggggag 2280

agccacgttc?cccaagaaaa?tgaagaagaa?gaggaaaaag?agcccagtca?ggcagctgcc 2340

atccaccccg?acaactgtga?agaaagtgaa?gtcagcgaga?gggaggccca?acctccctgt 2400

cccgaggccc?atggggagga?gttgggggga?tttccagagg?taggcagccc?agcctctccg 2460

ccagccagtg?gagggctcac?cgaggagccc?ctggggccca?tggaggggga?gctcccagga 2520

gaggcctgca?cactcactgc?ccatgaagga?agagggggca?agtgtaccga?ggaaggggat 2580

gcctcacagc?aagagggctg?caccttaggt?tctgacccca?tctgcctcag?tgagagccag 2640

gtttctgagg?aacaagaaga?gatgggaggg?caaagcagcg?cggcccaggc?cacggccagt 2700

gtgaatgcag?aggagatcaa?ggtagcccgt?attcatgagt?gtcagtgggt?ggtggaggat 2760

gctccaaacc?cggatgtcct?gctgtcacac?aaagatgacg?tgaaggaggg?agaaggtggt 2820

caggagagtt?tcccagagct?gccctcagag?gagtgaaagg?gacaatttgg?ctga 2874

<210>58

<211>928

<212>PRT

＜213〉mankind

<400>58

Met?Gly?Gly?Ser?Ala?Ser?Ser?Gln?Leu?Asp?Glu?Gly?Lys?Cys?Ala?Tyr

1 5 10 15

Ile?Arg?Gly?Lys?Thr?Glu?Ala?Ala?Ile?Lys?Asp?Phe?Ser?Pro?Tyr?Tyr

20 25 30

Ser?Arg?Gln?Tyr?Ser?Val?Ala?Phe?Cys?Asn?His?Val?Arg?Thr?Glu?Val

35 40 45

Glu?Gln?Gln?Arg?Asp?Leu?Thr?Ser?Gln?Phe?Leu?Lys?Thr?Lys?Pro?Pro

50 55 60

Leu?Ala?Pro?Gly?Thr?Ile?Leu?Tyr?Glu?Ala?Glu?Leu?Ser?Gln?Phe?Ser

65 70 75 80

Glu?Asp?Ile?Lys?Lys?Trp?Lys?Glu?Arg?Tyr?Val?Val?Val?Lys?Asn?Asp

85 90 95

Tyr?Ala?Val?Glu?Ser?Tyr?Glu?Asn?Lys?Glu?Ala?Tyr?Gln?Arg?Gly?Ala

100 105 110

Ala?Pro?Lys?Cys?Arg?Ile?Leu?Pro?Ala?Gly?Gly?Lys?Val?Leu?Thr?Ser

115 120 125

Glu?Asp?Glu?Tyr?Asn?Leu?Leu?Ser?Asp?Arg?His?Phe?Pro?Asp?Pro?Leu

130 135 140

Ala?Ser?Ser?Glu?Lys?Glu?Asn?Thr?Gln?Pro?Phe?Val?Val?Leu?Pro?Lys

145 150 155 160

Glu?Phe?Pro?Val?Tyr?Leu?Trp?Gln?Pro?Phe?Phe?Arg?His?Gly?Tyr?Phe

165 170 175

Cys?Phe?His?Glu?Ala?Ala?Asp?Gln?Lys?Arg?Phe?Ser?Ala?Leu?Leu?Ser

180 185 190

Asp?Cys?Val?Arg?His?Leu?Asn?His?Asp?Tyr?Met?Lys?Gln?Met?Thr?Phe

195 200 205

Glu?Ala?Gln?Ala?Phe?Leu?Glu?Ala?Val?Gln?Phe?Phe?Arg?Gln?Glu?Lys

210 215 220

Gly?His?Tyr?Gly?Ser?Trp?Glu?Met?Ile?Thr?Gly?Asp?Glu?Ile?Gln?Ile

225 230 235 240

Leu?Ser?Asn?Leu?Val?Met?Glu?Glu?Leu?Leu?Pro?Thr?Leu?Gln?Thr?Asp

245 250 255

Leu?Leu?Pro?Lys?Met?Lys?Gly?Lys?Lys?Asn?Asp?Arg?Lys?Arg?Thr?Trp

260 265 270

Leu?Gly?Leu?Leu?Glu?Glu?Ala?Tyr?Thr?Leu?Val?Gln?His?Gln?Val?Ser

275 280 285

Glu?Gly?Leu?Ser?Ala?Leu?Lys?Glu?Glu?Cys?Arg?Ala?Leu?Thr?Lys?Gly

290 295 300

Leu?Glu?Gly?Thr?Ile?Arg?Ser?Asp?Met?Asp?Gln?Ile?Val?Asn?Ser?Lys

305 310 315 320

Asn?Tyr?Leu?Ile?Gly?Lys?Ile?Lys?Ala?Met?Val?Ala?Gln?Pro?Ala?Glu

325 330 335

Lys?Ser?Cys?Leu?Glu?Ser?Val?Gln?Pro?Phe?Leu?Ala?Ser?Ile?Leu?Glu

340 345 350

Glu?Leu?Met?Gly?Pro?Val?Ser?Ser?Gly?Phe?Ser?Glu?Val?Arg?Val?Leu

355 360 365

Phe?Glu?Lys?Glu?Val?Asn?Glu?Val?Ser?Gln?Asn?Phe?Gln?Thr?Thr?Lys

370 375 380

Asp?Ser?Val?Gln?Leu?Lys?Glu?His?Leu?Asp?Arg?Leu?Met?Asn?Leu?Pro

385 390 395 400

Leu?His?Ser?Val?Lys?Met?Glu?Pro?Cys?Tyr?Thr?Lys?Val?Asn?Leu?Leu

405 410 415

His?Glu?Arg?Leu?Gln?Asp?Leu?Lys?Ser?Arg?Phe?Arg?Phe?Pro?His?Ile

420 425 430

Asp?Leu?Val?Val?Gln?Arg?Thr?Gln?Asn?Tyr?Met?Gln?Glu?Leu?Met?Glu

435 440 445

Asn?Ala?Val?Phe?Thr?Phe?Glu?Gln?Leu?Leu?Ser?Pro?His?Leu?Gln?Gly

450 455 460

Glu?Ala?Ser?Lys?Thr?Ala?Val?Ala?Ile?Glu?Lys?Val?Lys?Leu?Arg?Val

465 470 475 480

Leu?Lys?Gln?Tyr?Asp?Tyr?Asp?Ser?Ser?Thr?Ile?Arg?Lys?Lys?Ile?Phe

485 490 495

Gln?Glu?Ala?Leu?Val?Gln?Ile?Thr?Leu?Pro?Thr?Val?Gln?Lys?Ala?Leu

500 505 510

Ala?Ser?Thr?Cys?Lys?Pro?Glu?Leu?Gln?Lys?Tyr?Glu?Gln?Phe?Ile?Phe

515 520 525

Ala?Asp?His?Thr?Asn?Met?Ile?His?Val?Glu?Asn?Val?Tyr?Glu?Glu?Ile

530 535 540

Leu?His?Gln?Ile?Leu?Leu?Asp?Glu?Thr?Leu?Lys?Val?Ile?Lys?Glu?Ala

545 550 555 560

Ala?Ile?Leu?Lys?Lys?His?Asn?Leu?Phe?Glu?Asp?Asn?Met?Ala?Leu?Pro

565 570 575

Ser?Glu?Ser?Val?Ser?Ser?Leu?Thr?Asp?Leu?Lys?Pro?Pro?Thr?Gly?Ser

580 585 590

Asn?Gln?Ala?Ser?Pro?Ala?Arg?Arg?Ala?Ser?Ala?Ile?Leu?Pro?Gly?Val

595 600 605

Leu?Gly?Ser?Glu?Thr?Leu?Ser?Asn?Glu?Val?Phe?Gln?Glu?Ser?Glu?Glu

610 615 620

Glu?Lys?Gln?Pro?Glu?Val?Pro?Ser?Ser?Leu?Ala?Lys?Gly?Glu?Ser?Leu

625 630 635 640

Ser?Leu?Pro?Gly?Pro?Ser?Pro?Pro?Pro?Asp?Gly?Thr?Glu?Gln?Val?Ile

645 650 655

Ile?Ser?Arg?Val?Asp?Asp?Pro?Val?Val?Asn?Pro?Val?Ala?Thr?Glu?Asp

660 665 670

Thr?Ala?Gly?Leu?Pro?Gly?Thr?Cys?Ser?Ser?Glu?Leu?Glu?Phe?Gly?Gly

675 680 685

Thr?Leu?Glu?Asp?Glu?Glu?Pro?Ala?Gln?Glu?Glu?Pro?Glu?Pro?Ile?Thr

690 695 700

Ala?Ser?Gly?Ser?Leu?Lys?Ala?Leu?Arg?Lys?Leu?Leu?Thr?Ala?Ser?Val

705 710 715 720

Glu?Val?Pro?Val?Asp?Ser?Ala?Pro?Val?Met?Glu?Glu?Asp?Thr?Asn?Gly

725 730 735

Glu?Ser?His?Val?Pro?Gln?Glu?Asn?Glu?Glu?Glu?Glu?Glu?Lys?Glu?Pro

740 745 750

Ser?Gln?Ala?Ala?Ala?Ile?His?Pro?Asp?Asn?Cys?Glu?Glu?Ser?Glu?Val

755 760 765

Ser?Glu?Arg?Glu?Ala?Gln?Pro?Pro?Cys?Pro?Glu?Ala?His?Gly?Glu?Glu

770 775 780

Leu?Gly?Gly?Phe?Pro?Glu?Val?Gly?Ser?Pro?Ala?Ser?Pro?Pro?Ala?Ser

785 790 795 800

Gly?Gly?Leu?Thr?Glu?Glu?Pro?Leu?Gly?Pro?Met?Glu?Gly?Glu?Leu?Pro

805 810 815

Gly?Glu?Ala?Cys?Thr?Leu?Thr?Ala?His?Glu?Gly?Arg?Gly?Gly?Lys?Cys

820 825 830

Thr?Glu?Glu?Gly?Asp?Ala?Ser?Gln?Gln?Glu?Gly?Cys?Thr?Leu?Gly?Ser

835 840 845

Asp?Pro?Ile?Cys?Leu?Ser?Glu?Ser?Gln?Val?Ser?Glu?Glu?Gln?Glu?Glu

850 855 860

Met?Gly?Gly?Gln?Ser?Ser?Ala?Ala?Gln?Ala?Thr?Ala?Ser?Val?Asn?Ala

865 870 875 880

Glu?Glu?Ile?Lys?Val?Ala?Arg?Ile?His?Glu?Cys?Gln?Trp?Val?Val?Glu

885 890 895

Asp?Ala?Pro?Asn?Pro?Asp?Val?Leu?Leu?Ser?His?Lys?Asp?Asp?Val?Lys

900 905 910

Glu?Gly?Glu?Gly?Gly?Gln?Glu?Ser?Phe?Pro?Glu?Leu?Pro?Ser?Glu?Glu

915 920 925

<210>59

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP12 of GIG39

<400>59

aagcttgagt?gct 13

<210>60

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG39

<400>60

aagctttttt?ttttta 16

<210>61

<211>3693

<212>DNA

＜213〉mankind

<400>61

ccagtattga?tcgggagagc?cggagcgagc?tcttcgggga?gcagcgatgc?gaccctccgg 60

gacggccggg?gcagcgctcc?tggcgctgct?ggctgcgctc?tgcccggcga?gtcgggctct 120

ggaggaaaag?aaagtttgcc?aatgcacgag?taacaagctc?acgcagttgg?gcacttttga 180

agatcatttt?ctcagcctcc?agaggatgtt?caataactgt?gaggtggtcc?ttgggaattt 240

ggaaattacc?tatgtgcaga?ggaattatga?tctttccttc?ttaaagacca?tccaggaggt 300

ggctggttat?gtcctcattg?ccctcaacac?agtggagcga?attcctttgg?aaaacctgca 360

gatcatcaga?ggaaatatgt?actacgaaaa?ttcctatgcc?ttagcagtct?tatctaacta 420

tgatgcaaat?aaaaccggac?tgaaggagct?gcccatgaga?aatttacagg?aaatcctgca 480

tggcgccgtg?cggttcagca?acaaccctgc?cctgtgcaac?gtggagagca?tccagtggcg 540

ggacatagtc?agcagtgact?ttctcagcaa?catgtcgatg?gacttccaga?accacctggg 600

cagctgccaa?aagtgtgatc?caagctgtcc?caatgggagc?tgctggggtg?caggagagga 660

gaactgccag?aaactgacca?aaatcatctg?tgcccagcag?tgctccgggc?gctgccgtgg 720

caagtccccc?agtgactgct?gccacaacca?gtgtgctgca?ggctgcacag?gcccccggga 780

gagcgactgc?ctggtctgcc?gcaaattccg?agacgaagcc?acgtgcaagg?acacctgccc 840

cccactcatg?ctctacaacc?ccaccacgta?ccagatggat?gtgaaccccg?agggcaaata 900

cagctttggt?gccacctgcg?tgaagaagtg?tccccgtaat?tatgtggtga?cagatcacgg 960

ctcgtgcgtc?cgagcctgtg?gggccgacag?ctatgagatg?gaggaagacg?gcgtccgcaa 1020

gtgtaagaag?tgcgaagggc?cttgccgcaa?agtgtgtaac?ggaataggta?ttggtgaatt 1080

taaagactca?ctctccataa?atgctacgaa?tattaaacac?ttcaaaaact?gcacctccat 1140

cagtggcgat?ctccacatcc?tgccggtggc?atttaggggt?gactccttca?cacatactcc 1200

tcctctggat?ccacaggaac?tggatattct?gaaaaccgta?aaggaaatca?cagggttttt 1260

gctgattcag?gcttggcctg?aaaacaggac?ggacctccat?gcctttgaga?acctagaaat 1320

catacgcggc?aggaccaagc?aacatggtca?gttttctctt?gcagtcgtca?gcctgaacat 1380

aacatccttg?ggattacgct?ccctcaagga?gataagtgat?ggagatgtga?taatttcagg 1440

aaacaaaaat?ttgtgctatg?caaatacaat?aaactggaaa?aaactgtttg?ggacctccgg 1500

tcagaaaacc?aaaattataa?gcaacagagg?tgaaaacagc?tgcaaggcca?caggccaggt 1560

ctgccatgcc?ttgtgctccc?ccgagggctg?ctggggcccg?gagcccaggg?actgcgtctc 1620

ttgccggaat?gtcagccgag?gcagggaatg?cgtggacaag?tgcaaccttc?tggagggtga 1680

gccaagggag?tttgtggaga?actctgagtg?catacagtgc?cacccagagt?gcctgcctca 1740

ggccatgaac?atcacctgca?caggacgggg?accagacaac?tgtatccagt?gtgcccacta 1800

cattgacggc?ccccactgcg?tcaagacctg?cccggcagga?gtcatgggag?aaaacaacac 1860

cctggtctgg?aagtacgcag?acgccggcca?tgtgtgccac?ctgtgccatc?caaactgcac 1920

ctacggatgc?actgggccag?gtcttgaagg?ctgtccaacg?aatgggccta?agatcccgtc 1980

catcgccact?gggatggtgg?gggccctcct?cttgctgctg?gtggtggccc?tggggatcgg 2040

cctcttcatg?cgaaggcgcc?acatcgttcg?gaagcgcacg?ctgcggaggc?tgctgcagga 2100

gagggagctt?gtggagcctc?ttacacccag?tggagaagct?cccaaccaag?ctctcttgag 2160

gatcttgaag?gaaactgaat?tcaaaaagat?caaagtgctg?ggctccggtg?cgttcggcac 2220

ggtgtataag?ggactctgga?tcccagaagg?tgagaaagtt?aaaattcccg?tcgctatcaa 2280

ggaattaaga?gaagcaacat?ctccgaaagc?caacaaggaa?atcctcgatg?aagcctacgt 2340

gatggccagc?gtggacaacc?cccacgtgtg?ccgcctgctg?ggcatctgcc?tcacctccac 2400

cgtgcagctc?atcacgcagc?tcatgccctt?cggctgcctc?ctggactatg?tccgggaaca 2460

caaagacaat?attggctccc?agtacctgct?caactggtgt?gtgcagatcg?caaagggcat 2520

gaactacttg?gaggaccgtc?gcttggtgca?ccgcgacctg?gcagccagga?acgtactggt 2580

gaaaacaccg?cagcatgtca?agatcacaga?ttttgggctg?gccaaactgc?tgggtgcgga 2640

agagaaagaa?taccatgcag?aaggaggcaa?agtgcctatc?aagtggatgg?cattggaatc 2700

aattttacac?agaatctata?cccaccagag?tgatgtctgg?agctacgggg?tgaccgtttg 2760

ggagttgatg?acctttggat?ccaagccata?tgacggaatc?cctgccagcg?agatctcctc 2820

catcctggag?aaaggagaac?gcctccctca?gccacccata?tgtaccatcg?atgtctacat 2880

gatcatggtc?aagtgctgga?tgatagacgc?agatagtcgc?ccaaagttcc?gtgagttgat 2940

catcgaattc?tccaaaatgg?cccgagaccc?ccagcgctac?cttgtcattc?agggggatga 3000

aagaatgcat?ttgccaagtc?ctacagactc?caacttctac?cgtgccctga?tggatgaaga 3060

agacatggac?gacgtggtgg?atgccgacga?gtacctcatc?ccacagcagg?gcttcttcag 3120

cagcccctcc?acgtcacgga?ctcccctcct?gagctctctg?agtgcaacca?gcaacaattc 3180

caccgtggct?tgcattgata?gaaatgggct?gcaaagctgt?cccatcaagg?aagacagctt 3240

cttgcagcga?tacagctcag?accccacagg?cgccttgact?gaggacagca?tagacgacac 3300

cttcctccca?gtgcctgaat?acataaacca?gtccgttccc?aaaaggcccg?ctggctctgt 3360

gcagaatcct?gtctatcaca?atcagcctct?gaaccccgcg?cccagcagag?acccacacta 3420

ccaggacccc?cacagcactg?cagtgggcaa?ccccgagtat?ctcaacactg?tccagcccac 3480

ctgtgtcaac?agcacattcg?acagccctgc?ccactgggcc?cagaaaggca?gccaccaaat 3540

tagcctggac?aaccctgact?accagcagga?cttctttccc?aaggaagcca?agccaaatgg 3600

catctttaag?ggctccacag?ctgaaaatgc?agaataccta?agggtcgcgc?cacaaagcag 3660

tgaatttatt?ggagcatgac?cacggaggat?agt 3693

<210>62

<211>1210

<212>PRT

＜213〉mankind

<400>62

Met?Arg?Pro?Ser?Gly?Thr?Ala?Gly?Ala?Ala?Leu?Leu?Ala?Leu?Leu?Ala

1 5 10 15

Ala?Leu?Cys?Pro?Ala?Ser?Arg?Ala?Leu?Glu?Glu?Lys?Lys?Val?Cys?Gln

20 25 30

Cys?Thr?Ser?Asn?Lys?Leu?Thr?Gln?Leu?Gly?Thr?Phe?Glu?Asp?His?Phe

35 40 45

Leu?Ser?Leu?Gln?Arg?Met?Phe?Asn?Asn?Cys?Glu?Val?Val?Leu?Gly?Asn

50 55 60

Leu?Glu?Ile?Thr?Tyr?Val?Gln?Arg?Asn?Tyr?Asp?Leu?Ser?Phe?Leu?Lys

65 70 75 80

Thr?Ile?Gln?Glu?Val?Ala?Gly?Tyr?Val?Leu?Ile?Ala?Leu?Asn?Thr?Val

85 90 95

Glu?Arg?Ile?Pro?Leu?Glu?Asn?Leu?Gln?Ile?Ile?Arg?Gly?Asn?Met?Tyr

100 105 110

Tyr?Glu?Asn?Ser?Tyr?Ala?Leu?Ala?Val?Leu?Ser?Asn?Tyr?Asp?Ala?Asn

115 120 125

Lys?Thr?Gly?Leu?Lys?Glu?Leu?Pro?Met?Arg?Asn?Leu?Gln?Glu?Ile?Leu

130 135 140

His?Gly?Ala?Val?Arg?Phe?Ser?Asn?Asn?Pro?Ala?Leu?Cys?Asn?Val?Glu

145 150 155 160

Ser?Ile?Gln?Trp?Arg?Asp?Ile?Val?Ser?Ser?Asp?Phe?Leu?Ser?Asn?Met

165 170 175

Ser?Met?Asp?Phe?Gln?Asn?His?Leu?Gly?Ser?Cys?Gln?Lys?Cys?Asp?Pro

180 185 190

Ser?Cys?Pro?Asn?Gly?Ser?Cys?Trp?Gly?Ala?Gly?Glu?Glu?Asn?Cys?Gln

195 200 205

Lys?Leu?Thr?Lys?Ile?Ile?Cys?Ala?Gln?Gln?Cys?Ser?Gly?Arg?Cys?Arg

210 215 220

Gly?Lys?Ser?Pro?Ser?Asp?Cys?Cys?His?Asn?Gln?Cys?Ala?Ala?Gly?Cys

225 230 235 240

Thr?Gly?Pro?Arg?Glu?Ser?Asp?Cys?Leu?Val?Cys?Arg?Lys?Phe?Arg?Asp

245 250 255

Glu?Ala?Thr?Cys?Lys?Asp?Thr?Cys?Pro?Pro?Leu?Met?Leu?Tyr?Asn?Pro

260 265 270

Thr?Thr?Tyr?Gln?Met?Asp?Val?Asn?Pro?Glu?Gly?Lys?Tyr?Ser?Phe?Gly

275 280 285

Ala?Thr?Cys?Val?Lys?Lys?Cys?Pro?Arg?Asn?Tyr?Val?Val?Thr?Asp?His

290 295 300

Gly?Ser?Cys?Val?Arg?Ala?Cys?Gly?Ala?Asp?Ser?Tyr?Glu?Met?Glu?Glu

305 310 315 320

Asp?Gly?Val?Arg?Lys?Cys?Lys?Lys?Cys?Glu?Gly?Pro?Cys?Arg?Lys?Val

325 330 335

Cys?Asn?Gly?Ile?Gly?Ile?Gly?Glu?Phe?Lys?Asp?Ser?Leu?Ser?Ile?Asn

340 345 350

Ala?Thr?Asn?Ile?Lys?His?Phe?Lys?Asn?Cys?Thr?Ser?Ile?Ser?Gly?Asp

355 360 365

Leu?His?Ile?Leu?Pro?Val?Ala?Phe?Arg?Gly?Asp?Ser?Phe?Thr?His?Thr

370 375 380

Pro?Pro?Leu?Asp?Pro?Gln?Glu?Leu?Asp?Ile?Leu?Lys?Thr?Val?Lys?Glu

385 390 395 400

Ile?Thr?Gly?Phe?Leu?Leu?Ile?Gln?Ala?Trp?Pro?Glu?Asn?Arg?Thr?Asp

405 410 415

Leu?His?Ala?Phe?Glu?Asn?Leu?Glu?Ile?Ile?Arg?Gly?Arg?Thr?Lys?Gln

420 425 430

His?Gly?Gln?Phe?Ser?Leu?Ala?Val?Val?Ser?Leu?Asn?Ile?Thr?Ser?Leu

435 440 445

Gly?Leu?Arg?Ser?Leu?Lys?Glu?Ile?Ser?Asp?Gly?Asp?Val?Ile?Ile?Ser

450 455 460

Gly?Asn?Lys?Asn?Leu?Cys?Tyr?Ala?Asn?Thr?Ile?Asn?Trp?Lys?Lys?Leu

465 470 475 480

Phe?Gly?Thr?Ser?Gly?Gln?Lys?Thr?Lys?Ile?Ile?Ser?Asn?Arg?Gly?Glu

485 490 495

Asn?Ser?Cys?Lys?Ala?Thr?Gly?Gln?Val?Cys?His?Ala?Leu?Cys?Ser?Pro

500 505 510

Glu?Gly?Cys?Trp?Gly?Pro?Glu?Pro?Arg?Asp?Cys?Val?Ser?Cys?Arg?Asn

515 520 525

Val?Ser?Arg?Gly?Arg?Glu?Cys?Val?Asp?Lys?Cys?Asn?Leu?Leu?Glu?Gly

530 535 540

Glu?Pro?Arg?Glu?Phe?Val?Glu?Asn?Ser?Glu?Cys?Ile?Gln?Cys?His?Pro

545 550 555 560

Glu?Cys?Leu?Pro?Gln?Ala?Met?Asn?Ile?Thr?Cys?Thr?Gly?Arg?Gly?Pro

565 570 575

Asp?Asn?Cys?Ile?Gln?Cys?Ala?His?Tyr?Ile?Asp?Gly?Pro?His?Cys?Val

580 585 590

Lys?Thr?Cys?Pro?Ala?Gly?Val?Met?Gly?Glu?Asn?Asn?Thr?Leu?Val?Trp

595 600 605

Lys?Tyr?Ala?Asp?Ala?Gly?His?Val?Cys?His?Leu?Cys?His?Pro?Asn?Cys

610 615 620

Thr?Tyr?Gly?Cys?Thr?Gly?Pro?Gly?Leu?Glu?Gly?Cys?Pro?Thr?Asn?Gly

625 630 635 640

Pro?Lys?Ile?Pro?Ser?Ile?Ala?Thr?Gly?Met?Val?Gly?Ala?Leu?Leu?Leu

645 650 655

Leu?Leu?Val?Val?Ala?Leu?Gly?Ile?Gly?Leu?Phe?Met?Arg?Arg?Arg?His

660 665 670

Ile?Val?Arg?Lys?Arg?Thr?Leu?Arg?Arg?Leu?Leu?Gln?Glu?Arg?Glu?Leu

675 680 685

Val?Glu?Pro?Leu?Thr?Pro?Ser?Gly?Glu?Ala?Pro?Asn?Gln?Ala?Leu?Leu

690 695 700

Arg?Ile?Leu?Lys?Glu?Thr?Glu?Phe?Lys?Lys?Ile?Lys?Val?Leu?Gly?Ser

705 710 715 720

Gly?Ala?Phe?Gly?Thr?Val?Tyr?Lys?Gly?Leu?Trp?Ile?Pro?Glu?Gly?Glu

725 730 735

Lys?Val?Lys?Ile?Pro?Val?Ala?Ile?Lys?Glu?Leu?Arg?Glu?Ala?Thr?Ser

740 745 750

Pro?Lys?Ala?Asn?Lys?Glu?Ile?Leu?Asp?Glu?Ala?Tyr?Val?Met?Ala?Ser

755 760 765

Val?Asp?Asn?Pro?His?Val?Cys?Arg?Leu?Leu?Gly?Ile?Cys?Leu?Thr?Ser

770 775 780

Thr?Val?Gln?Leu?Ile?Thr?Gln?Leu?Met?Pro?Phe?Gly?Cys?Leu?Leu?Asp

785 790 795 800

Tyr?Val?Arg?Glu?His?Lys?Asp?Asn?Ile?Gly?Ser?Gln?Tyr?Leu?Leu?Asn

805 810 815

Trp?Cys?Val?Gln?Ile?Ala?Lys?Gly?Met?Asn?Tyr?Leu?Glu?Asp?Arg?Arg

820 825 830

Leu?Val?His?Arg?Asp?Leu?Ala?Ala?Arg?Asn?Val?Leu?Val?Lys?Thr?Pro

835 840 845

Gln?His?Val?Lys?Ile?Thr?Asp?Phe?Gly?Leu?Ala?Lys?Leu?Leu?Gly?Ala

850 855 860

Glu?Glu?Lys?Glu?Tyr?His?Ala?Glu?Gly?Gly?Lys?Val?Pro?Ile?Lys?Trp

865 870 875 880

Met?Ala?Leu?Glu?Ser?Ile?Leu?His?Arg?Ile?Tyr?Thr?His?Gln?Ser?Asp

885 890 895

Val?Trp?Ser?Tyr?Gly?Val?Thr?Val?Trp?Glu?Leu?Met?Thr?Phe?Gly?Ser

900 905 910

Lys?Pro?Tyr?Asp?Gly?Ile?Pro?Ala?Ser?Glu?Ile?Ser?Ser?Ile?Leu?Glu

915 920 925

Lys?Gly?Glu?Arg?Leu?Pro?Gln?Pro?Pro?Ile?Cys?Thr?Ile?Asp?Val?Tyr

930 935 940

Met?Ile?Met?Val?Lys?Cys?Trp?Met?Ile?Asp?Ala?Asp?Ser?Arg?Pro?Lys

945 950 955 960

Phe?Arg?Glu?Leu?Ile?Ile?Glu?Phe?Ser?Lys?Met?Ala?Arg?Asp?Pro?Gln

965 970 975

Arg?Tyr?Leu?Val?Ile?Gln?Gly?Asp?Glu?Arg?Met?His?Leu?Pro?Ser?Pro

980 985 990

Thr?Asp?Ser?Asn?Phe?Tyr?Arg?Ala?Leu?Met?Asp?Glu?Glu?Asp?Met?Asp

995 1000 1005

Asp?Val?Val?Asp?Ala?Asp?Glu?Tyr?Leu?Ile?Pro?Gln?Gln?Gly?Phe?Phe

1010 1015 1020

Ser?Ser?Pro?Ser?Thr?Ser?Arg?Thr?Pro?Leu?Leu?Ser?Ser?Leu?Ser?Ala

1025 1030 1035 1040

Thr?Ser?Asn?Asn?Ser?Thr?Val?Ala?Cys?Ile?Asp?Arg?Asn?Gly?Leu?Gln

1045 1050 1055

Ser?Cys?Pro?Ile?Lys?Glu?Asp?Ser?Phe?Leu?Gln?Arg?Tyr?Ser?Ser?Asp

1060 1065 1070

Pro?Thr?Gly?Ala?Leu?Thr?Glu?Asp?Ser?Ile?Asp?Asp?Thr?Phe?Leu?Pro

1075 1080 1085

Val?Pro?Glu?Tyr?Ile?Asn?Gln?Ser?Val?Pro?Lys?Arg?Pro?Ala?Gly?Ser

1090 1095 1100

Val?Gln?Asn?Pro?Val?Tyr?His?Asn?Gln?Pro?Leu?Asn?Pro?Ala?Pro?Ser

1105 1110 1115 1120

Arg?Asp?Pro?His?Tyr?Gln?Asp?Pro?His?Ser?Thr?Ala?Val?Gly?Asn?Pro

1125 1130 1135

Glu?Tyr?Leu?Asn?Thr?Val?Gln?Pro?Thr?Cys?Val?Asn?Ser?Thr?Phe?Asp

1140 1145 1150

Ser?Pro?Ala?His?Trp?Ala?Gln?Lys?Gly?Ser?His?Gln?Ile?Ser?Leu?Asp

1155 1160 1165

Asn?Pro?Asp?Tyr?Gln?Gln?Asp?Phe?Phe?Pro?Lys?Glu?Ala?Lys?Pro?Asn

1170 1175 1180

Gly?Ile?Phe?Lys?Gly?Ser?Thr?Ala?Glu?Asn?Ala?Glu?Tyr?Leu?Arg?Val

1185 1190 1195 1200

Ala?Pro?Gln?Ser?Ser?Glu?Phe?Ile?Gly?Ala

1205 1210

<210>63

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP7 of GIG40

<400>63

aagcttaacg?agg 13

<210>64

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG40

<400>64

aagctttttt?tttttg 16

<210>65

<211>1939

<212>DNA

＜213〉mankind

<400>65

tggcacaatg?aagtgggtaa?cctttatttc?ccttcttttt?ctctttagct?cggcttattc 60

caggggtgtg?tttcgtcgag?atgcacacaa?gagtgaggtt?gctcatcggt?ttaaagattt 120

gggagaagaa?aatttcaaag?ccttggtgtt?gattgccttt?gctcagtatc?ttcagcagtg 180

tccatttgaa?gatcatgtaa?aattagtgaa?tgaagtaact?gaatttgcaa?aaacatgtgt 240

tgctgatgag?tcagctgaaa?attgtgacaa?atcacttcat?accctttttg?gagacaaatt 300

atgcacagtt?gcaactcttc?gtgaaaccta?tggtgaaatg?gctgactgct?gtgcaaaaca 360

agaacctgag?agaaatgaat?gcttcttgca?acacaaagat?gacaacccaa?acctcccccg 420

attggtgaga?ccagaggttg?atgtgatgtg?cactgctttt?catgacaatg?aagagacatt 480

tttgaaaaaa?tacttatatg?aaattgccag?aagacatcct?tacttttatg?ccccggaact 540

ccttttcttt?gctaaaaggt?ataaagctgc?ttttacagaa?tgttgccaag?ctgctgataa 600

agctgcctgc?ctgttgccaa?agctcgatga?acttcgggat?gaagggaagg?cttcgtctgc 660

caaacagaga?ctcaagtgtg?ccagtctcca?aaaatttgga?gaaagagctt?tcaaagcatg 720

ggcagtagct?cgcctgagcc?agagatttcc?caaagctgag?tttgcagaag?tttccaagtt 780

agtgacagat?cttaccaaag?tccacacgga?atgctgccat?ggagatctgc?ttgaatgtgc 840

tgatgacagg?gcggaccttg?ccaagtatat?ctgtgaaaat?caagattcga?tctccagtaa 900

actgaaggaa?tgctgtgaaa?aacctctgtt?ggaaaaatcc?cactgcattg?ccgaagtgga 960

aaatgatgag?atgcctgctg?acttgccttc?attagctgct?gattttgttg?aaagtaagga 1020

tgtttgcaaa?aactatgctg?aggcaaagga?tgtcttcctg?ggcatgtttt?tgtatgaata 1080

tgcaagaagg?catcctgatt?actctgtcgt?gctgctgctg?agacttgcca?agacatatga 1140

aaccactcta?gagaagtgct?gtgccgctgc?agatcctcat?gaatgctatg?ccaaagtgtt 1200

cgatgaattt?aaacctcttg?tggaagagcc?tcagaattta?atcaaacaaa?attgtgagct 1260

ttttgagcag?cttggagagt?acaaattcca?gaatgcgcta?ttagttcgtt?acaccaagaa 1320

agtaccccaa?gtgtcaactc?caactcttgt?agaggtctca?agaaacctag?gaaaagtggg 1380

cagcaaatgt?tgtaaacatc?ctgaagcaaa?aagaatgccc?tgtgcagaag?actatctatc 1440

cgtggtcctg?aaccagttat?gtgtgttgca?tgagaaaacg?ccagtaagtg?acagagtcac 1500

caaatgctgc?acagaatcct?tggtgaacag?gcgaccatgc?ttttcagctc?tggaagtcga 1560

tgaaacatac?gttcccaaag?agtttaatgc?tgaaacattc?accttccatg?cagatatatg 1620

cacactttct?gagaaggaga?gacaaatcaa?gaaacaaact?gcacttgttg?agcttgtgaa 1680

acacaagccc?aaggcaacaa?aagagcaact?gaaagctgtt?atggatgatt?tcgcagcttt 1740

tgtagagaag?tgctgcaagg?ctgacgataa?ggagacctgc?tttgccgagg?agggtaaaaa 1800

acttgttgct?gcaagtcaag?ctgccttagg?cttataacat?cacatttaaa?agcatctcag 1860

cctaccatga?gaataagaga?aagaaaatga?agatcaaaag?cttattcatc?tgtttttctt 1920

tttcgttggt?gtaaagcca 1939

<210>66

<211>609

<212>PRT

＜213〉mankind

<400>66

Met?Lys?Trp?Val?Thr?Phe?Ile?Ser?Leu?Leu?Phe?Leu?Phe?Ser?Ser?Ala

1 5 10 15

Tyr?Ser?Arg?Gly?Val?Phe?Arg?Arg?Asp?Ala?His?Lys?Ser?Glu?Val?Ala

20 25 30

His?Arg?Phe?Lys?Asp?Leu?Gly?Glu?Glu?Asn?Phe?Lys?Ala?Leu?Val?Leu

35 40 45

Ile?Ala?Phe?Ala?Gln?Tyr?Leu?Gln?Gln?Cys?Pro?Phe?Glu?Asp?His?Val

50 55 60

Lys?Leu?Val?Asn?Glu?Val?Thr?Glu?Phe?Ala?Lys?Thr?Cys?Val?Ala?Asp

65 70 75 80

Glu?Ser?Ala?Glu?Asn?Cys?Asp?Lys?Ser?Leu?His?Thr?Leu?Phe?Gly?Asp

85 90 95

Lys?Leu?Cys?Thr?Val?Ala?Thr?Leu?Arg?Glu?Thr?Tyr?Gly?Glu?Met?Ala

100 105 110

Asp?Cys?Cys?Ala?Lys?Gln?Glu?Pro?Glu?Arg?Asn?Glu?Cys?Phe?Leu?Gln

115 120 125

His?Lys?Asp?Asp?Asn?Pro?Asn?Leu?Pro?Arg?Leu?Val?Arg?Pro?Glu?Val

130 135 140

Asp?Val?Met?Cys?Thr?Ala?Phe?His?Asp?Asn?Glu?Glu?Thr?Phe?Leu?Lys

145 150 155 160

Lys?Tyr?Leu?Tyr?Glu?Ile?Ala?Arg?Arg?His?Pro?Tyr?Phe?Tyr?Ala?Pro

165 170 175

Glu?Leu?Leu?Phe?Phe?Ala?Lys?Arg?Tyr?Lys?Ala?Ala?Phe?Thr?Glu?Cys

180 185 190

Cys?Gln?Ala?Ala?Asp?Lys?Ala?Ala?Cys?Leu?Leu?Pro?Lys?Leu?Asp?Glu

195 200 205

Leu?Arg?Asp?Glu?Gly?Lys?Ala?Ser?Ser?Ala?Lys?Gln?Arg?Leu?Lys?Cys

210 215 220

Ala?Ser?Leu?Gln?Lys?Phe?Gly?Glu?Arg?Ala?Phe?Lys?Ala?Trp?Ala?Val

225 230 235 240

Ala?Arg?Leu?Ser?Gln?Arg?Phe?Pro?Lys?Ala?Glu?Phe?Ala?Glu?Val?Ser

245 250 255

Lys?Leu?Val?Thr?Asp?Leu?Thr?Lys?Val?His?Thr?Glu?Cys?Cys?His?Gly

260 265 270

Asp?Leu?Leu?Glu?Cys?Ala?Asp?Asp?Arg?Ala?Asp?Leu?Ala?Lys?Tyr?Ile

275 280 285

Cys?Glu?Asn?Gln?Asp?Ser?Ile?Ser?Ser?Lys?Leu?Lys?Glu?Cys?Cys?Glu

290 295 300

Lys?Pro?Leu?Leu?Glu?Lys?Ser?His?Cys?Ile?Ala?Glu?Val?Glu?Asn?Asp

305 310 315 320

Glu?Met?Pro?Ala?Asp?Leu?Pro?Ser?Leu?Ala?Ala?Asp?Phe?Val?Glu?Ser

325 330 335

Lys?Asp?Val?Cys?Lys?Asn?Tyr?Ala?Glu?Ala?Lys?Asp?Val?Phe?Leu?Gly

340 345 350

Met?Phe?Leu?Tyr?Glu?Tyr?Ala?Arg?Arg?His?Pro?Asp?Tyr?Ser?Val?Val

355 360 365

Leu?Leu?Leu?Arg?Leu?Ala?Lys?Thr?Tyr?Glu?Thr?Thr?Leu?Glu?Lys?Cys

370 375 380

Cys?Ala?Ala?Ala?Asp?Pro?His?Glu?Cys?Tyr?Ala?Lys?Val?Phe?Asp?Glu

385 390 395 400

Phe?Lys?Pro?Leu?Val?Glu?Glu?Pro?Gln?Asn?Leu?Ile?Lys?Gln?Asn?Cys

405 410 415

Glu?Leu?Phe?Glu?Gln?Leu?Gly?Glu?Tyr?Lys?Phe?Gln?Asn?Ala?Leu?Leu

420 425 430

Val?Arg?Tyr?Thr?Lys?Lys?Val?Pro?Gln?Val?Ser?Thr?Pro?Thr?Leu?Val

435 440 445

Glu?Val?Ser?Arg?Asn?Leu?Gly?Lys?Val?Gly?Ser?Lys?Cys?Cys?Lys?His

450 455 460

Pro?Glu?Ala?Lys?Arg?Met?Pro?Cys?Ala?Glu?Asp?Tyr?Leu?Ser?Val?Val

465 470 475 480

Leu?Asn?Gln?Leu?Cys?Val?Leu?His?Glu?Lys?Thr?Pro?Val?Ser?Asp?Arg

485 490 495

Val?Thr?Lys?Cys?Cys?Thr?Glu?Ser?Leu?Val?Asn?Arg?Arg?Pro?Cys?Phe

500 505 510

Ser?Ala?Leu?Glu?Val?Asp?Glu?Thr?Tyr?Val?Pro?Lys?Glu?Phe?Asn?Ala

515 520 525

Glu?Thr?Phe?Thr?Phe?His?Ala?Asp?Ile?Cys?Thr?Leu?Ser?Glu?Lys?Glu

530 535 540

Arg?Gln?Ile?Lys?Lys?Gln?Thr?Ala?Leu?Val?Glu?Leu?Val?Lys?His?Lys

545 550 555 560

Pro?Lys?Ala?Thr?Lys?Glu?Gln?Leu?Lys?Ala?Val?Met?Asp?Asp?Phe?Ala

565 570 575

Ala?Phe?Val?Glu?Lys?Cys?Cys?Lys?Ala?Asp?Asp?Lys?Glu?Thr?Cys?Phe

580 585 590

Ala?Glu?Glu?Gly?Lys?Lys?Leu?Val?Ala?Ala?Ser?Gln?Ala?Ala?Leu?Gly

595 600 605

Leu

<210>67

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP8 of GIG42

<400>67

aagcttttac?cgc 13

<210>68

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG42

<400>68

aagctttttt?tttttg 16

<210>69

<211>1106

<212>DNA

＜213〉mankind

<400>69

ttccctttcc?tctgccagta?caactagacc?cggcgtctgg?cgtccccggt?gcccagcatt 60

ctgcggggca?ggcggattaa?ttggaattct?tcaaaatgtc?aggtgtggta?cccacagccc 120

ctgaacagcc?tgcaggtgaa?atggaaaatc?aaacaaaacc?accagatcca?aggcctgatg 180

ctcctcctga?atacaattct?cattttttac?caggaccccc?tggaacagct?gtccctccac 240

ctactggcta?cccaggaggc?ttgcctatgg?gatactacag?tccacagcaa?cccagtacct 300

tccctttgta?ccagtcagtt?ggtggtatcc?atcctgtccg?gtatcagcct?ggcaaatatc 360

ctatgccaaa?tcagtctgtt?ccaataacat?ggatgccagg?gccaactcct?atggcaaact 420

gccctcctgg?tctggaatac?ttagttcagt?tggacaacat?acatgttctt?cagcattttg 480

agcctctgga?aatgatgaca?tgttttgaaa?ctaataatag?atatgatatt?aaaaacaact 540

cagaccagat?ggtttacatt?gtaaccgaag?acacagatga?ctttaccagg?aatgcctatc 600

ggacactaag?gcccttcgtc?ctccgggtca?ctgattgtat?gggccgagaa?atcatgacaa 660

tgcagagacc?cttcagatgc?acctgctgtt?gcttctgttg?cccctctgcc?agacaagagc 720

tggaggtgca?gtgtcctcct?ggtgtcacca?ttggctttgt?tgcggaacat?tggaacctgt 780

gcagggcggt?gtacagcatc?caaaatgaga?agaaagaaaa?tgtgatgaga?gttcgtgggc 840

catgctcaac?ctatggctgt?ggttcagatt?ctgtttttga?ggtcaaatcc?cttgatggca 900

tatccaacat?cggcagtatt?atccggaagt?ggaatggttt?gttatcagca?atggcagatg 960

ctgaccattt?tgacattcac?ttcccactag?acctggatgt?gaagatgaaa?gccatgattt 1020

ttggagcttg?cttcctcatt?gacttcatgt?attttgaaag?atctccacca?caacgttcaa 1080

gatagagaga?cacagcaagc?catcaa 1106

<210>70

<211>329

<212>PRT

＜213〉mankind

<400>70

Met?Ser?Gly?Val?Val?Pro?Thr?Ala?Pro?Glu?Gln?Pro?Ala?Gly?Glu?Met

1 5 10 15

Glu?Asn?Gln?Thr?Lys?Pro?Pro?Asp?Pro?Arg?Pro?Asp?Ala?Pro?Pro?Glu

20 25 30

Tyr?Asn?Ser?His?Phe?Leu?Pro?Gly?Pro?Pro?Gly?Thr?Ala?Val?Pro?Pro

35 40 45

Pro?Thr?Gly?Tyr?Pro?Gly?Gly?Leu?Pro?Met?Gly?Tyr?Tyr?Ser?Pro?Gln

50 55 60

Gln?Pro?Ser?Thr?Phe?Pro?Leu?Tyr?Gln?Ser?Val?Gly?Gly?Ile?His?Pro

65 70 75 80

Val?Arg?Tyr?Gln?Pro?Gly?Lys?Tyr?Pro?Met?Pro?Asn?Gln?Ser?Val?Pro

85 90 95

Ile?Thr?Trp?Met?Pro?Gly?Pro?Thr?Pro?Met?Ala?Asn?Cys?Pro?Pro?Gly

100 105 110

Leu?Glu?Tyr?Leu?Val?Gln?Leu?Asp?Asn?Ile?His?Val?Leu?Gln?His?Phe

115 120 125

Glu?Pro?Leu?Glu?Met?Met?Thr?Cys?Phe?Glu?Thr?Asn?Asn?Arg?Tyr?Asp

130 135 140

Ile?Lys?Asn?Asn?Ser?Asp?Gln?Met?Val?Tyr?Ile?Val?Thr?Glu?Asp?Thr

145 150 155 160

Asp?Asp?Phe?Thr?Arg?Asn?Ala?Tyr?Arg?Thr?Leu?Arg?Pro?Phe?Val?Leu

165 170 175

Arg?Val?Thr?Asp?Cys?Met?Gly?Arg?Glu?Ile?Met?Thr?Met?Gln?Arg?Pro

180 185 190

Phe?Arg?Cys?Thr?Cys?Cys?Cys?Phe?Cys?Cys?Pro?Ser?Ala?Arg?Gln?Glu

195 200 205

Leu?Glu?Val?Gln?Cys?Pro?Pro?Gly?Val?Thr?Ile?Gly?Phe?Val?Ala?Glu

210 215 220

His?Trp?Asn?Leu?Cys?Arg?Ala?Val?Tyr?Ser?Ile?Gln?Asn?Glu?Lys?Lys

225 230 235 240

Glu?Asn?Val?Met?Arg?Val?Arg?Gly?Pro?Cys?Ser?Thr?Tyr?Gly?Cys?Gly

245 250 255

Ser?Asp?Ser?Val?Phe?Glu?Val?Lys?Ser?Leu?Asp?Gly?Ile?Ser?Asn?Ile

260 265 270

Gly?Ser?Ile?Ile?Arg?Lys?Trp?Asn?Gly?Leu?Leu?Ser?Ala?Met?Ala?Asp

275 280 285

Ala?Asp?His?Phe?Asp?Ile?His?Phe?Pro?Leu?Asp?Leu?Asp?Val?Lys?Met

290 295 300

Lys?Ala?Met?Ile?Phe?Gly?Ala?Cys?Phe?Leu?Ile?Asp?Phe?Met?Tyr?Phe

305 310 315 320

Glu?Arg?Ser?Pro?Pro?Gln?Arg?Ser?Arg

325

<210>71

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP10 of GIG43

<400>71

aagcttccac?gta 13

<210>72

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG43

<400>72

aagctttttt?tttttg 16

<210>73

<211>1715

<212>DNA

＜213〉mankind

<400>73

ggagttccgc?tcctctctcc?aaccggggtc?cccctccagc?gaccctaaag?cttcccagac 60

ttccgcttca?attcctgtcc?gccccccacg?cccacctcaa?cgtggagcgc?agtggtctcc 120

gaggagcgcc?ggagctgccc?cgcctgccca?gcgggatcag?cacttcgcat?caaggcccaa 180

gaaaagcaag?tcctccagcg?ttctgagcac?ccgggcctga?gggaaggtcc?taacagcccc 240

cgggagccag?tctccaacgc?ctcccgcagc?agcccgccgc?tcccaggtgc?ccgcgtgcgc 300

cgctgccgcc?gcaatcccgc?acgcgtcccg?cgcccgcccc?actttgccta?tccccgggac 360

taagacggga?atcctgtgaa?gcagctccag?ctatgtgtga?agaagaggac?agcactgcct 420

tggtgtgtga?caatggctct?gggctctgta?aggccggctt?tgctggggac?gatgctccca 480

gggctgtttt?cccatccatt?gtgggacgtc?ccagacatca?gggggtgatg?gtgggaatgg 540

gacaaaaaga?cagctacgtg?ggtgacgaag?cacagagcaa?aagaggaatc?ctgaccctga 600

agtacccgat?agaacatggc?atcatcacca?actgggacga?catggaaaag?atctggcacc 660

actctttcta?caatgagctt?cgtgttgccc?ctgaagagca?tcccaccctg?ctcacggagg 720

cacccctgaa?ccccaaggcc?aaccgggaga?aaatgactca?aattatgttt?gagactttca 780

atgtcccagc?catgtatgtg?gctatccagg?cggtgctgtc?tctctatgcc?tctggacgca 840

caactggcat?cgtgctggac?tctggagatg?gtgtcaccca?caatgtcccc?atctatgagg 900

gctatgcctt?gccccatgcc?atcatgcgtc?tggatctggc?tggccgagat?ctcactgact 960

acctcatgaa?gatcctgact?gagcgtggct?attccttcgt?tactactgct?gagcgtgaga 1020

ttgtccggga?catcaaggag?aaactgtgtt?atgtagctct?ggactttgaa?aatgagatgg 1080

ccactgccgc?atcctcatcc?tcccttgaga?agagttacga?gttgcctgat?gggcaagtga 1140

tcaccatcgg?aaatgaacgt?ttccgctgcc?cagagaccct?gttccagcca?tccttcatcg 1200

ggatggagtc?tgctggcatc?catgaaacca?cctacaacag?catcatgaag?tgtgatattg 1260

acatcaggaa?ggacctctat?gctaacaatg?tcctatcagg?gggcaccact?atgtaccctg 1320

gcattgccga?ccgaatgcag?aaggagatca?cggccctagc?acccagcacc?atgaagatca 1380

agatcattgc?ccctccggag?cgcaaatact?ctgtctggat?cggtggctcc?atcctggcct 1440

ctctgtccac?cttccagcag?atgtggatca?gcaaacagga?atacgatgaa?gccgggcctt 1500

ccattgtcca?ccgcaaatgc?ttctaaaaca?ctttcctgct?cctctctgtc?tctagcacac 1560

aactgtgaat?gtcctgtgga?attatgcctt?cagttctttt?ccaaatcatt?cctagccaaa 1620

gctctgactc?gttacctatg?tgttttttaa?taaatctgaa?ataggctact?ggtaaaaaaa 1680

aaaaaaaaaa?aaaaaaaaaa?aaaaaaaaaa?aaaaa 1715

<210>74

<211>377

<212>PRT

＜213〉mankind

<400>74

Met?Cys?Glu?Glu?Glu?Asp?Ser?Thr?Ala?Leu?Val?Cys?Asp?Asn?Gly?Ser

1 5 10 15

Gly?Leu?Cys?Lys?Ala?Gly?Phe?Ala?Gly?Asp?Asp?Ala?Pro?Arg?Ala?Val

20 25 30

Phe?Pro?Ser?Ile?Val?Gly?Arg?Pro?Arg?His?Gln?Gly?Val?Met?Val?Gly

35 40 45

Met?Gly?Gln?Lys?Asp?Ser?Tyr?Val?Gly?Asp?Glu?Ala?Gln?Ser?Lys?Arg

50 55 60

Gly?Ile?Leu?Thr?Leu?Lys?Tyr?Pro?Ile?Glu?His?Gly?Ile?Ile?Thr?Asn

65 70 75 80

Trp?Asp?Asp?Met?Glu?Lys?Ile?Trp?His?His?Ser?Phe?Tyr?Asn?Glu?Leu

85 90 95

Arg?Val?Ala?Pro?Glu?Glu?His?Pro?Thr?Leu?Leu?Thr?Glu?Ala?Pro?Leu

100 105 110

Asn?Pro?Lys?Ala?Asn?Arg?Glu?Lys?Met?Thr?Gln?Ile?Met?Phe?Glu?Thr

115 120 125

Phe?Asn?Val?Pro?Ala?Met?Tyr?Val?Ala?Ile?Gln?Ala?Val?Leu?Ser?Leu

130 135 140

Tyr?Ala?Ser?Gly?Arg?Thr?Thr?Gly?Ile?Val?Leu?Asp?Ser?Gly?Asp?Gly

145 150 155 160

Val?Thr?His?Asn?Val?Pro?Ile?Tyr?Glu?Gly?Tyr?Ala?Leu?Pro?His?Ala

165 170 175

Ile?Met?Arg?Leu?Asp?Leu?Ala?Gly?Arg?Asp?Leu?Thr?Asp?Tyr?Leu?Met

180 185 190

Lys?Ile?Leu?Thr?Glu?Arg?Gly?Tyr?Ser?Phe?Val?Thr?Thr?Ala?Glu?Arg

195 200 205

Glu?Ile?Val?Arg?Asp?Ile?Lys?Glu?Lys?Leu?Cys?Tyr?Val?Ala?Leu?Asp

210 215 220

Phe?Glu?Asn?Glu?Met?Ala?Thr?Ala?Ala?Ser?Ser?Ser?Ser?Leu?Glu?Lys

225 230 235 240

Ser?Tyr?Glu?Leu?Pro?Asp?Gly?Gln?Val?Ile?Thr?Ile?Gly?Asn?Glu?Arg

245 250 255

Phe?Arg?Cys?Pro?Glu?Thr?Leu?Phe?Gln?Pro?Ser?Phe?Ile?Gly?Met?Glu

260 265 270

Ser?Ala?Gly?Ile?His?Glu?Thr?Thr?Tyr?Asn?Ser?Ile?Met?Lys?Cys?Asp

275 280 285

Ile?Asp?Ile?Arg?Lys?Asp?Leu?Tyr?Ala?Asn?Asn?Val?Leu?Ser?Gly?Gly

290 295 300

Thr?Thr?Met?Tyr?Pro?Gly?Ile?Ala?Asp?Arg?Met?Gln?Lys?Glu?Ile?Thr

305 310 315 320

Ala?Leu?Ala?Pro?Ser?Thr?Met?Lys?Ile?Lys?Ile?Ile?Ala?Pro?Pro?Glu

325 330 335

Arg?Lys?Tyr?Ser?Val?Trp?Ile?Gly?Gly?Ser?Ile?Leu?Ala?Ser?Leu?Ser

340 345 350

Thr?Phe?Gln?Gln?Met?Trp?Ile?Ser?Lys?Gln?Glu?Tyr?Asp?Glu?Ala?Gly

355 360 365

Pro?Ser?Ile?Val?His?Arg?Lys?Cys?Phe

370 375

<210>75

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP16 of GIG46

<400>75

aagctttaga?gcg 13

<210>76

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG46

<400>76

aagctttttt?ttttta 16

<210>77

<211>2117

<212>DNA

＜213〉mankind

<400>77

gtctgtgtgc?agaggggatt?caacttcaat?ttttctgcag?tggctctgag?tccagcccct 60

tacttaaaga?tctggaaagc?atgaagactg?ggcttttttt?cctatgtctc?ttgggaactg 120

cagctgcaat?cccgacaaat?gcaagattat?tatctgatca?ttccaaacca?actgctgaaa 180

cggtagcacc?cgacaacact?gcaatcccca?gtttaagggc?tgaagatgaa?gaaaatgaaa 240

aagaaacagc?agtatccaca?gaagacgatt?cccaccataa?ggctgaaaaa?tcatcagtac 300

taaagtcaaa?agaggaaagc?catgaacagt?cagcagaaca?gggcaagagt?tctagccaag 360

agctgggatt?gaaggatcaa?gaggacagtg?atggtgactt?aagtgtgaat?ttggagtatg 420

caccaactga?aggtacattg?gacataaaag?aagatatgag?tgagcctcag?gagaaaaaac 480

tctcagagaa?cactgattttt?tggctcctg?gtgttagttc?cttcacagat?tctaaccaac 540

aagaaagtat?cacaaagaga?gaggaaaacc?aagaacaacc?tagaaattat?tcacatcatc 600

agttgaacag?gagcagtaaa?catagccaag?gcctaaggga?tcaaggaaac?caagagcagg 660

atccaaatat?ttccaatgga?gaagaggaag?aagaaaaaga?gccaggtgaa?gttggtaccc 720

acaatgataa?ccaagaaaga?aagacagaat?tgcccaggga?gcatgctaac?agcaagcagg 780

aggaagacaa?tacccaatct?gatgatattt?tggaagagtc?tgatcaacca?actcaagtaa 840

gcaagatgca?ggaggatgaa?tttgatcagg?gtaaccaaga?acaagaagat?aactccaatg 900

cagaaatgga?agaggaaaat?gcatcgaacg?tcaataagca?cattcaagaa?actgaatggc 960

agagtcaaga?gggtaaaact?ggcctagaag?ctatcagcaa?ccacaaagag?acagaagaaa 1020

agactgtttc?tgaggctctg?ctcatggaac?ctactgatga?tggtaatacc?acgcccagaa 1080

atcatggagt?tgatgatgat?ggcgatgatg?atggcgatga?tggcggcact?gatggcccca 1140

ggcacagtgc?aagtgatgac?tacttcatcc?caagccaggc?ctttctggag?gccgagagag 1200

ctcaatccat?tgcctatcac?ctcaaaattg?aggagcaaag?agaaaaagta?catgaaaatg 1260

aaaatatagg?taccactgag?cctggagagc?accaagaggc?caagaaagca?gagaactcat 1320

caaatgagga?ggaaacgtca?agtgaaggca?acatgagggt?gcatgctgtg?gattcttgca 1380

tgagcttcca?gtgtaaaaga?ggccacatct?gtaaggcaga?ccaacaggga?aaacctcact 1440

gtgtctgcca?ggatccagtg?acttgtcctc?caacaaaacc?ccttgatcaa?gtttgtggca 1500

ctgacaatca?gacctatgct?agttcctgtc?atctattcgc?tactaaatgc?agactggagg 1560

ggaccaaaaa?ggggcatcaa?ctccagctgg?attattttgg?agcctgcaaa?tctattccta 1620

cttgtacgga?ctttgaagtg?attcagtttc?ctctacggat?gagagactgg?ctcaagaata 1680

tcctcatgca?gctttatgaa?gccaactctg?aacacgctgg?ttatctaaat?gagaagcaga 1740

gaaataaagt?caagaaaatt?tacctggatg?aaaagaggct?tttggctggg?gaccatccca 1800

ttgaccttct?cttaagggac?tttaagaaaa?actaccacat?gtatgtgtat?cctgtgcact 1860

ggcagtttag?tgaacttgac?caacacccta?tggatagagt?cttgacacat?tctgaacttg 1920

ctcctctgcg?agcatctctg?gtgcccatgg?aacactgcat?aacccgtttc?tttgaggagt 1980

gtgaccccaa?caaggataag?cacatcaccc?tgaaggagtg?gggccactgc?tttggaatta 2040

aagaagagga?catagatgaa?aatctcttgt?tttgaacgaa?gattttaaag?aactcaactt 2100

tccagcatcc?tcctctg 2117

<210>78

<211>664

<212>PRT

＜213〉mankind

<400>78

Met?Lys?Thr?Gly?Leu?Phe?Phe?Leu?Cys?Leu?Leu?Gly?Thr?Ala?Ala?Ala

1 5 10 15

Ile?Pro?Thr?Asn?Ala?Arg?Leu?Leu?Ser?Asp?His?Ser?Lys?Pro?Thr?Ala

20 25 30

Glu?Thr?Val?Ala?Pro?Asp?Asn?Thr?Ala?Ile?Pro?Ser?Leu?Arg?Ala?Glu

35 40 45

Asp?Glu?Glu?Asn?Glu?Lys?Glu?Thr?Ala?Val?Ser?Thr?Glu?Asp?Asp?Ser

50 55 60

His?His?Lys?Ala?Glu?Lys?Ser?Ser?Val?Leu?Lys?Ser?Lys?Glu?Glu?Ser

65 70 75 80

His?Glu?Gln?Ser?Ala?Glu?Gln?Gly?Lys?Ser?Ser?Ser?Gln?Glu?Leu?Gly

85 90 95

Leu?Lys?Asp?Gln?Glu?Asp?Ser?Asp?Gly?Asp?Leu?Ser?Val?Asn?Leu?Glu

100 105 110

Tyr?Ala?Pro?Thr?Glu?Gly?Thr?Leu?Asp?Ile?Lys?Glu?Asp?Met?Ser?Glu

115 120 125

Pro?Gln?Glu?Lys?Lys?Leu?Ser?Glu?Asn?Thr?Asp?Phe?Leu?Ala?Pro?Gly

130 135 140

Val?Ser?Ser?Phe?Thr?Asp?Ser?Asn?Gln?Gln?Glu?Ser?Ile?Thr?Lys?Arg

145 150 155 160

Glu?Glu?Asn?Gln?Glu?Gln?Pro?Arg?Asn?Tyr?Ser?His?His?Gln?Leu?Asn

165 170 175

Arg?Ser?Ser?Lys?His?Ser?Gln?Gly?Leu?Arg?Asp?Gln?Gly?Asn?Gln?Glu

180 185 190

Gln?Asp?Pro?Asn?Ile?Ser?Asn?Gly?Glu?Glu?Glu?Glu?Glu?Lys?Glu?Pro

195 200 205

Gly?Glu?Val?Gly?Thr?His?Asn?Asp?Asn?Gln?Glu?Arg?Lys?Thr?Glu?Leu

210 215 220

Pro?Arg?Glu?His?Ala?Asn?Ser?Lys?Gln?Glu?Glu?Asp?Asn?Thr?Gln?Ser

225 230 235 240

Asp?Asp?Ile?Leu?Glu?Glu?Ser?Asp?Gln?Pro?Thr?Gln?Val?Ser?Lys?Met

245 250 255

Gln?Glu?Asp?Glu?Phe?Asp?Gln?Gly?Asn?Gln?Glu?Gln?Glu?Asp?Asn?Ser

260 265 270

Asn?Ala?Glu?Met?Glu?Glu?Glu?Asn?Ala?Ser?Asn?Val?Asn?Lys?His?Ile

275 280 285

Gln?Glu?Thr?Glu?Trp?Gln?Ser?Gln?Glu?Gly?Lys?Thr?Gly?Leu?Glu?Ala

290 295 300

Ile?Ser?Asn?His?Lys?Glu?Thr?Glu?Glu?Lys?Thr?Val?Ser?Glu?Ala?Leu

305 310 315 320

Leu?Met?Glu?Pro?Thr?Asp?Asp?Gly?Asn?Thr?Thr?Pro?Arg?Asn?His?Gly

325 330 335

Val?Asp?Asp?Asp?Gly?Asp?Asp?Asp?Gly?Asp?Asp?Gly?Gly?Thr?Asp?Gly

340 345 350

Pro?Arg?His?Ser?Ala?Ser?Asp?Asp?Tyr?Phe?Ile?Pro?Ser?Gln?Ala?Phe

355 360 365

Leu?Glu?Ala?Glu?Arg?Ala?Gln?Ser?Ile?Ala?Tyr?His?Leu?Lys?Ile?Glu

370 375 380

Glu?Gln?Arg?Glu?Lys?Val?His?Glu?Asn?Glu?Asn?Ile?Gly?Thr?Thr?Glu

385 390 395 400

Pro?Gly?Glu?His?Gln?Glu?Ala?Lys?Lys?Ala?Glu?Asn?Ser?Ser?Asn?Glu

405 410 415

Glu?Glu?Thr?Ser?Ser?Glu?Gly?Asn?Met?Arg?Val?His?Ala?Val?Asp?Ser

420 425 430

Cys?Met?Ser?Phe?Gln?Cys?Lys?Arg?Gly?His?Ile?Cys?Lys?Ala?Asp?Gln

435 440 445

Gln?Gly?Lys?Pro?His?Cys?Val?Cys?Gln?Asp?Pro?Val?Thr?Cys?Pro?Pro

450 455 460

Thr?Lys?Pro?Leu?Asp?Gln?Val?Cys?Gly?Thr?Asp?Asn?Gln?Thr?Tyr?Ala

465 470 475 480

Ser?Ser?Cys?His?Leu?Phe?Ala?Thr?Lys?Cys?Arg?Leu?Glu?Gly?Thr?Lys

485 490 495

Lys?Gly?His?Gln?Leu?Gln?Leu?Asp?Tyr?Phe?Gly?Ala?Cys?Lys?Ser?Ile

500 505 510

Pro?Thr?Cys?Thr?Asp?Phe?Glu?Val?Ile?Gln?Phe?Pro?Leu?Arg?Met?Arg

515 520 525

Asp?Trp?Leu?Lys?Asn?Ile?Leu?Met?Gln?Leu?Tyr?Glu?Ala?Asn?Ser?Glu

530 535 540

His?Ala?Gly?Tyr?Leu?Asn?Glu?Lys?Gln?Arg?Asn?Lys?Val?Lys?Lys?Ile

545 550 555 560

Tyr?Leu?Asp?Glu?Lys?Arg?Leu?Leu?Ala?Gly?Asp?His?Pro?Ile?Asp?Leu

565 570 575

Leu?Leu?Arg?Asp?Phe?Lys?Lys?Asn?Tyr?His?Met?Tyr?Val?Tyr?Pro?Val

580 585 590

His?Trp?Gln?Phe?Ser?Glu?Leu?Asp?Gln?His?Pro?Met?Asp?Arg?Val?Leu

595 600 605

Thr?His?Ser?Glu?Leu?Ala?Pro?Leu?Arg?Ala?Ser?Leu?Val?Pro?Met?Glu

610 615 620

His?Cys?Ile?Thr?Arg?Phe?Phe?Glu?Glu?Cys?Asp?Pro?Asn?Lys?Asp?Lys

625 630 635 640

His?Ile?Thr?Leu?Lys?Glu?Trp?Gly?His?Cys?Phe?Gly?Ile?Lys?Glu?Glu

645 650 655

Asp?Ile?Asp?Glu?Asn?Leu?Leu?Phe

660

<210>79

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP2 of PIG33

<400>79

aagcttcgac?tgt 13

<210>80

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG33

<400>80

aagctttttt?ttttta 16

<210>81

<211>1349

<212>DNA

＜213〉mankind

<400>81

agagggacta?ggctgggtgt?ggagctgcag?cgtatccaca?ggccccagga?tgcaggccct 60

ggtgctactc?ctctgcattg?gagccctcct?cgggcacagc?agctgccaga?accctgccag 120

ccccccggag?gagggctccc?ctgaccccga?cagcacaggg?gcgctggtgg?aggaggagga 180

tcctttcttc?aaagtccccg?tgaacaagct?ggcagcggct?gtctccaact?tcggctatga 240

cctgtaccgg?gtgcgatcca?gcatgagccc?cacgaccaac?gtgctcctgt?ctcctctcag 300

tgtggccacg?gccctctcgg?ccctctcgct?gggagcggag?cagcgaacag?aatccatcat 360

tcaccgggct?ctctactatg?acttgattag?cagcccagac?atccatggta?cctataagga 420

gctccttgac?acggtcactg?ccccccagaa?gaacctcaag?agtgcctccc?ggatcgtctt 480

tgagaagaag?ctgcgcataa?aatccagctt?tgtggcacct?ctggaaaagt?catatgggac 540

caggcccaga?gtcctgacgg?gcaaccctcg?cttggacctg?caagagatca?acaactgggt 600

gcaggcgcag?atgaaaggga?agctcgccag?gtccacaaag?gaaattcccg?atgagatcag 660

cattctcctt?ctcggtgtgg?cgcacttcaa?ggggcagtgg?gtaacaaagt?ttgactccag 720

aaagacttcc?ctcgaggatt?tctacttgga?tgaagagagg?accgtgaggg?tccccatgat 780

gtcggaccct?aaggctgttt?tacgctatgg?cttggattca?gatctcagct?gcaagattgc 840

ccagctgccc?ttgaccggaa?gcatgagtat?catcttcttc?ctgcccctga?aagtgaccca 900

gaatttgacc?ttgatagagg?agagcctcac?ctccgagttc?attcatgaca?tagaccgaga 960

actgaagacc?gtgcaggcgg?tcctcactgt?ccccaagctg?aagctgagtt?atgaaggcga 1020

agtcaccaag?tccctgcagg?agatgaagct?gcaatccttg?tttgattcac?cagactttag 1080

caagatcaca?ggcaaaccca?tcaagctgac?tcaggtggaa?caccgggctg?gctttgagtg 1140

gaacgaggat?ggggcgggaa?ccacccccag?cccagggctg?cagcctgccc?acctcacctt 1200

cccgctggac?tatcacctta?accagccttt?catcttcgta?ctgagggaca?cagacacagg 1260

ggcccttctc?ttcattggca?agattctgga?ccccaggggc?ccctaatatc?ccagtttaat 1320

attccaatac?cctagaagaa?aacccgagg 1349

<210>82

<211>418

<212>PRT

＜213〉mankind

<400>82

Met?Gln?Ala?Leu?Val?Leu?Leu?Leu?Cys?Ile?Gly?Ala?Leu?Leu?Gly?His

1 5 10 15

Ser?Ser?Cys?Gln?Asn?Pro?Ala?Ser?Pro?Pro?Glu?Glu?Gly?Ser?Pro?Asp

20 25 30

Pro?Asp?Ser?Thr?Gly?Ala?Leu?Val?Glu?Glu?Glu?Asp?Pro?Phe?Phe?Lys

35 40 45

Val?Pro?Val?Asn?Lys?Leu?Ala?Ala?Ala?Val?Ser?Asn?Phe?Gly?Tyr?Asp

50 55 60

Leu?Tyr?Arg?Val?Arg?Ser?Ser?Met?Ser?Pro?Thr?Thr?Asn?Val?Leu?Leu

65 70 75 80

Ser?Pro?Leu?Ser?Val?Ala?Thr?Ala?Leu?Ser?Ala?Leu?Ser?Leu?Gly?Ala

85 90 95

Glu?Gln?Arg?Thr?Glu?Ser?Ile?Ile?His?Arg?Ala?Leu?Tyr?Tyr?Asp?Leu

100 105 110

Ile?Ser?Ser?Pro?Asp?Ile?His?Gly?Thr?Tyr?Lys?Glu?Leu?Leu?Asp?Thr

115 120 125

Val?Thr?Ala?Pro?Gln?Lys?Asn?Leu?Lys?Ser?Ala?Ser?Arg?Ile?Val?Phe

130 135 140

Glu?Lys?Lys?Leu?Arg?Ile?Lys?Ser?Ser?Phe?Val?Ala?Pro?Leu?Glu?Lys

145 150 155 160

Ser?Tyr?Gly?Thr?Arg?Pro?Arg?Val?Leu?Thr?Gly?Asn?Pro?Arg?Leu?Asp

165 170 175

Leu?Gln?Glu?Ile?Asn?Asn?Trp?Val?Gln?Ala?Gln?Met?Lys?Gly?Lys?Leu

180 185 190

Ala?Arg?Ser?Thr?Lys?Glu?Ile?Pro?Asp?Glu?Ile?Ser?Ile?Leu?Leu?Leu

195 200 205

Gly?Val?Ala?His?Phe?Lys?Gly?Gln?Trp?Val?Thr?Lys?Phe?Asp?Ser?Arg

210 215 220

Lys?Thr?Ser?Leu?Glu?Asp?Phe?Tyr?Leu?Asp?Glu?Glu?Arg?Thr?Val?Arg

225 230 235 240

Val?Pro?Met?Met?Ser?Asp?Pro?Lys?Ala?Val?Leu?Arg?Tyr?Gly?Leu?Asp

245 250 255

Ser?Asp?Leu?Ser?Cys?Lys?Ile?Ala?Gln?Leu?Pro?Leu?Thr?Gly?Ser?Met

260 265 270

Ser?Ile?Ile?Phe?Phe?Leu?Pro?Leu?Lys?Val?Thr?Gln?Asn?Leu?Thr?Leu

275 280 285

Ile?Glu?Glu?Ser?Leu?Thr?Ser?Glu?Phe?Ile?His?Asp?Ile?Asp?Arg?Glu

290 295 300

Leu?Lys?Thr?Val?Gln?Ala?Val?Leu?Thr?Val?Pro?Lys?Leu?Lys?Leu?Ser

305 310 315 320

Tyr?Glu?Gly?Glu?Val?Thr?Lys?Ser?Leu?Gln?Glu?Met?Lys?Leu?Gln?Ser

325 330 335

Leu?Phe?Asp?Ser?Pro?Asp?Phe?Ser?Lys?Ile?Thr?Gly?Lys?Pro?Ile?Lys

340 345 350

Leu?Thr?Gln?Val?Glu?His?Arg?Ala?Gly?Phe?Glu?Trp?Asn?Glu?Asp?Gly

355 360 365

Ala?Gly?Thr?Thr?Pro?Ser?Pro?Gly?Leu?Gln?Pro?Ala?His?Leu?Thr?Phe

370 375 380

Pro?Leu?Asp?Tyr?His?Leu?Asn?Gln?Pro?Phe?Ile?Phe?Val?Leu?Arg?Asp

385 390 395 400

Thr?Asp?Thr?Gly?Ala?Leu?Leu?Phe?Ile?Gly?Lys?Ile?Leu?Asp?Pro?Arg

405 410 415

Gly?Pro

<210>83

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP9 of PIG35

<400>83

aagcttcatt?ccg 13

<210>84

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG35

<400>84

aagctttttt?tttttc 16

<210>85

<211>430

<212>DNA

＜213〉mankind

<400>85

ggaagcactt?accctccact?tcctcctcct?gtttggcttc?tgtctcacct?agacccgtcc 60

ggtcgcagac?tgtctccgag?acgcttcctg?tccgaatcag?catgattctt?cagaggctct 120

tcaggttctc?ctctgtcatt?cggtcagccg?tctcagtcca?tttgcggagg?aacattggtg 180

ttacagcagt?ggcatttaat?aaggaacttg?atcctataca?gaaactcttt?gtggacaaga 240

ttagagaata?caaatctaag?cgacagacat?ctggaggacc?tgttgatgct?agttcagagt 300

atcagcaaga?gctggagagg?gagcttttta?agctcaagca?aatgtttggt?aatgcagaca 360

tgaatacatt?tcccaccttc?aaatttgaag?atcccaaatt?tgaagtcatc?gaaaaacccc 420

aggcctgaag 430

<210>86

<211>108

<212>PRT

＜213〉mankind

<400>86

Met?Ile?Leu?Gln?Arg?Leu?Phe?Arg?Phe?Ser?Ser?Val?Ile?Arg?Ser?Ala

1 5 10 15

Val?Ser?Val?His?Leu?Arg?Arg?Asn?Ile?Gly?Val?Thr?Ala?Val?Ala?Phe

20 25 30

Asn?Lys?Glu?Leu?Asp?Pro?Ile?Gln?Lys?Leu?Phe?Val?Asp?Lys?Ile?Arg

35 40 45

Glu?Tyr?Lys?Ser?Lys?Arg?Gln?Thr?Ser?Gly?Gly?Pro?Val?Asp?Ala?Ser

50 55 60

Ser?Glu?Tyr?Gln?Gln?Glu?Leu?Glu?Arg?Glu?Leu?Phe?Lys?Leu?Lys?Gln

65 70 75 80

Met?Phe?Gly?Asn?Ala?Asp?Met?Asn?Thr?Phe?Pro?Thr?Phe?Lys?Phe?Glu

85 90 95

Asp?Pro?Lys?Phe?Glu?Val?Ile?Glu?Lys?Pro?Gln?Ala

100 105

<210>87

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP9 of PIG36

<400>87

aagcttcat?ccg 13

<210>88

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG36

<400>88

aagctttttt?tttttg 16

<210>89

<211>2289

<212>DNA

＜213〉mankind

<400>89

gcaatacatg?gctactaagt?ctttgatcat?aagtcgaatt?tatagacctg?gaatttgcca 60

tcctagtctt?tcctttttag?taagacttct?gtcctctggc?agtgcatatg?gtaggtctct 120

aatgtttctg?catctccagg?aagatgcaga?tccttatttt?tgctgggaaa?tccttctaaa 180

tagaaatgta?acatttttat?aaaaacagat?taatgtgttt?ttcacttagt?aaatgttttc 240

aagagctgaa?ttgagaagga?aagagactgg?agtggttaat?ggtgatttga?tttctggcat 300

tctgagtttt?ctgctacaat?tagctgcatt?acttggtgcc?aaagagcagt?ggggaattgt 360

tgagttgctg?tatcctttaa?aaaaaaacaa?aaaacttgtt?attttgaaag?aacttaaggc 420

tcacaagatg?ttacaaaaat?agtagagtgg?ccttacccta?gatccagttt?tccccattta 480

taacatttca?cttagtccat?tttcggaacc?agaaaattaa?cattggcata?atgctattaa 540

ctaaactaca?gacctttttt?caatttcgcc?agtttttcca?cacatattca?tttagttgct 600

ggatactttt?aattcttgct?gatttgtaaa?ctggccttgc?ttggatacaa?caggaaagat 660

actatctgga?taaagttcta?cagttttaga?gagactatta?acacattaat?gtgttccttt 720

gtcatgagca?ataccctgcc?tacactgctt?ctaaattttc?tgatttgttt?ggctgtttgg 780

catctgaaac?aatccaagac?aaacttagaa?agattaggca?acacaaaaca?cagtaagacc 840

tgttcatagc?ttgttgccta?gaaaaccagg?tagcaggata?ttctagatgc?ttcctgctgc 900

ttctacgtga?gtaggattag?cactggggac?aaaataagga?gtttagagta?aaccagtatt 960

tcagtcaaga?gttagttggc?acttagttaa?tggcactgga?aatagcttgt?ggagagaata 1020

gaatacaatg?gtatagactc?ctaatgtttg?ataaaatact?attttcagag?tggtagagag 1080

gttttatttg?cctaaatagc?cgttattaaa?tggaataaca?accacattag?accaaattaa 1140

ttgcaaacac?agcggcaacc?tggggagaag?ttgaaactcc?agttttgtgg?attacagttt 1200

tgagttttat?gattgacatt?tttaagtccc?ctatttaagg?ggtcaagatt?ataacaatgt 1260

gtgtcttact?aagtttctag?gtcattgtga?gcacttgata?aatatttgct?gaatgttgtt 1320

tttttgaatg?aacataagat?agaaacaaaa?acttctcatc?cagttaacta?gagtgaatgt 1380

agggagaatt?gttttgcttg?taacatggag?agtttatttt?caagtgagga?aagagaaaaa 1440

aattactcag?acttgttcct?ggtgaagtgc?attctctgtt?tgtatacttt?ttgatggaga 1500

aattgatcta?tagaactgct?taattttttg?aggcatttag?acagcaatga?aaggtagttc 1560

tccacaggac?accgaatcaa?aaggagagac?cagactctgg?cctcataccc?agcctatttg 1620

aaacaagcta?tctagtttct?cctgcagaca?ccttgtcaac?aacatgcaac?agtgtcaggt 1680

gccttgcagg?aaaataatct?gagtcccaag?ctagcctgtg?ctcatccaca?atctcaatga 1740

acatgtcaag?gaagaatttg?cagagactca?agggaagcac?aatgggataa?ggtaatcact 1800

ttcagtgaaa?aactgttttc?ctgaaaacag?gcttggacac?aattgaaagc?tggcttcctg 1860

caaacacacc?aagagtctgt?aatctagcct?atccattata?tgtcctttat?tattcatgat 1920

atcctattct?tctaccttgt?tgcctggtaa?ctttttctga?ggactgagtt?tctgcagcga 1980

tgcggtgcac?tcttcctgtg?atgaggaaac?atctgggccc?ccttctgcag?gctttggaag 2040

atgatgtgtc?ttgtcaaggg?gtaaagggca?aatggattta?atttctgctt?aaaactatca 2100

tagacgttcc?aaatagaata?tgtaaaattt?ctctgtatta?gaaaaagaaa?cgtgatacca 2160

attgtatatt?ttcttttctt?tatttattct?ctgtaagtct?gtcagatgat?aaattgtaaa 2220

taacaatgat?taaagagtca?tgcttctgaa?aaaaaaaaaa?aaaaaaaaaa?aaaaaaaaaa 2280

aaaaaaaaa 2289

<210>90

<211>69

<212>PRT

＜213〉mankind

<400>90

Met?Phe?Ser?Arg?Ala?Glu?Leu?Arg?Arg?Lys?Glu?Thr?Gly?Val?Val?Asn

1 5 10 15

Gly?Asp?Leu?Ile?Ser?Gly?Ile?Leu?Ser?Phe?Leu?Leu?Gln?Leu?Ala?Ala

20 25 30

Leu?Leu?Gly?Ala?Lys?Glu?Gln?Trp?Gly?Ile?Val?Glu?Leu?Leu?Tyr?Pro

35 40 45

Leu?Lys?Lys?Asn?Lys?Lys?Leu?Val?Ile?Leu?Lys?Glu?Leu?Lys?Ala?His

50 55 60

Lys?Met?Leu?Gln?Lys

65

<210>91

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP32 of MIG20

<400>91

aagcttcctg?caa 13

<210>92

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of MIG20

<400>92

aagctttttt?ttttta 16

<210>93

<211>1087

<212>DNA

＜213〉mankind

<400>93

cgtagcagct?atgcagcttg?aaatccaagt?agcactaaat?tttattattt?cgtatttgta 60

caataagctt?cccaggagac?gtgtcaacat?ttttggtgaa?gaacttgaaa?gacttcttaa 120

gaagaaatat?gaagggcact?ggtatcctga?aaagccatac?aaaggatcgg?ggtttagatg 180

tatacacata?ggggagaaag?tggacccagt?gattgaacaa?gcatccaaag?agagtggttt 240

ggacattgat?gatgttcgtg?gcaatctgcc?acaggatctt?agtgtttggg?tcgacccatt 300

tgaggtttct?taccaaattg?gtgaaaaggg?accagtgaag?gtgctttacg?tggatgataa 360

taatgaaaat?ggatgtgagt?tggataagga?gatcaaaaac?agctttaacc?cagaggccca 420

ggtttttatg?cccataagtg?acccagcctc?atcagtgtcc?agctctccat?cgcctccttt 480

tggtcactct?gctgctgtaa?gccctacctt?catgccccgg?tccactcagc?ctttaacctt 540

taccactgcc?acttttgctg?ccaccaagtt?cggctctacc?aaaatgaaga?atagtggccg 600

tagcaacaag?gttgcacgta?cttctcccat?caacctcggc?ttgaatgtga?atgacctctt 660

gaagcagaaa?gccatctctt?cctcaatgca?ctctctgtat?gggcttggct?tgggtagcca 720

gcagcagcca?cagcaacagc?agcagccagc?ccagccgcca?ccgccaccac?caccaccaca 780

gcagcaacaa?cagcagaaaa?cctctgctct?ttctcctaat?gccaaggaat?ttatttttcc 840

taatatgcag?ggtcaaggta?gtagtaccaa?tggaatgttc?ccaggtgaca?gcccccttaa 900

cctcagtcct?ctccagtaca?gtaatgcctt?tgatgtgttt?gcagcctatg?gaggcctcaa 960

tgagaagtct?tttgtagatg?gcttgaattt?tagcttaaat?aacatgcagt?attctaacca 1020

gcaattccag?cctgttatgg?ctaactaaaa?aaaagaaaat?gtatcgtaca?agttaaaatg 1080

cacgggc 1087

<210>94

<211>345

<212>PRT

＜213〉mankind

<400>94

Met?Gln?Leu?Glu?Ile?Gln?Val?Ala?Leu?Asn?Phe?Ile?Ile?Ser?Tyr?Leu

1 5 10 15

Tyr?Asn?Lys?Leu?Pro?Arg?Arg?Arg?Val?Asn?Ile?Phe?Gly?Glu?Glu?Leu

20 25 30

Glu?Arg?Leu?Leu?Lys?Lys?Lys?Tyr?Glu?Gly?His?Trp?Tyr?Pro?Glu?Lys

35 40 45

Pro?Tyr?Lys?Gly?Ser?Gly?Phe?Arg?Cys?Ile?His?Ile?Gly?Glu?Lys?Val

50 55 60

Asp?Pro?Val?Ile?Glu?Gln?Ala?Ser?Lys?Glu?Ser?Gly?Leu?Asp?Ile?Asp

65 70 75 80

Asp?Val?Arg?Gly?Asn?Leu?Pro?Gln?Asp?Leu?Ser?Val?Trp?Val?Asp?Pro

85 90 95

Phe?Glu?Val?Ser?Tyr?Gln?Ile?Gly?Glu?Lys?Gly?Pro?Val?Lys?Val?Leu

100 105 110

Tyr?Val?Asp?Asp?Asn?Asn?Glu?Asn?Gly?Cys?Glu?Leu?Asp?Lys?Glu?Ile

115 120 125

Lys?Asn?Ser?Phe?Asn?Pro?Glu?Ala?Gln?Val?Phe?Met?Pro?Ile?Ser?Asp

130 135 140

Pro?Ala?Ser?Ser?Val?Ser?Ser?Ser?Pro?Ser?Pro?Pro?Phe?Gly?His?Ser

145 150 155 160

Ala?Ala?Val?Ser?Pro?Thr?Phe?Met?Pro?Arg?Ser?Thr?Gln?Pro?Leu?Thr

165 170 175

Phe?Thr?Thr?Ala?Thr?Phe?Ala?Ala?Thr?Lys?Phe?Gly?Ser?Thr?Lys?Met

180 185 190

Lys?Asn?Ser?Gly?Arg?Ser?Asn?Lys?Val?Ala?Arg?Thr?Ser?Pro?Ile?Asn

195 200 205

Leu?Gly?Leu?Asn?Val?Asn?Asp?Leu?Leu?Lys?Gln?Lys?Ala?Ile?Ser?Ser

210 215 220

Ser?Met?His?Ser?Leu?Tyr?Gly?Leu?Gly?Leu?Gly?Ser?Gln?Gln?Gln?Pro

225 230 235 240

Gln?Gln?Gln?Gln?Gln?Pro?Ala?Gln?Pro?Pro?Pro?Pro?Pro?Pro?Pro?Pro

245 250 255

Gln?Gln?Gln?Gln?Gln?Gln?Lys?Thr?Ser?Ala?Leu?Ser?Pro?Asn?Ala?Lys

260 265 270

Glu?Phe?Ile?Phe?Pro?Asn?Met?Gln?Gly?Gln?Gly?Ser?Ser?Thr?Asn?Gly

275 280 285

Met?Phe?Pro?Gly?Asp?Ser?Pro?Leu?Asn?Leu?Ser?Pro?Leu?Gln?Tyr?Ser

290 295 300

Asn?Ala?Phe?Asp?Val?Phe?Ala?Ala?Tyr?Gly?Gly?Leu?Asn?Glu?Lys?Ser

305 310 315 320

Phe?Val?Asp?Gly?Leu?Asn?Phe?Ser?Leu?Asn?Asn?Met?Gln?Tyr?Ser?Asn

325 330 335

Gln?Gln?Phe?Gln?Pro?Val?Met?Ala?Asn

340 345

<210>95

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP10 of PIG49

<400>95

aagcttccac?gta 13

<210>96

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG49

<400>96

aagctttttt?ttttta 16

<210>97

<211>826

<212>DNA

＜213〉mankind

<400>97

ggcgctgagt?tttgtctccc?cggccgtctg?ggcgcgcgcg?ggtgtcccag?aatgaaatat 60

gactgaggac?tctcagagaa?actttcgttc?agtatattat?gagaaagtgg?ggtttcgtgg 120

agttgaagaa?aagaaatcat?tagaaattct?cctaaaagat?gaccgtctgg?atactgagaa 180

actttgtact?tttagtcaga?ggttccctct?cccgtccatg?taccgtgcat?tggtatggaa 240

ggtgcttcta?ggaatcttgc?ctccacacca?cgagtcccat?gccaaggtga?tgatgtatcg 300

taaggagcag?tacttggatg?tccttcatgc?cctgaaagtc?gttcgctttg?ttagtgatgc 360

cacacctcag?gctgaagtct?atctccgcat?gtatcagctg?gagtctggga?agttacctcg 420

aagtccctct?tttccactgc?caaaagcgtt?tgaacaatac?ttgaatctgg?aagatggcag 480

actgctgact?catctgagga?tgtgttccgc?ggcgcccaaa?cttccttatg?atctctggtt 540

caagaggtgc?tttgcgggat?gtttgcctga?atccagttta?cagagggttt?gggataaagt 600

tgtgagtgga?tcctgtaaga?tcctagtttt?tgtagctgtc?gaaattttat?taacctttaa 660

aataaaagtt?atggcactga?acagtgcaga?gaagataaca?aagtttctgg?aaaatattcc 720

ccaggacagc?tcagacgcga?tcgtgagcaa?ggccattgac?ttgtggcaca?aacactgtgg 780

gaccccggtc?cattcaagct?gaacgcaccc?gctggttgtg?gaccgt 826

<210>98

<211>247

<212>PRT

＜213〉mankind

<400>98

Met?Thr?Glu?Asp?Ser?Gln?Arg?Asn?Phe?Arg?Ser?Val?Tyr?Tyr?Glu?Lys

1 5 10 15

Val?Gly?Phe?Arg?Gly?Val?Glu?Glu?Lys?Lys?Ser?Leu?Glu?Ile?Leu?Leu

20 25 30

Lys?Asp?Asp?Arg?Leu?Asp?Thr?Glu?Lys?Leu?Cys?Thr?Phe?Ser?Gln?Arg

35 40 45

Phe?Pro?Leu?Pro?Ser?Met?Tyr?Arg?Ala?Leu?Val?Trp?Lys?Val?Leu?Leu

50 55 60

Gly?Ile?Leu?Pro?Pro?His?His?Glu?Ser?His?Ala?Lys?Val?Met?Met?Tyr

65 70 75 80

Arg?Lys?Glu?Gln?Tyr?Leu?Asp?Val?Leu?His?Ala?Leu?Lys?Val?Val?Arg

85 90 95

Phe?Val?Ser?Asp?Ala?Thr?Pro?Gln?Ala?Glu?Val?Tyr?Leu?Arg?Met?Tyr

100 105 110

Gln?Leu?Glu?Ser?Gly?Lys?Leu?Pro?Arg?Ser?Pro?Ser?Phe?Pro?Leu?Pro

115 120 125

Lys?Ala?Phe?Glu?Gln?Tyr?Leu?Asn?Leu?Glu?Asp?Gly?Arg?Leu?Leu?Thr

130 135 140

His?Leu?Arg?Met?Cys?Ser?Ala?Ala?Pro?Lys?Leu?Pro?Tyr?Asp?Leu?Trp

145 150 155 160

Phe?Lys?Arg?Cys?Phe?Ala?Gly?Cys?Leu?Pro?Glu?Ser?Ser?Leu?Gln?Arg

165 170 175

Val?Trp?Asp?Lys?Val?Val?Ser?Gly?Ser?Cys?Lys?Ile?Leu?Val?Phe?Val

180 185 190

Ala?Val?Glu?Ile?Leu?Leu?Thr?Phe?Lys?Ile?Lys?Val?Met?Ala?Leu?Asn

195 200 205

Ser?Ala?Glu?Lys?Ile?Thr?Lys?Phe?Leu?Glu?Asn?Ile?Pro?Gln?Asp?Ser

210 215 220

Ser?Asp?Ala?Ile?Val?Ser?Lys?Ala?Ile?Asp?Leu?Trp?His?Lys?His?Cys

225 230 235 240

Gly?Thr?Pro?Val?His?Ser?Ser

245

<210>99

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP22 of PIG51

<400>99

aagcttttga?tcc 13

<210>100

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG51

<400>100

aagctttttt?tttttg 16

<210>101

<211>207

<212>DNA

＜213〉mankind

<400>101

acgagactgc?acggattgtt?ttaagaaaat?ggcagacaaa?ccagacatgg?gggaaatcgc 60

cagcttcgat?aaggccaagc?tgaagaaaac?ggagacgcag?gagaagaaca?ccctgccgac 120

caaagagacc?attgagcagg?agaagcggag?tgaaatttcc?taagatcctg?gaggatttcc 180

tacccccgtc?ctcttcgaga?ccccagt 207

<210>102

<211>44

<212>PRT

＜213〉mankind

<400>102

Met?Ala?Asp?Lys?Pro?Asp?Met?Gly?Glu?Ile?Ala?Ser?Phe?Asp?Lys?Ala

1 5 10 15

Lys?Leu?Lys?Lys?Thr?Glu?Thr?Gln?Glu?Lys?Asn?Thr?Leu?Pro?Thr?Lys

20 25 30

Glu?Thr?Ile?Glu?Gln?Glu?Lys?Arg?Ser?Glu?Ile?Ser

35 40

<210>103

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP12 of MIG12

<400>103

aagcttgagt?gct 13

<210>104

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of MIG12

<400>104

aagctttttt?tttttc 16

<210>105

<211>1527

<212>DNA

＜213〉mankind

<400>105

agaatgctgg?agcctttgcc?ctgttgggac?gctgcgaaag?atctgaaaga?acctcagtgc 60

cctcctgggg?acagggtggg?tgtgcagcct?gggaactcca?gggtttggca?gggcaccatg 120

gagaaagccg?gtttggcttg?gacgcgtggc?acaggggtgc?aatcagaggg?gacttgggaa 180

agccagcggc?aggacagtga?tgccctccca?agtccggagc?tgctacccca?agatcaggac 240

aagcctttcc?tgaggaaggc?ctgcagcccc?agcaacatac?ctgctgtcat?cattacagac 300

atgggcaccc?aggaggatgg?ggccttggag?gagacgcagg?gaagccctcg?gggcaacctg 360

cccctgagga?aactgtcctc?ttcctcggcc?tcctccacgg?gcttctcctc?atcctacgaa 420

gactcagagg?aggacatctc?cagtgaccct?gagcgcaccc?tggaccccaa?ctcagccttc 480

ctgcataccc?tggaccagca?gaaacccaga?gtgagcaaat?catggaggaa?gataaaaaac 540

atggtgcact?ggtctccctt?cgtcatgtcc?ttcaagaaga?agtacccctg?gatccagctg 600

gcaggacacg?cagggagttt?caaggcagct?gccaatggca?ggatcctgaa?gaagcactgt 660

gagtcagagc?agcgctgcct?ggaccggctg?atggtggatg?tgctgaggcc?cttcgtacct 720

gcctaccatg?gggatgtggt?gaaggacggg?gagcgctaca?accagatgga?cgacctgctg 780

gccgacttcg?actcgccctg?tgtgatggac?tgcaagatgg?gaatcaggac?ctacctggag 840

gaggagctca?cgaaggcccg?gaagaagccc?agcctgcgga?aggacatgta?ccagaagatg 900

atcgaggtgg?accccgaggc?ccccaccgag?gaggaaaaag?cacagcgggc?tgtgaccaag 960

ccacggtaca?tgcagtggcg?ggagaccatc?agctccacgg?ccaccctggg?gttcaggatc 1020

gagggaatca?agaaagaaga?cggcaccgtg?aaccgggact?tcaagaagac?caaaacgagg 1080

gagcaggtca?ccgaggcctt?cagagagttc?actaaaggaa?accataacat?cctgatcgcc 1140

tatcgggacc?ggctgaaggc?cattcgaacc?actctagaag?tttctccctt?cttcaagtgc 1200

cacgaggtca?ttggcagctc?cctcctcttc?atccacgaca?agaaggaaca?ggccaaagtg 1260

tggatgatcg?actttgggaa?aaccacgccc?ctgcctgagg?gccagaccct?gcagcatgac 1320

gtcccctggc?aggaggggaa?ccgggaggat?ggctacctct?cggggctcaa?taacctcgtc 1380

gacatcctga?ccgagatgtc?ccaggatgcc?ccactcgcct?gagctgccca?cgccctccct 1440

ggcccccgcc?tgggcctcct?ttcctcctcc?tgtgcttcct?ttctcgttcc?taacttttcc 1500

ttcacttaca?cctgactgac?cctcctg 1527

<210>106

<211>472

<212>PRT

＜213〉mankind

<400>106

Met?Leu?Glu?Pro?Leu?Pro?Cys?Trp?Asp?Ala?Ala?Lys?Asp?Leu?Lys?Glu

1 5 10 15

Pro?Gln?Cys?Pro?Pro?Gly?Asp?Arg?Val?Gly?Val?Gln?Pro?Gly?Asn?Ser

20 25 30

Arg?Val?Trp?Gln?Gly?Thr?Met?Glu?Lys?Ala?Gly?Leu?Ala?Trp?Thr?Arg

35 40 45

Gly?Thr?Gly?Val?Gln?Ser?Glu?Gly?Thr?Trp?Glu?Ser?Gln?Arg?Gln?Asp

50 55 60

Ser?Asp?Ala?Leu?Pro?Ser?Pro?Glu?Leu?Leu?Pro?Gln?Asp?Gln?Asp?Lys

65 70 75 80

Pro?Phe?Leu?Arg?Lys?Ala?Cys?Ser?Pro?Ser?Asn?Ile?Pro?Ala?Val?Ile

85 90 95

Ile?Thr?Asp?Met?Gly?Thr?Gln?Glu?Asp?Gly?Ala?Leu?Glu?Glu?Thr?Gln

100 105 110

Gly?Ser?Pro?Arg?Gly?Asn?Leu?Pro?Leu?Arg?Lys?Leu?Ser?Ser?Ser?Ser

115 120 125

Ala?Ser?Ser?Thr?Gly?Phe?Ser?Ser?Ser?Tyr?Glu?Asp?Ser?Glu?Glu?Asp

130 135 140

Ile?Ser?Ser?Asp?Pro?Glu?Arg?Thr?Leu?Asp?Pro?Asn?Ser?Ala?Phe?Leu

145 150 155 160

His?Thr?Leu?Asp?Gln?Gln?Lys?Pro?Arg?Val?Ser?Lys?Ser?Trp?Arg?Lys

165 170 175

Ile?Lys?Asn?Met?Val?His?Trp?Ser?Pro?Phe?Val?Met?Ser?Phe?Lys?Lys

180 185 190

Lys?Tyr?Pro?Trp?Ile?Gln?Leu?Ala?Gly?His?Ala?Gly?Ser?Phe?Lys?Ala

195 200 205

Ala?Ala?Asn?Gly?Arg?Ile?Leu?Lys?Lys?His?Cys?Glu?Ser?Glu?Gln?Arg

210 215 220

Cys?Leu?Asp?Arg?Leu?Met?Val?Asp?Val?Leu?Arg?Pro?Phe?Val?Pro?Ala

225 230 235 240

Tyr?His?Gly?Asp?Val?Val?Lys?Asp?Gly?Glu?Arg?Tyr?Asn?Gln?Met?Asp

245 250 255

Asp?Leu?Leu?Ala?Asp?Phe?Asp?Ser?Pro?Cys?Val?Met?Asp?Cys?Lys?Met

260 265 270

Gly?Ile?Arg?Thr?Tyr?Leu?Glu?Glu?Glu?Leu?Thr?Lys?Ala?Arg?Lys?Lys

275 280 285

Pro?Ser?Leu?Arg?Lys?Asp?Met?Tyr?Gln?Lys?Met?Ile?Glu?Val?Asp?Pro

290 295 300

Glu?Ala?Pro?Thr?Glu?Glu?Glu?Lys?Ala?Gln?Arg?Ala?Val?Thr?Lys?Pro

305 310 315 320

Arg?Tyr?Met?Gln?Trp?Arg?Glu?Thr?Ile?Ser?Ser?Thr?Ala?Thr?Leu?Gly

325 330 335

Phe?Arg?Ile?Glu?Gly?Ile?Lys?Lys?Glu?Asp?Gly?Thr?Val?Asn?Arg?Asp

340 345 350

Phe?Lys?Lys?Thr?Lys?Thr?Arg?Glu?Gln?Val?Thr?Glu?Ala?Phe?Arg?Glu

355 360 365

Phe?Thr?Lys?Gly?Asn?His?Asn?Ile?Leu?Ile?Ala?Tyr?Arg?Asp?Arg?Leu

370 375 380

Lys?Ala?Ile?Arg?Thr?Thr?Leu?Glu?Val?Ser?Pro?Phe?Phe?Lys?Cys?His

385 390 395 400

Glu?Val?Ile?Gly?Ser?Ser?Leu?Leu?Phe?Ile?His?Asp?Lys?Lys?Glu?Gln

405 410 415

Ala?Lys?Val?Trp?Met?Ile?Asp?Phe?Gly?Lys?Thr?Thr?Pro?Leu?Pro?Glu

420 425 430

Gly?Gln?Thr?Leu?Gln?His?Asp?Val?Pro?Trp?Gln?Glu?Gly?Asn?Arg?Glu

435 440 445

Asp?Gly?Tyr?Leu?Ser?Gly?Leu?Asn?Asn?Leu?Val?Asp?Ile?Leu?Thr?Glu

450 455 460

Met?Ser?Gln?Asp?Ala?Pro?Leu?Ala

465 470

<210>107

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP10 of PIG37

<400>107

aagcttccac?gta 13

<210>108

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of PIG37

<400>108

aagctttttt?tttttg 16

<210>109

<211>415

<212>DNA

＜213〉mankind

<400>109

gcagcccgac?tagcagtcta?gaggcctgag?gcttctgggt?cctggtgacg?gggctggcat 60

gaccccgggg?gtcgtccatg?ccagtccgcc?tcagtcgcag?agggtccctc?ggcaagcgcc 120

ctgtgagtgg?gccattcgga?acattggaca?gaagcccaaa?gagccaaatt?gtcacaattg 180

tggaacccac?attggcctga?gatccaaaac?gcttcgaggc?accccaaatt?acctgcccat 240

tcgtcaggac?acccacccac?ccagtgttat?attctgcctc?gccggagtgg?gtgttcccgg 300

gggcacttgc?cgaccagccc?cttgcgtccc?caggtttgca?gctctcccct?gggccactaa 360

ccatcctggc?ccgggctgcc?tgtctgacct?ccgtgcctag?tcgtggctct?ccatc 415

<210>110

<211>113

<212>PRT

＜213〉mankind

<400>110

Met?Thr?Pro?Gly?Val?Val?His?Ala?Ser?Pro?Pro?Gln?Ser?Gln?Arg?Val

1 5 10 15

Pro?Arg?Gln?Ala?Pro?Cys?Glu?Trp?Ala?Ile?Arg?Asn?Ile?Gly?Gln?Lys

20 25 30

Pro?Lys?Glu?Pro?Asn?Cys?His?Asn?Cys?Gly?Thr?His?Ile?Gly?Leu?Arg

35 40 45

Ser?Lys?Thr?Leu?Arg?Gly?Thr?Pro?Asn?Tyr?Leu?Pro?Ile?Arg?Gln?Asp

50 55 60

Thr?His?Pro?Pro?Ser?Val?Ile?Phe?Cys?Leu?Ala?Gly?Val?Gly?Val?Pro

65 70 75 80

Gly?Gly?Thr?Cys?Arg?Pro?Ala?Pro?Cys?Val?Pro?Arg?Phe?Ala?Ala?Leu

85 90 95

Pro?Trp?Ala?Thr?Asn?His?Pro?Gly?Pro?Gly?Cys?Leu?Ser?Asp?Leu?Arg

100 105 110

Ala

<210>111

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP12 of GIG44

<400>111

aagcttgagt?gct 13

<210>112

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG44

<400>112

aagctttttt?tttttg 16

<210>113

<211>723

<212>DNA

＜213〉mankind

<400>113

cgggagaacg?ataatgcaaa?gtgctatgtt?cttggctgtt?caacacgact?gcagacccat 60

ggacaagagc?gcaggcagtg?gccacaagag?cgaggagaag?cgagaaaaga?tgaaacggac 120

ccttttaaaa?gattggaaga?cccgtttgag?ctacttctta?caaaattcct?ctactcctgg 180

gaagcccaaa?accggcaaaa?aaagcaaaca?gcaagctttc?atcaagcctt?ctcctgagga 240

agcacagctg?tggtcagaag?catttgacga?gctgctagcc?agcaaatatg?gtcttgctgc 300

attcagggct?tttttaaagt?cggaattctg?tgaagaaaat?attgaattct?ggctggcctg 360

tgaagacttc?aaaaaaacca?aatcacccca?aaagctgtcc?tcaaaagcaa?ggaaaatata 420

tactgacttc?atagaaaagg?aagctccaaa?agagataaac?atagattttc?aaaccaaaac 480

tctgattgcc?cagaatatac?aagaagctac?aagtggctgc?tttacaactg?cccagaaaag 540

ggtatacagc?ttgatggaga?acaactctta?tcctcgtttc?ttggagtcag?aattctacca 600

ggacttgtgt?aaaaagccac?aaatcaccac?agagcctcat?gctacatgaa?atgtaaaagg 660

gagcccagaa?atggaggaca?tttcattctt?tttcctgagg?ggaaggactg?tgacctgcca 720

taa 723

<210>114

<211>211

<212>PRT

＜213〉mankind

<400>114

Met?Gln?Ser?Ala?Met?Phe?Leu?Ala?Val?Gln?His?Asp?Cys?Arg?Pro?Met

1 5 10 15

Asp?Lys?Ser?Ala?Gly?Ser?Gly?His?Lys?Ser?Glu?Glu?Lys?Arg?Glu?Lys

20 25 30

Met?Lys?Arg?Thr?Leu?Leu?Lys?Asp?Trp?Lys?Thr?Arg?Leu?Ser?Tyr?Phe

35 40 45

Leu?Gln?Asn?Ser?Ser?Thr?Pro?Gly?Lys?Pro?Lys?Thr?Gly?Lys?Lys?Ser

50 55 60

Lys?Gln?Gln?Ala?Phe?Ile?Lys?Pro?Ser?Pro?Glu?Glu?Ala?Gln?Leu?Trp

65 70 75 80

Ser?Glu?Ala?Phe?Asp?Glu?Leu?Leu?Ala?Ser?Lys?Tyr?Gly?Leu?Ala?Ala

85 90 95

Phe?Arg?Ala?Phe?Leu?Lys?Ser?Glu?Phe?Cys?Glu?Glu?Asn?Ile?Glu?Phe

100 105 110

Trp?Leu?Ala?Cys?Glu?Asp?Phe?Lys?Lys?Thr?Lys?Ser?Pro?Gln?Lys?Leu

115 120 125

Ser?Ser?Lys?Ala?Arg?Lys?Ile?Tyr?Thr?Asp?Phe?Ile?Glu?Lys?Glu?Ala

130 135 140

Pro?Lys?Glu?Ile?Asn?Ile?Asp?Phe?Gln?Thr?Lys?Thr?Leu?Ile?Ala?Gln

145 150 155 160

Asn?Ile?Gln?Glu?Ala?Thr?Ser?Gly?Cys?Phe?Thr?Thr?Ala?Gln?Lys?Arg

165 170 175

Val?Tyr?Ser?Leu?Met?Glu?Asn?Asn?Ser?Tyr?Pro?Arg?Phe?Leu?Glu?Ser

180 185 190

Glu?Phe?Tyr?Gln?Asp?Leu?Cys?Lys?Lys?Pro?Gln?Ile?Thr?Thr?Glu?Pro

195 200 205

His?Ala?Thr

210

<210>115

<211>13

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the primer H-AP4 of GIG31

<400>115

aagcttctca?acg 13

<210>116

<211>16

<212>DNA

＜213〉artificial sequence

<220>

＜223〉the oligo-dT anchor primer of GIG31

<400>116

aagctttttt?ttttta 16

Claims

1. people's cancer suppressor protein, it has and is selected from the NO:2 by SEQ ID, SEQ ID NO:6, SEQID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:58, SEQ ID NO:62, SEQID NO:66, SEQ ID NO:70, SEQ ID NO:74, SEQ ID NO:78, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:90, SEQ ID NO:94, SEQ ID NO:98, SEQ ID NO:102, SEQ ID NO:106, aminoacid sequence in the group that SEQ ID NO:110 and SEQ ID NO:114 form.

2. people's cancer suppressor protein according to claim 1, wherein, described cancer is the cancer that is selected from the tissue in the group of being made up of normal breast, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.

3. human tumor suppressor gene of the proto-protein described in the claim 1 of encoding, described human tumor suppressor gene is by being selected from the NO:1 by SEQ ID, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQID NO:53, SEQ ID NO:57, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:77, SEQ ID NO:81, SEQ ID NO:85, SEQ ID NO:89, SEQ ID NO:93, SEQ ID NO:97, SEQ ID NO:101, SEQ ID NO:105, dna sequence dna in the group that SEQ ID NO:109 and SEQ ID NO:113 form is represented.

4. human tumor suppressor gene according to claim 3, wherein, described cancer is the cancer that is selected from the tissue in the group of being made up of normal breast, brain, heart, muscle, large intestine, thymus gland, spleen, kidney, liver, small intestine, placenta, lung and peripheral blood.